Pharmacogenetics of vigabatrin and clobazam by Jose, Prathibha Elizabeth Ann
PHARMACOGENETICS OF VIGABATRIN AND CLOBAZAM
Thesis submitted in accordance with the requirements of the
University of Liverpool for the degree of Doctor in Philosophy
Prathibha Elizabeth Ann Jose
June 2009
Author’s declaration
I, Prathibha Elizabeth Ann Jose, declare that the research presented in this thesis was
carried out by myself in the Department of Pharmacologyat University of Liverpool.
It is an original piece of work. The views expressedare solely of the author.
Prathibha Elizabeth Ann Jose
Acknowledgements
I would like thank my supervisor Prof. Munir Pirmohamed for allowing me to
undertake this project and for his support, help and advice given throughout the
project.
Manythanks to Dr. Tim Green for being my co-supervisor and for all his expertise
and advice on biochemical methods, without whose support my work never would
have been possible. I am grateful to Dr. Ana Alfirevic who has been very kind,
understanding and supportive throughout my PhD. Special thanks to Dr. Graham
Green, on expert advice onplatelet isolation. Dr. Pete Dixon was always prompt and
willing to answer any questionsrelating to the patients involved in my work. I would
not have been able to successfully complete my thesis without his help. I am grateful
to Dr. Abhishek Srivastava for his expert advice on HPLC. Mygreat appreciation
and gratitude goes to Dr. Ajith Sreekandan Nair for his friendship and help in
formatting mythesis.
My thesis was part of a multicentre project. I would like to thank all the co-
investigators of the project - Prof. Chadwick, Prof. Marson, Prof.Williamson, Dr.
Jorgenson and Dr. Kyle, from the University of Liverpool, Prof. Goldstein, Prof.
Sander and Dr. Sisodiya from University College, London, Dr. Johnson from
Imperial College, London and Prof. Bentley from SangerInstitute, Cambridge.
‘Service with a smile’; how else I can describe Ms. Jennifer Hellier and Dr. John
Tjia, without whom HPLC assays would not have been possible. Thanks to Dr.
Andrea Davies for always being there with pragmatic advice on science andlife.
Special thanks to Ms. Eunice Zhang for her support and help in printing mythesis.
I would like to express mygratitude to all the staff in the Dept. of Pharmacology, in
particular to the supporting staff, Ms Janet Lampard and Mr. Rayfortheir help.
Now, myfellow lab mates, especially Sameh, Kate, Eunice, Lakshman, Mohammed,
Joe, Fabio, Viv, Natalie, Andrew andall the co-postgraduates of Pharmacology for
the joyous moments we had, without whom my work would never have been that
pleasantandfruitful.
Next, I would like to thank each member of my family, well-wishers and friends,
especially my parents and myin-laws.
Finally yet importantly, my gratitude and special thanks to my husbandPatrick and
myloving son John, without whose support this would not have been possible.
Contents
Author’s declaration ...........cccccscccesceccsccececceccscceccesceseseseesesssesesseesseens z
ACKNOW]ledGeMENMs............ccsssrcsssssccssssccsssscssssssssssscssssesssssscsssssssssesssssesssssssessssssssssees 3
LS Of WANScic ccccccasscncssccscecs 50600 tas ses aseseeesecsess tbe teseseesiecsebeeeamenseSS 14
ADDPEVIGUOTSesses cexavmcmsnassanssasn eeawasereRTO17
Publications and COMMUNICATIONS00 s6ns0ss000cccssascesnsneesaseneecnmeewanenecomnenses 20
PSUAGhives eee ers res ere ere epeeerrnooneeeees 21
Chapter 1 23
Introduction 23
LoL. EPW@psy  scccssscccssscscssscvssscscsosesssssvssonsveascassavasacsessssoseceesasusassoesssvovsessosounesronsasses 24
1.1.1. Classification of epilepsy... ccceeeecceseeseeseesceeceseeeeeseeseeseeeeeeeeneeseens 24
1.1.2. Epidemiologyof epilepsy ...... cece eeeeseeeseeeeceteeeeeneeeeeeeseeneeeseesseesseeneeeaees 25
1.1.3. Aetiology of epilepsy.......cccecccccccecseeteeneeececseeeeeeeeeeeeseseaeeeaeeneeeaeenaeeaee 25
1.1.4. Mechanismsofseizure generation... cece seeeeeeeseeeeeeseceseenseesseeseenaee 25
1.1.5. Treatment of epilepsy ........ cc eeccecceceeeeeeteeeneeeeeeeeeeeeeeeseeseaeeesseseseesseesaes 28
LLG: ASSIS MUGSsic nsintiinmnnsiiniinines sth cca atua RST maa oe aeRNR Bl
1.2. Clobazam (CLB)...........ccssssccssssssssccssssccsssssssccscssssccsecssssscccssssccessssscssescssssesees 35
L.2. 1, SCAT: Of BCUOM.....nannenennnncnnenwnsib in mnmib thi lssc 5siSTR 36
Meats EARy Nreeraremerareo cere ecanraereReap tesmrareeanNNcreememmanmeone 36
1.2.3. Metabolism ........ccccececceseeeeeeeceeceeeeeeeeceseeeeeaeeaececsecsessessscssseseeseeseeseenasees 37
L2A. AdveMUG CHSC cscssccranaensansssnan a s5 esas snseneenuneanenmnes samncemsnsmnemMmnmessans 39
4
1.2.5. Drug interactions ......ccceccccccececeseeseeseeseeeeseeseeeeeseceeeeaeeaeeaesaeeaeeaeeaeeaee 39
1.2.6. USCS... ccceeccceseesecesecetecseceeceeeseceseceeessecsaeesseseeseseseseseseeeeseeeseeaeessecseeaeenaee 39
1.3. Vigabatrim............cceccsccescccecceccsccsccecseecceseesesenssesenssessenseeseeseesesaes40
1.3.1. Mechanism Of action... ceeeceeeeeseeseeeeesecsessecnsesessecsssssessessessesseeseeseenee 4]
D322. PBEMOETTSTGS, <n ecannnsemnssisniitmnnnon nb dibin sian sain AS RTR RRASANTE 41
1 3a MGBOLISII. secsmssnmsvecarmon amanmzeaenncmnnanrseRRREREETAESTRSERRUTTE ER 42
1.3.4. Drug interactions ........ccccccccccessceseceseceeeeneceeecneceaeeeeeseneeaeceaeeeeseeseaeenseeate 42
1.3.5. Adverse drug effects ......cccccccccccsccsecesesseceeeeeeeaeceseeeceseeeaeseeeeeeeseenseeaes 42
1.3.6. USOS...ccccccccesceceseeeeseeeeseeseeeeseceeeeeeeseeeceecesseeesseeessessesecsessesecsussessesessesagegs 43
LA. Pharmacogeneuts cenic 44
14.1, Genetic variations in RUMAH SENOME ccccrssssscncmaccnnonmmemmaesrremmmamrensaas 46
1.4.2. History of pharmacogenetics 00.0... cceeceeeeeeesreeeeeeseseeeeseesseeseesseseeeseesaes 48
1 AS. WHER G6 WE TOW?nnncdc.oeECTS 54
1.4.4. Translation of pharmacogenetics into the CHINIC.....eeeeee eeeeeeeeeeeee 57
1.5. Aims of the thesis..............csssccsssssscsssoscssecessssesscsesscseseserseessneceesseeeesseeessnsseens 62
Chapter2 63
GABAtransaminase — characterisation of phenotype-genotyperelationship 63
Dds. MCRHOGSscsissserccscanersnaasssnesvnnssnsnvonsancnnsvonsnesvoncaesavonseunesenesenserneccsususeanersesauaneeonsens 66
Dido, ¢ NABUBTIAIS or excecscrrceseqersemioersnensnaxsvnnswnnementnneveneunnonnenonsnannnannnnas sist Sites Tai 66
22.2. StyPOPSaise oases eoareseereeracmmmsmmmnenmemumcessmeonnameeceneeneereees 66
2.2.3. Platelet isOlation.........ccccceccececeeeseeeeeeseeeeeseeseeeseeseecsecssessseesaseseseseeneenaes 67
2.2.4. GABA-T assay standardisation .............-r-0s00sososs once saoncasasesvenssessnavonennexase 68
5
2.2.4.1, GABA-T ACtIVILV .eececcccceesceeeeteceneenseeneeeseensesicesaecnseeeesaeseseeneseaesneeeseenages 68
2.2.4.2. Assessment ofstorage on GABA-TACHIVItY .oeeececceccetteeteeeteetetteeeneeneees 71
2.2.4.3. Measurement ofGABA-Tactivity using a 96 well plateformat........... 71
2.2.4.4. Assessmentofthe optimum time requiredfor the 1° reaction... 71
2.2.4.5. Effect ofthawing on platelet GABA-T ACTiIVILY ..eceecescesceeseteeseeteenseees 71
2.2.5. Prediction of putative functional SNPs in the ABAT gene... 72
2.2.6. GENOTYPING oo. eeeeceececcceseceteeneeeeeeeecseeeeeesecsseeseessesseeessceeeesseeseesseeseeeueegs 72
2.2.7. Genetype- pheietype cofrelanGn.........canciononmmomnee 76
2.2.8. Statistical analyses ........cccccesecccceseeseceeeeneceeceeeeeeeeeeeeeseeeseeneeeeesseeseaee 76
2.3. RESUIES ......sccsssccccssscccscccsccsccrsccceccscssscescssscccscscecesessscsosscsessscssossscsssecseseessecesseees 78
2.3.1. GABA-Tactivity is dependenton platelet isolation method.................. 78
2.3.2. GABA-Tactivity is not affected by storage... cee eeeeesseeteeneeteeesees 79
2.3.3. GABA-Tactivity using a miniaturised assay 0.0...cscsee eeeeeeeees 79
2.5.4, Optima time required forthe Tst TEACHONcconnonsonmsemcmmmer enn 80
2.3.5. GABA-Tactivity after removal from the freeZer.........eeeeeeeeeeeeees 81
2.3.6. Inhibition by vigabatrin (VGB)...... cece eeeeeeeeeseeseessseesseseseeesseseseeees 81
2.3.7. Putative functional SNPs predicted in ABAT...........:ccsssssesnessesssesensees 83
2.3.8. Allelic frequency of the selected SNPS.......c.cccececeeeceseesseeseseseeseeeseeees 84
2.3.9. Genotype Phehotype COClNOHscence86
DAs DISCUSSION esvsxnceasxcexansnesaravexenecessansnanneneneunanvensnpraescasnsensrernsnneesnennneeueseneseoseseansbiei 89
Chapter3 96
Estimation of GABA-Tactivity in patients with vigabatrin-induced visualfield
defects 96
Picts, UTTARseparacesncexssbaantenstnesionpeerennnstinndnnshecnneastatinhadteinasdesiisy Gbiediatdadechiadbiaiauaie 102
SB desWALIEo orss secon sacsessereUNWEITERASERRSTHA102
3.2.2. SUDJOCtS.... ce ccccccccccccsccessecssecesseeseccseecsseecsecessecseceseeecseseseceseeseetenseeenaees 102
3.2.3. GABA-T activity... ce ececccsceeseeceeeeenecneceecneceeceeceeceseeeseeeeeeeaeeaeeeesaeeaeeats 104
3.2.4. Statistical amalySes...... ce eeeeceseeseceeceeeeteceseceeeeeeeseseeeeeesseeeneeeeesneeseeeeaee 105
SiS IRECHIG scnescesncessessnacssssscsanncxmmnvancensonvenaswnascsannuscrsnansncsnnnuaNinsuseuTUas sxaRSTSNUSERSAREROND 106
3.3.1. GABA-ST activity.....ccccccccccccsscccseccsssccseccsseecseeeeseesecesseceseeeeeesesaeeneees 106
3.3.2. GABA-Tactivity in patients: ......c ce eeececeeeeeeeeeeneeeeeeeeesseseesaeeseeeaeenas 107
D4, DisCis§Gitsccscnsnavcannncmnmeninnnnncemnenmama108
Chapter4 115
Developmentand validation of an assay to simultaneously determine clobazam
andits active metabolite N-desmethylclobazam by HPLC...........eee115
4.2. Methods...........sccsssccssssscsssssccsscccssccesssscssssscesssssesssssesssssessssssssessssssessescessesesssesenes 118
Ano, REACenis BiG CHERICA5 rercosnessnsenannmnmcnmecreamer: 118
A222, EQuipMenntt..........ccccssocceseronssenenensneveoncevenbeeds dda ca bah cosa eta vets soveesesenezueys 118
Deis seEO)POOpgs cmaaerar ar cstaremraomermeenae omenUeno 119
4.2.4. Preparation of stock SOlUtiONS......... cc eceeceeeeeeeeeeeeetseeeseeeeeesseesseeeeeenee 121
4.2.5. Preparation of calibrators, quality controls and internal standard........ 121
4.2.6. Chromatographic Conditions...........cceeeescesscesecseeseceeseseesseeseseseeeaeeneey 122
4.2.7. Method validation... cccceceeseeseeseeceeseeseeeecneceeeneceecseeeeeeaeeaeeaeeaeeaeeaeens 126
Mecdeaths SRUAMALLILY WING) TROVELY svrcsicnsn coxcesasistnce ttt siettt hthsad sds itheARdi L27
AD), DIGI UTASIS scopcecemceeomeesnmscetsaenmsnmannanenenvesemaneen vammomaressanmemmeurennmenets 128
4.2.10. Measurementof clobazam and N-desmethylclobazamin patient
SAMPLES 0... cceesccecceseessessceeseesecssesseceseesecesecesecesesseessseeeessceseeseceseseeeeseneeneeeasenses 128
AS. Rests ssssnscinsssnansmnnncecmmeumnsssamaROTROTTERCRTERNEOAIES 129
4.3.1. Detection & chromatographybythe isocratic reverse phase HPLC
Meth” 00... eeeeeeeeeeeeeeseeseeseeseseceeceeeeeseeeeaeeaeseceseeseseseeeeeseeeeeesaeeseeaeeneeeeentens i
4.3.2. Detection & chromatography by the gradient reverse phase HPLC
Method oo... eeeeeeeeeeeseeeeseesseeeeeseceseceeeeseceeeseceeecseeeseseeeeaeceseseeeeaeeeaeessesnsesaeeeeed 133
4,3:3., ASSAY VALIGATION..........-ncrnnnnrensnnanennenesinsanncanntinintnannnc aida asked Steu si iesilaleaisai 137
4.3.4. Stability and reCOVETY oo... cee eceeceeeceseeeeeeeeeeeeseeeeeeeeeeeeneeensesaeesseeeeeaeed 141
4.4, DISCUsSiO1t,...r..ccseeovecersconsssopeenrtersesesusonseqreysonsevqesesrssscanseendasensssasisssuuasasbassansiwasts 143
Chapter 5 148
The impact of CYP2C19 polymorphismson the metabolism of clobazam, its
efficacy and toxicity 148
5.2. Methods..........cssssssssssssscsscssssssssssssscsssssssssssssesssssssssssssssssssssesesseeseesecseessesensenses 153
5.2.1. Study population 153
5.2.2. Measurement of clobazam (CLB) & N-desmethlylclobazam (NDCB)
NEVGIS. a0 50 cn. 23 aan axanveanse marcus etisnmennnsnean canes cememaReneeAeRnERERRERERNDS 155
5.2.3. Selection of SNPs in the CYP2C19 gene...eeeceee cesses eeeeeeeee 155
5.24. GROWPING .5.0.007.000nmmeanmmnmmeniRERONERET la?
5.2.5. Statistical Analyses ........cecceceeseeseceteeeeeeseeeseeseesseessesseeeesessseeeeseesesnaee 157
5.3. FROSUIES:...nceorserensserssesnssocaisaiineisissisiassdeatsarcssaneeERIKARSNTENENTE 159
dg SEMIS PURPLEcs...cesstacit eaacncatnasi ra metaaneeNCe RRNRRERR 159
3.3.2, Selection of putative functional SNPs in CYP2C19 scrscsesssmesssacnsvaxencass 160
5.3.3. Allele frequencies of the selected SNPS... ceeceeseeereeeeeeteeseeeneeseeenee 166
5.3.4. Association between CYP2C19 genotypes & clobazam
PHARHIACOLISHCS cccssassassssmereesnauseaerranearERROR 172
5.3.5. Association between CYP2C/9 genotypes and the efficacy of CLB ... 178
5.3.6. Association between CYP2C/9 genotypes and tolerance to CLB........ 183
5.3.7. Association between CYP2C19 genotypes & adverse effects to CLB. 184
BA. DISCUSSIO0 cccccsncsreemxoncenncemnccenerenemennenneanemenexenennemnencessaeumnnrennesnesmenecomenenennene 186
Chapter 6 193
General diSCUSSION...........c:ceceeeeeeeseeseeeeeeeeseeseeaeesecsecsecsessecsscsscssesessssesseseesesnaeees 193
BiblioaPhywsssvscascuscsescecsasaesxssnanenvcanccnsvecesncesunennesusvessanmacesvonenenenainsernnesmeansoaseacsuoerens2002
APPOHOINsos. ane cnn 000 cxnwen ses wen 150 00 608 008 908 400 0b0 999 mae TERETE EEE REERORRERNRETED221
List of figures
Figure 1.1. Schematic diagram representing the factors predisposing to, and
factors inhibiting seizure production. 26
Figure 1.2. A schematic representation of an action potential 28
Figure 1.3. Schematic diagram depicting the action of antiepileptic drugs on
the GABA synapse 34
Figure1.4. Metabolism of clobazam 38
Figure 1.5. The effect of SNPsin various parts of the gene 48
Figure 1.6. Shows the major developmentsin the history of
pharmacogenetics. 50
Figure 1.7. Different phases & associated challenges on the roadto clinical
implementation of pharmacogenomics 58
Figure 2.1. Showsthe 2 identical monomers of GABA-T with vigabatrin
boundto the active sites and pyridoxal phosphate 64
Figure 2.2. Schematic diagram showingplatelet isolation using OptiPrep™
as the density gradient 68
Figure 2.3. Shows the schematic representation of GABA-T assay 70
Figure 2.4. A schematic representation of Taqman chemistry 74
Figure 2.5. Allelic discrimination using Taqman technology 75
Figure 2.6. GABA-T activity using platelets isolated by different methods 78
Figure 2.7. Shows the GABA-Tactivity of platelets isolated the next day (0
week) and after one week. 79
Figure 2.8. Shows the GABA-Tactivity of platelets read on a 96 well plate.
80
10
Figure 2.9. Shows GABA-T activity when the first reaction was stoppedat
10-90min. 80
Figure 2.10. Shows GABA-T activity of platelets measured 30-150 min after
taking the platelets out of the freezer. 81
Figure 2.11. Showsinhibition of GABA-T activity by various concentrations
of vigabatrin. 82
Figure 2.12. A schematic representation of selected SNPs mapped on to
ABATgene. 83
Figure 2.13. An exampleofallelic discrimination plot of rs1731017 using real
time PCR. 84
Figure 2.14. Correlation of GABA-T activity in 32 healthy volunteers with
different SNP genotypes. 87
Figure 2.15. GABA-T activity in 32 healthy volunteers with different
genotypesfor the SNP rs1731017. 88
Figure 2.16. Showing the SNP rs1731017 in GABA transaminase enzyme.
94
Figure 3.1. Showing the structures of GABA (3.1a) and vigabatrin (3.1b). 97
Figure 3.2. Normal positions of the isopters. 98
Figure 3.3. Goldmannvisualfields 37 monthsafter start of vigabatrin
treatment (case 1, top), 28 monthsafter start of vigabatrin treatment (case 2,
centre), 38 monthsafter start of vigabatrin treatment (case 3, bottom). 99
Figure 3.4. GABA-T activity(expressed as nm/mg/ml)in platelets on the Y-
axis, using blood from onefasting healthy volunteer and blood withdrawn 2
hrs after food intake. 106
Figure 3.5. GABA-T activity (nm/mg/ml) in patients with and without
vigabatrin-induced visual field defects. 107
11
Figure 3.6. The values of individual patients are shown in the scatter
diagram. 108
Figure 4.1. Summaryof the extraction procedure usedto isolate clobazam
and N-desmethylclobazam from plasma . 120
Figure 4.2. Chemical structures of clobazam (CLB), N-desmethylclobazam
(NDCB) and the drugstried as internal standards. 123
Figure 4.3. Chromatogram showing chloroquine and primaquine used as
internal standard underthe isocratic HPLC conditions. 130
Figure 4.4. Chromatogram showing clozapine used as internal standard
underthe isocratic HPLC conditions. 131
Figure 4.5. Chromatogram showing primaquine under the isocratic HPLC
conditions. 132
Figure 4.6. Chromatograms of clobazam and N-desmethylclobazam using
primaquine (A) and chloroquine (B) as internal standard 134
Figure 4.7. Chromatograms of clobazam and N-desmethylclobazam using
clozapine (A) and primaquine (B) as internal standard 135
Figure 4.8. Representative chromatogramsof clobazam and
N-mesmethylclobazam. 136
Figure 4.9. Plots of standard curves to determine the concentration of (A)
Clobazam and (B) N-desmethylclobazam. 138
Figure 4.10. Chromatograms representing samples taken from two patients
who were on clobazam. 140
Figure 5.1. Chemical structures of anti-convulsants (a) clobazam and (b)
diazepam. 149
Figure 5.2. Shows the summaryofthe selection criteria used with the list of
SNPsselected to genotype. 160
12
Figure 5.3. Showslinkage disequilibrium (LD) of CYP2C719 gene. 164
Figure 5.4. Showing the SNPsselected by various programmesandthefinal
selection of SNPs 165
Figure 5.5. Showsthe association of the CYP2C19*2 genotypes
(rs4244285) with the mean NDCB/CLBconcentration 174
13
List of tables
Table 1.1. Drug options Dy SeIZULE tYPe.....eeeeceeeeteeeteeteeseeeeseeseteeeeseeaeeeenees 29
Table1. 2. Drug options by epilepsy SYNCrOMe ......... cc eceessesseceteeteeeeeeeseeeeeeeseeeeeee 30
Table 1.3. Summary of the proposed mechanismsof antiepileptic drug action .. 33
Table 1.4. Different types of inter-individual variations in human genome........... 47
Table 2.1. Putative functional SNPs in ABAT to genotype...eeeeeeeeeeeeeees 83
Table 2.2. Allelic frequency of genotyped SNPsin ABAT.........cccceceeceeseesteeteeeeees 85
Table 2.3. Demonstrates that the SNPs were in Hardy-Weinberg equilibrium
(as shown by the X? test) ...cccccccccccsssssssesssecssesssecsseesssessssesssesssecsssesssessssessseesssesssvetseeeaes 85
Table 3.1. Showing the demographic characteristics of patients recruited for
RS RYeconnnnianncreninsineuninnnt snetnnninnn cectensinoste enn sein nomneceamnnennieissine AATECIRN 104
Table 4.1. An outline of the mobile phase gradient programs consisting of
ammonium acetate 50mM (pH=5) and acetonitrile (ACN) buffer to elute
Clobazam and N-desmethylcloDaZam ..........ccccccsecscssccesseseceseeseeeeceeeeaeceeeeseeeneeeaeenee 124
Table 4.2. HPLC characteristics for the gradient run of reverse phase HPLC.. 125
Table 4.3. Intra-assay precision and accuracy of the low (LQC), medium
(MQC) and high (HQC) quality control samples of clobazam and N-
AesMethylCloDAZAM oo... ecececcecceseeseseeseeseseeseeeceeeseeeenecseeeeeeseeeeeesseeeenseseeessessesseseeeeeseees 139
Table 4.4. Inter-assay precision and accuracy of the low (LQC), medium
(MQC) and high (HQC) quality control samples for clobazam and N-
CesmethylCloDaZam .........cccccccccescssscsscescescesceeeeseeseeseeaecaececeeceececeseeeseceseessesssseeaseaeeseens 139
Table 4.5. Comparison of the QCs (Low Quality Control (LQC), Medium
Quality Control (MQC) & High Quality Control (HQC)) of clobazam............0..... 141
Table 4.6. Comparison of the QCs (Low Quality Control (LQC), Medium
Quality Control (MQC) & High Quality Control (HQC)) of N-
AesmMethylCloDaZaM .........ccccccescccesceseeseseeseeeeeeseeeeseeeeeeceessecseeesseeseseesessesessesessesseeseeaseas 142
Table 4.7. Percentage recovery from plasma at 3 concentrations, (LQC-
70ng/ml, MQC-300ng/ml and HQC-762.19ng/ml) of clobazam, and (LQC-700
ng/ml, MQC-2000ng/ml and HQC-6097.56ng/ml) of N-desmethylclobazam ..... 143
Table 5.1. Demographic characteristics of patients in this study .......0.00.. ue. 159
Table 5.2. Proven functional SNPs in CYP2C19 from CYP2C19 allele
NOMENCl]atUre WED SitC o.oo... eeececeeccecccceceeeessssessescecccccceesesesseeeeeeeeeeceeeeesseeeeeeeeeeeseeeeees 161
14
Table 5.3. Tagging SNPs in CYP2C19 identified by Haploview using
HAPMAP data... ccccccccccccccsscesscssccseseseesssceccsseesecesecssecsecsscesecsaeeseceseeseeesesseeeaeeseeeseeeaees 163
Table 5.4. Allelic frequency of genotyped SNPs in CYP2C19ues 166
Table 5.5. Shows the SNPsin Hardy - Weinberg equilibrium (as shown by
the X? test) .occccecccsccscssesssessesseessesssesssesssecssesssessuessesssesssesssesssesssesssessesssecsssssesasesssecsvessess 167
Table 5.6. Demographic characteristics of patients stratified by genotypes at
SNP 184244285 ooo ccccccscescssesseseeseecsesscsecsecsesecsecseeecseeeseeseescsecseneceeaesaeeeeecaeneeeeeaes 168
Table 5.7. Demographic characteristics of patients stratified by genotypesat
SNP 1812248560 0000... ccccccccccccsccssesscesccscesceseeseeseesecsessecsecseeseesecsaeseeseesesseeaeeeceeeeeseeeeens 169
Table 5.8. Demographic characteristics of patients stratified by genotypes at
1811568732... ccccccccccccscescsscscescseesecscsecsesscsecsecseecsecseeecsecseecaeeseeeseeceeeaeereneeney 170
Table 5.9. Showing the comparison of pharmacokinetic parameters of
CLIss.sa 0 sts oo cm rena rmerenemanennemarananmmaneemRsamRARUReTaR AR AANNRARTSTE ONE UERAENOTES MERBTRRENESE 172
Table 5.10. Association between the CYP2C19*2 (rs4244285) genotypes
arid Globazairi PHANMMECOKINGUCS. ..csccccccnasevesassaunsnsnancnamnmecurnenenaasnsxasnes sexe ammsenmcomes 173
Table 5.11. Association between CYP2C19*17 rs12248560 genotypes and
clobazam and NDCB COneceniralions ..........-ninaisssncasscrcastsncecene easeasec: 175
Table 5.12. Association between rs11567832 genotypes and clobazam
PHArMACOKINETICS.........ceccceccccesceececceseeseeseeseeseeaeeseesececececeeeeceeessesaesaesaeceeeseeeseeseeegs 176
Table 5.13. The distribution of pharmacokinetic parameters in patients who
had inducers as co-medications (1) compared with patients who were not on
these CO-MEICATIONS (0)...eeeccecceceeeteeteceeceeceeeeeeeseeeeeseeaesseesetseeaeeeessessessessesseesee 177
Table 5.14. The details of the multiple regression done for NDCB/CLBratio.... 178
Table 5.15. Efficacy of clobazam amongstthe rs4244285 genotypes................ 179
Table 5.16. Shows the parameters of the logistic regression model for
SEIZUPS THORN «ar nneevcccrn.nininiinsiais i ccaI RRIASERE ROSACEA EREN HSN UACES ED MV SET 180
Table 5.17. Shows the parameters of the logistic regression model for
SHIZUPS TEBGOIN canenennnroveaanennansannrannannanoeiniiitth isha shteh UO USARGiaN mR MRNA ER TNRDR 181
Table 5.18. Shows the parameters of the logistic regression of 50% seizure
PEC UICHOM .pycercrcesnrnernensnsaeneumeecwsemonsnaemanaenasnsssnnasasv sannsiniled8 58.0 5 5ISIAHORTON 182
Table 5.19. Showing the parameters of the logistic regression of 50%
SEIZUPE FEGUCTION .o....cccccceccceseeseseeseeeceeseeeeseeseescaeeseececsecseseeseescsesseesseessessecaseasseeasiesaey 182
Table 5.20. Showing the distribution of pharmacokinetic parameters in
patients who developed tolerance (1) and patients who did not develop
tOlErANCE (0). o.ecccccccseeceseteeseeeeeseeesesceeesesceesscssescsesescsssesscsesessssseesseeasseeesssseeeseeseneeeey 184
15
Table 5.21. Association between rs11568732 genotypes and adverse
FEACTIONS oo. eeeecccscssscesscssecsscessceseesecesecssesecesecseecsesesesesscsecesecesesseesseeeseseeeseseaeseceaeenaes 185
Table 5.22. Association between rs4244285 genotypes and adverse
FEACTIONS 0... eeecsscccscescescesceeseesesecseecesessesecseeseeseseeseeaccsseeaseasseeaeeaceeseeasaeseeaseasseeaseeeeee 185
Table 5.23. Association between rs12248560 genotypes and adverse
PRSEROTIGA scccamrscancesasseeanasnsmsmansmeee assureceeetaeenSLSSERUT 186
16
ABAT
ACTH
ACN
AEDs
AET
ANOVA
bp
BRCA 1
BRCA2
BSA
BZDs
C/D
Cr
Cat
CBZ
CNS
CLB
CLOPS
CNV
CYP 450
DNA
EEG
EM
ESE
ESM
FDA
FBM
FRET
GABA
GABA-T
GBP
Abbreviations
4-aminobutyrate aminotransferase gene
adrenocorticotrophic hormone.
acetonitrile
antiepileptic drugs
2-aminoethylisothiouronium bromide hydrobromide
analysis of variance
basepairs
breast cancer1, early onset
breast cancer2, early onset
bovine serum albumin
benzodiazepines
concentration divided by dose ratio
chloride
calcium
carbamazepine
central nervous system
clobazam
clobazam prospective cohort study
copy numbervariation
cytochrome P450
deoxyribonucleic acid
electroencephalograph
extensive metaboliser
exon splicing enhancers
ethosuximide
Food and Drug Administration
felbamate
fluorescence resonance energy transfer
gamma-aminobutyric acid
GABAtransaminase enzyme
gabapentin
17
GC-MS
G-6PD
GWAS
H-W
HER2/NEU
HQC
InDel
IS
K
LEV
LC-MS
LEC
LTA
LTG
MQC
MAF
NADH
NAD*
Na"
NC
NCBI
NDCB
NICE
nm/mg/ml
OCP
OxC
PB
PCR
PAR
PHT
PM
PPI
gas chromatography—massspectrometry
glucose-6-phophate dehydrogenase
genome wideassociation study
Hardy-Weinberg
humanepidermal growth factor receptor 2
high quality control
insertion/deletion
internal standard
potassium
levetiracetam
liquid chromatography-mass spectrometry
low quality control
lymphotoxin-a
lamotrigine
medium quality control
minorallele frequency
dihydronicotinamide adenine dinucleotide-coenzyme Q
reductase
dihydronicotinamide adenine dinucleotide
sodium
negative control
National Centre for Biotechnology Information
N-desmethylclobazam
National Institute for Health and Clinical Excellence
nanometre/milligram/ml
oral contraceptivepill
oxcarbazepine
phenobarbital
polymerase chain reaction
peak area ratio
phenytoin
poor metabolizer
proton pumpinhibitor
18
QC
RMP
RNA
sec
SNP
STR
SEM
SV2A
TCA
TDM
TGB
TPM
UM
VGB
VKORC1
VNTR
VPA
VVFD
VFD
ZNS
5HT3 receptor
quality control
red bloodcell
resting memberane potential
ribonucleic acid
seconds
single nucleotide polymorphism
short tandem repeat
standard error of the mean
synaptic vesicle protein 2A
tricyclic antidepressant
therapeutic drug monitoring
tiagabine
topiramate
ultra rapid metabolizer
vigabatrin
vitamin K epoxide reductase complex subunit 1
varying numberoftandem repeat
valproic acid
vigabatrin inducedvisual field defect
visual field defect
zonisamide
5-hydroxytryptamine receptor
19
Publications and communications
Prathibha Jose, Ana Alfirevic, Tim P Green, Munir Pirmohamed. GABA-
Transaminase — characterisation of phenotype-genotype relationship. British Journal
of Pharmacology, Winter conference, Brighton, 2007. Poster presentation.
Prathibha Jose, Ana Alfirevic, Tim P Green, Munir Pirmohamed. GABA-
transaminase — characterisation of phenotype-genotype relationship. Cold spring
Harbour/Wellcome Trust pharmacogenetics conference, Cambridge, 2007. Oral
presentation.
Prathibha Jose, Ana Alfirevic, Tim P Green, Munir Pirmohamed. Developmentof a
novel HPLC method for the simultaneous estimation of clobazam and its active
metabolite N-desmethylclobazam. Bristol-Liverpool Postgraduate conference, 2008.
Oral presentation.
Prathibha Jose, Ana Alfirevic, Tim P Green, Munir Pirmohamed. GABA-
transaminase — characterisation of phenotype-genotype relationship. Manuscript in
preparation.
Prathibha Jose, Ana Alfirevic, Tim P Green, Munir Pirmohamed. Development of a
novel HPLC method for the simultaneous estimation of clobazam andits active
metabolite N-desmethylclobazam. Manuscript in preparation.
Prathibha Jose, Ana Alfirevic, Tim P Green, Andrea Jorgensen, Munir Pirmohamed.
The impact of CYP2C/9 polymorphismson the metabolism, efficacy and toxicity of
clobazam. Manuscript in preparation.
20
Abstract
Both vigabatrin (VGB) and clobazam (CLB)are effective antiepileptic drugs (AEDs)
that act on the GABA system. There is significant variation in the efficacy and
toxicity of many AEDsincluding VGB and CLB. The aim of the thesis was to
investigate the mechanismsresponsible for the variation in response to VGB and
CLB.
VGBis used as add-on therapy and is particularly important in the treatment of
infantile spasms. Howeverit causes visual field defect (VFD) in around 30-40% of
patients, the aetiology of which is not yet fully understood. Genetic variants in the
drug target could be important. VGB inhibits the GABA transaminase (GABA-T)
enzyme which catabolises GABA, the primary inhibitory neurotransmitter in the
central nervous system (CNS). Weinvestigated the effect of genetic variants on
GABA-T activity in healthy volunteers. A platelet GABA-T activity assay was
standardised. The nonsynonymous single nucleotide polymorphism (SNP),
1s1731017, reduced GABA-Tactivity in healthy volunteers, although there is no
evidence to suggest that it is associated with VFD in patients. GABA-T activity,
measured in platelets of patients with VGB-induced VFD was 2-fold lower than in
patients who had been on VGBbut had not developed VFD. The molecularbasis of
this is unknown,but needsfurther investigation.
CLBis efficacious in manytypes of epilepsies, but is also associated with tolerance.
Drowsiness, dizziness and weight gain are its major adverse effects. Thereis a large
variation in dose, plasma concentrations and the occurrence of tolerance among
patients. Genetic variants affecting the pharmacokinetic pathways could influence
the metabolism, efficacy and toxicity of CLB. CYP2C19 is the main enzyme
al
involved in the metabolism of CLB and its major metabolite is N-
desmethylclobazam (NDCB). Therefore we investigated the influence of CYP2C19
genetic variants on the metabolism, efficacy and toxicity of CLB and NDCB.First
we developed a high pressure liquid chromatography (HPLC) assay to estimate the
concentration of CLB and NDCB.This assay was reproducible with high specificity
and sensitivity. CYP2C19*2 (rs4244285) homozygous minorallele patients had 5.7-
and 4.7-fold higher NDCB concentration than homozygous major allele and
heterozygous patients, respectively. There was nosignificant difference between the
homozygous major and heterozygous groups. The numberof patients who achieved
more than 50 percent seizure reduction (p=0.05) and seizure freedom (p=0.014) was
significantly higher in those with homozygous minor alleles when compared to
patients with heterozygous and homozygous major alleles of CYP2C19*2.
CYP2C19*2 was a covariate for NDCB/CLB ratio and efficacy. Patients
homozygous for CYP2C19*17 (rs12248560) were on a significantly higher dose of
CLB than patients lacking this allele (v=0.016). rs11568732 offered protection
against the developmentof dizziness (p=0.04).
In summary, in this thesis, I have focused on 2 drugs acting on the GABAsystem.
The identification of a phenotypic difference in GABA-Tactivity between patients
with and without vigabatrin induced visual field defect (VVFD) is a significant
finding which needs further investigation. CYP2C19 plays an importantrole in the
metabolism of CLB. The data show that polymorphismsin the CYP2C/9 geneaffect
the pharmacokinetics of CLB, and importantly may also influence efficacy and
toxicity. The data presented in this thesis show that further investigation to
individualise therapy with VGB and CLB,based onboth clinical and genetic factors,
is a research area that merits further attention.
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Chapter 1
Introduction
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1.1. Epilepsy
Epilepsy is a common chronic neurological disorder characterized by spontaneous
recurrence of unprovoked seizures. Epilepsy affects people of all ages. The disorder
is not fully understood; therefore classification of seizure types and syndromes is
ongoing and often not possible in many patients. Many factors affect the
classification of epilepsy, complicating the assessment and treatment of individuals.
These include concomitant medical conditions, learning disabilities, neurological
deficits, psychological, psychiatric problems and progressive conditions (Forsgren,
2004).
1.1.1. Classification of epilepsy
The most accepted classification of epilepsy is the International League Against
Epilepsy classification which was published in 1989 (Dodson, 2004). However,
recommendations to alter this classification have been made (Berg, et al., 2010;
Shinnar, 2010). The new information that has accrued through modern neuroimaging,
genomic technologies, and advances in molecular biology has now been incorporated
in this classification. There is a departure from the previousclassification which was
mainly based on seizure patterns, development (focal or generalised), associated
features (loss of consciousness) and epilepsy syndromes. The present classification
has tried to look at the seizure presentation, seizure type, epileptic syndrome,
aetiology and associated mental retardation. This helps the clinician to make a better
diagnosis and administer therapeutic strategies to patients even if they depart from
the prototype. The completeclassification is reproduced in appendix 1 (Commission
24
on Classification and Terminology of the International League Against Epilepsy,
2010).
1.1.2. Epidemiology of epilepsy
The incidence of epilepsy in developed countries is about 40-70 per 100,000 people
per year. Recent studies have suggested that the incidence of epilepsy in developing
countries is approximately twice that in industrialized countries. Poor sanitation,
inadequacies in the health system and higher risk of brain infections could be
contributing to the higher incidence found in the former. 90% of epilepsy cases
worldwide are from the developing countries. The prevalence of epilepsy in
developed countries is approximately 4-10 per 1,000 people, and that in developing
countries is about 6 to 10 per 1,000 with the cumulative lifetime incidence being
about 3%. Around 50 million people in the world have epilepsy (Forsgren, 2004).
1.1.3. Aetiology of epilepsy
The aetiology of epilepsy in a large proportion of patients is not known (50-70%).
Other causes include head trauma, central nervous system infections and tumors. For
the younger population, perinatal complications, congenital, developmental and
genetic conditions are the most commoncauses of epilepsy. Cerebrovascular disease
is the most commonrisk factor in the elderly. A family history of epilepsy seems to
increase the propensity to develop epilepsy (Forsgren, 2004).
1.1.4. Mechanismsof seizure generation
Brain injury due to the above causes is important in the aetiology of epilepsy. Recent
evidence shows that an epileptic region of the brain consists of multiple small
distributed hyperexcitable networks. Abnormal discharges which are not detectable
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clinically occur in this network. Clinical seizures occur when micro seizures enlarge
and affect the surrounding normal regions of the brain (Dichter, 2009).
Neurochemically, an imbalance between excitatory and inhibitory neurotransmission
processes has been proposed (Figure 1.1). The resting membrane potential (RMP) of
a neuron is -70mV. Anyofthe factors which increase this membrane potential can
predispose to seizure production. Sodium influx, calcium currents and paroxysmal
depolarization raises the membranepotential which could lead to seizures. Potassium
efflux, chloride influx and low pH tend to lower the RMP,thereby inhibiting neurons
and preventing seizures. Seizures occur when the factors which predispose to seizures
predominate over those which inhibit seizures, as illustrated in Figure 1.1.
 
 Factors predisposing
to seizure production: Factorsinhibiting
  
Na’ influx seizure production:
Ca™ currents K ene
Paroxysmal CI influx
depolarization Low pH  
 
 
    Seizure !!!!   
Control
 
  
Figure 1.1. Schematic diagram representing the factors predisposing to, and
factors inhibiting seizure production. An imbalance can lead to seizure
production. Na * - sodium; Ca‘ - calcium; K* - potassium; Cl ~ - chloride
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Neurotransmissionis facilitated by action potentials. An action potential is caused by
an exchange ofions across the neuronal membrane. During an action potential, due to
a stimulus, sodium channels open leading to an influx of sodium ions as shownin
Figure 1.2. This makes the neurons more positive and depolarized (from -70 mV to
+30 mV). The potassium channels then open causing an efflux of potassium ions,
leading to repolarization. The sodium channels close at this time restoring the resting
membrane potential as shown in the Figure 1.2. This is an excitatory postsynaptic
potential. Glutamate and acetylcholine facilitate this transmission. There are
inhibitory postsynaptic potentials in which negative ions flow into the cells or
positive ions flow out of the cells, inhibiting the propagation of nerve impulses.
Gamma aminobutyric acid (GABA)is an inhibitory neurotransmitter which reduces
depolarization of neurons. In epilepsy, there is repetitive firing of neurons, with
repetitive stimulation of inhibitory synapses. However the inhibitory events are not
successful in controlling the excitatory activity resulting in seizures. Calcium
channels are involved in neurotransmission in the thalomocortical region which has
been implicated in absence seizures.
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Figure 1.2. A schematic representation of an action potential
1.1.5. Treatmentof epilepsy
The treatment of epilepsy depends on the epilepsy type (Table 1.1), epilepsy
syndrome (Table 1.2), age of the patient and whether the patient is pregnant or not
(http://www.nice.org.uk/CG020NICEguideline). AEDs are the mainstay of treatment
of epilepsy. Around 70% ofthe patients respondto the currently available treatment.
Other treatment options include ketogenic diet and surgery.
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Usually drug treatmentis started with a single drug at low dose and slowly increased
at 1-2 week intervals. This enables clinicians to evaluate the clinical progress after
each changein dose/ drug andalso to avoid adverse drug effects. If patients still have
seizures after achieving the full dose of the first drug, the second drug is introduced
slowly. Information sheets about drugs are given to patients. Blood levels of drugs
are used to monitor compliance, possible adverse effects and reasons for incomplete
seizure control (http://www.nice.org.uk/CG020NICEguideline).
Table 1.1. Drug options by seizure type
 
 
       
Seizure type [First-line drugs Second-line ther drugs Drugs to be
drugs hat may be avoided
onsidered \(may worsen
seizures)
Generalised }Carbamazepine* IClobazam Acetazolamide [Tiagabine
tonic—clonic Lamotrigine” Levetiracetam [Clonazepam Vigabatrin
Sodium valproate [Oxcarbazepine‘{Phenobarbital*
Topiramate *° Phenytoin*
Primidone “*
[Absence IEthosuximide lobazam
Lamotrigine? Clonazepam
Sodium valproate [Topiramate*
Myoclonic Sodium valproate lobazam arbamazepine®
Topiramate aay Clonazepam bas
Lamotrigine xcarbazepine®
Levetiracetam [Tiagabine
Piracetam Vigabatrin
Topiramate*
Tonic Lamotrigine? lobazam Acetazolamide [Carbamazepine
Sodium valproate lonazepam henobarbital’ xcarbazepine®
[Levetiracetam [Phenytoin®
(Topiramate* rimidone’,°
Atonic Lamotrigine” lobazam cetazolamide [Carbamazepine’
Sodium valproate lonazepam henobarbital* xcarbazepine®
evetiracetam |Primidone “* Phenytoin*
opiramate*
Focal with/ arbamazepine* lobazam cetazolamide
without amotrigine” abapentin lonazepam
secondary xcarbazepine’,” evetiracetam [Phenobarbital *
generalisation [Sodium valproate henytoin® rimidone ““
opiramate *” iagabine  
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a. Hepatic enzyme-inducing AED.
b. Should be used asa first choice when the older drugs do not stop seizures or cause
adverse effects
c. Should rarely be initiated — if a barbiturate is required, phenobarbitalis preferred.
d. In children, for severe myoclonic epilepsy of infancy (see Table 2).
Adopted from NICE guidelines (http://www.nice.org.uk/CG020NICEguideline)
Table1. 2. Drug options by epilepsy syndrome
 
       
[Epilepsy First-line drugs Second-line |Other drugs rugs to be
syndrome drugs avoided
(may worsen
Seizures)
Childhood Ethosuximide Levetiracetam \Carbamazepine’ ,
absence epilepsy Lamotrigine° Topiramate* Phenytoin*,
Sodium valproate [Oxcarbazepine’
iagabine
lVigabatrin
Juvenile absence Lamotrigine” Levetiracetam Carbamazepine’,
epilepsy Sodium valproate [Topiramate* Phenytoin’,
}Oxcarbazepine’,
Tiagabine
'Vigabatrin
Juvenile myoclonic Lamotrigine? Clobazam Acetazolamide [Carbamazepine,
epilepsy Sodium valproate Clonazepam Phenytoin’,
Levetiracetam }Oxcarbazepine’,
Topiramate* Tiagabine
Vigabatrin
Generalised {Carbamazepine* Levetiracetam |[Acetazolamide [Tiagabine
tonic-clonic seizures qLamotrigine” Clobazam Vigabatrin
Sodium valproate Clonazepam
Topiramate *” Oxcarbazepine*
Phenobarbital’
Phenytoin®
Primidone “*
Focal epilepsies: arbamazepine® Clobazam Acetazolamide
cryptogenic, Lamorsine Gabapentin iClonazepam
symptomatic Oxcarbazepine *” evetiracetam _[Phenobarbital*
Sodium valproate  [Phenytoin* Primidone °“*
Topiramate *” iagabine
Infantile spasms Steroids Clobazam INitrazepam [Carbamazepine
Vigabatrin” Clonazepam xcarbazepine®
Sodium valproate
opiramate*   
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Benign epilepsy with [Carbamazepine* Levetiracetam |Sulthiame®
centrotemporal spikes|Lamotrigine” (Topiramate*
xcarbazepine *”
Sodium valproate
Benign epilepsy with {Carbamazepine* Levetiracetam
iparoxysms amotrigine” Topiramate®
xcarbazepine *”
Sodium valproate
Severe myoclonic lobazam Levetiracetam |Phenobarbital* {Carbamazepine*
epilepsy of infancy lonazepam Stiripentole Lamotrigine
Sodium valproate xcarbazepine®
Topiramate *” Wicabatrin
Continuousspike lobazam Levetiracetam (Carbamazepine*
wave of slow sleep lonazepam Topiramate® Oxcarbazepine*
IEthosuximide Vigabatrin
Lamotrigine”
Sodium valproateSteroids‘
_Lennox—Gastaut Lamotrigine” Clobazam Felbamate* [Cabamazeping
syndrome Sodium valproate Clonazepam xcarbazepine®
Topiramate *” Ethosuximide
Levetiracetam
[Landau-Kleffner Lamotrigine’. Levetiracetam |Sulthiame © [Carbamazepine’
syndrome Steroids Topiramate® Oxcarbazepine*
Sodium valproate   
a). Hepatic enzyme-inducing AED. b). Should be used as a first choice when the
older drugs do not stop seizures or cause adverseeffects. c). should rarely be initiated
if a barbiturate is required, phenobarbital is preferred. d) Steroids: prednisolone or
ACTH(adrenocorticotrophic hormone). e). Not licensed in the UK, but available by
importation. Adopted NICE
(http://www.nice.org.uk/CGO20NICEguideline).
from guidelines
1.1.6. Antiepileptic drugs
There is an armamentarium of AEDs available on the market to treat epilepsy
patients. AEDs can be grouped according to their major mechanismsof action. Most
of the AEDsact on a combination of ion channels but may also have other unknown
mechanismsof action (Meldrum, 1996).
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Mechanism of action of AEDs:
In a nutshell:
1. Some AEDsstabilize the inactive configuration of the sodium (Na’) channel,
preventing high-frequency neuronal firing, e.g., phenytoin, carbamazepine,
lamotrigine, oxcarbazepine.
Low-voltage calcium (Ca2" currents (T-type) are responsible for the
rhythmic thalamocortical spike and wave patterns of generalized absence
seizures. Some AEDsblock these channels, inhibiting the underlying slow
depolarizations necessary to generate spike-wave bursts, e.g., ethosuximide,
valproic acid.
The GABA-A receptor mediates chloride (Cl) influx, leading to
hyperpolarization of the cell and inhibition. AEDs may act to enhance Cl
influx, e.g., phenobarbital, benzodiazepines.
4, Glutamate, the main excitatory neurotransmitter in the CNS, binds to multiple
receptor sites that differ in activation and inactivation time courses,
desensitization kinetics, conductance, and ion permeability. AEDs that modify
these receptors are antagonistic to glutamate; e.g., felbamate, topiramate.
5. Carbonic anhydraseinhibition results in hyperpolarization and an increase in
6.
seizure threshold ofthe cells, e.g., acetazolamide.
Synaptic vesicle protein 2A binding: SV2Aappears to be important for the
availability of calcium-dependent neurotransmitter vesicles ready to release
their content. Levetiracetam binds to SV2A.
Table 1.3.gives a summary of the proposed mechanisms of AEDsaction
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Table 1.3. Summary of the proposed mechanismsofantiepileptic drugs
 
  
(AEDs) action
Established Na~ Ca2* kK" Inhibitory Excitatory
AEDs channels channels channels transmission transmission
PHT +++
CBZ +++
ESM +++
PB + +++ 4
BZDs +++
VPA + - ++ +
New AEDs
LTG +++ +
OxC +44 > +
ZNS ++ ++
VGB se ep
TGB +++
GBP +t + ++
FBM ++ ++ ++ ++
TPM ++ ++ ++ at
LEV + + +     
+++, primary action; ++, probable action; +, possible action.
PHT= phenytoin; CBZ = carbamazepine; ESM = ethosuximide; PB=
phenobarbital; BZDs = benzodiazepines; VPA= valproic acid; LTG=
lamotrigine; OXC = oxcarbazepine; ZNS= zonisamide; VGB= vigabatrin;
TGB= tiagabine; GBP= gabapentin; FBM= felbamate; TPM=
topiramate; LEV= levetiracetam
Data from Upton, 1994, Schachter, 1995,Macdonald and Kelly, 1995,
Meldrum, 1996, Coulter, 1997, White, 1999, adopted from Kwan,et al., 2001.
Many of the AEDspotentiate the effect of GABA. Figure 1.3 shows the AEDsthat
act on the GABA synapse. GABAis synthesized from glutamic acid by glutamic acid
decarboxylase enzymes (GAD1 and GAD2). Valproic acid and gabapentin increase
the production of GABA (Patsalos, 2005). GABAis transported to the vesicles by
GABAtransporters and released into the synapse. Valproic acid is proposed to
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augmentthis (Rowley,et al., 1995). Gabapentin increases the nonvesicular release of
GABA(Gotz,etal., 1993).
L- glutamic acid
Valproic acid
Gabapentin GADI
GAD2
Presynaptic
neuron
CattSABAVigabatrin
uccinic Gabapentin
semi aldehyde
  
  
(VGAT)
       Valproic acid
 
 
(GAT1)   
  
 
(GAT?) , GABA
oN Tiagabine PhenobarbitalValproic acid Benzodiazepines
Vigabatrin
GABA_ B GABA A
Receptor Receptor
Postsynaptic     
Neuron
Figure 1.3. Schematic diagram depicting the action of antiepileptic drugs
(AEDs) on the GABA synapse. GAT: GABA Transporter, VGAT: Vesicular
GABA Transporter, GAD- Glutamic acid decarboxylase, GABA-T- GABA-tr
nsaminase enyme
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GABAacts on its receptors - GABA A, GABA B and GABA C. GABA A and
GABAB receptors are ubiquitous in distribution in the central nervous system
(Bowery, et al., 1984). However, GABA is predominantly present in theretina.
Phenobarbital (Macdonald,et al., 1989; Twyman,et al., 1989) and benzodiazepines
(Macdonald and Kelly, 1995) act on GABA A receptors and bring about CNS
inhibition. From the synapse, GABA reuptake is facilitated by GABA transporters
(GAT1, GAT2 and GAT3). Tiagabine inhibits GAT1 (Braestrup, et al., 1990).
Valproic acid (Leach,et al., 1996; Sills, et al., 1996) and VGB (Leach,et al., 1996)
too are proposedto increase the concentration of GABA byinhibiting GABAuptake.
GABAis metabolised by GABA transaminase (GABA-T) enzyme. VGB (Lippert, et
al., 1977) and gabapentin (Leach, et al., 1997) inhibit GABA-T and raise the
concentration of GABA.
In spite of these drugs, around 30% of epilepsy patients suffer from breakthrough
seizures. Clobazam (CLB) (Guberman,et al., 1990; Michael and Marson, 2008) and
vigabatrin (VGB) (Bruni, et al., 2000; Guberman and Bruni, 2000) have been used
successfully in manyofthese refractory cases (Loiseau,et al., 1986).
1.2. Clobazam (CLB)
CLBis a 1,5-benzodiazepine that has been available for more than 3 decades. It was
first introduced as an anxiolytic. Its antiepileptic property has been known about
since 1973 (Barzaghi, et al., 1973; Gastaut and Low, 1979). N-desmethylclobazam
(NDCB),its active metabolite, exerts a major influence onits antiepileptic properties
and adverse drug reactions (Gastaut and Low, 1979). The onset of action of CLB is
fast andit is effective against a broad spectrum of seizure disorders (Munn,etal.,
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1988; Canadian Clobazam Cooperative Group, 1991; Michael and Marson, 2008).
CLB has been available in Europe since 1973.
1.2.1. Mechanism of action
GABAis the primary inhibitory neurotransmitter in human brain. CLB acts on
GABAA postsynaptic receptors present in almost all cortical neurons. This results in
allosteric modification of the GABA receptor and enhancesinhibition. Binding of
CLBto the benzodiazepine recognition site on the GABA receptor increases the
frequency of GABA A receptor opening without significantly affecting the mean
open time or conductance of the channel. CLB can activate the GABA A receptor
only in the presence of GABA. CLB acts on the alpha-3 containing GABA A
receptors presentin reticular neurons and prevents absenceseizures. It also increases
the number of sodium channels in the inactive state (Meldrum and Chapman, 1986).
This could be the reason for termination of generalized epileptic activity on the EEG.
CLB also reduces conductance in calcium channels and decreases neurotransmitter
release (Meldrum and Chapman,1986; Sieghart, 1992).
1.2.2. Pharmacokinetics
CLBis absorbed rapidly attaining peak plasma concentration between 1-4 hours. 82-
90 % of CLB bindsto protein. The free (unbound) CLBisactive.It is lipophilic and
has a high volume ofdistribution (Dalby, 2004). The half life of CLB is 11 to 77
hours in healthy subjects and 12 to 13 hours in patients on AEDs which induce the
activity of CYP450 (Greenblatt, et al., 1981; Bun, et al., 1990). The half-life of
NDCBalso follows a similar pattern. The half-life of NDCB is 50 hrs (Bun,et al.,
1990). The concentration of NDCBis 10 to 20 times higher than that of CLB (Bun,et
al., 1990). The concentration of CLB is proportional to the dose in an individual
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patient but exhibits great inter-individual variation. However, the concentration of
NDCBis not proportional to the CLB dose but also exhibits great inter-individual
variation (Guberman,et al., 1990; Bardy,et al., 1991). The concentration of CLB and
NDCB in the brain is 15% lower than that of their respective steady state
concentrations (Arendt, et al., 1987). The lipophilicity of NDCBis lowerthan that of
CLB.The affinity ofNDCB for GABAA receptors is 10 fold lower than that of CLB
(Greenblatt, et al., 1983). Therefore, the impact of NDCBonthe efficacy and adverse
drug effects of CLB is unpredictable.
1.2.3. Metabolism
CLB is metabolized to at least 12 metabolites. Its major metabolic pathway is de-
alkylation to NDCB, mediated by CYP2B6, CYP3A4 and CYP2C19 as demonstrated
using Baculovirus-expressed P450s (Giraud, et al., 2004). CLB is also converted to
4’-hydroxyclobazam by CYP2C19. NDCBis primarily metabolized by CYP2C19,to
4’-hydroxydesmethylclobazam. 4’-hydroxyclobazam is de-methylated to 4-
hydroxydesmethyl clobazam, mainly by CYP2C9, CYP2B6 and CYP3A4. (Giraud,
et al., 2004) (Figure 1.4). This is further metabolised by conjugation and excreted in
bile as glucuronate, andin bile and urine as a sulphate.
CYP3A4 and CYP2C19 are the main enzymesinvolved in the demethylation of CLB,
since the amount of CYP2B6 in humanliver is much less (0.2%) (Shimada,etal.,
1994). CYP2C19 is the main contributor to the hydroxylation of NCLB to OH-
NCLB. Thehydroxylation pathway of CLB is minor,sincepatients treated with CLB
have a high concentration ofNDCB,but hydroxyclobazam is undetectable (Giraud,et
al., 2004). Thus, CYP2C19 is the main enzymeinvolved in the metabolism of CLB
and its metabolite NDCB. Therefore, polymorphisms in CYP2C1/9 could affect the
aT
metabolism of CLB.This could lead to high or low concentrations ofNDCB and CB,
affecting the efficacy and adverse effects of CLB (Contin, et al., 2002; Giraud, etal.,
2004). Patients homozygous for deficient CYP2C/9 alleles lack enzymeactivity (De
Morais, et al., 1994). Studies have shown that these patients have a higher
concentration of NDCB andare at a higher risk of adverse effects (Contin, et al.,
2002; Seo,et al., 2008).
Clobazam
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Figure 1.4. Metabolism of clobazam
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1.2.4. Adverse drug effects
Tiredness, mild and transient drowsiness, particularly with the initial dose, nausea,
dizziness, ataxia and weight gain, disturbed sleep cycles and muscle weakness are
common complaints. Side effects are more prevalent in patients with comedications
with other AEDs or other medications, than with monotherapy with CLB (Dalby,
2004). Side effects have been reported in clinical trials and only 5 to 15% of these
adverse effects are of importance leading to a change in dose or termination of
treatment (Koeppen, 1985; Koeppen,et al., 1987). The incidence of tolerance varies
amongstudies from 7.5% (Canadian Study Group for Childhood Epilepsy, 1998) to
77% (Allen, et al., 1983) . Tolerance occurs in patients on high doses of CLB andit
can be reduced byintermittent treatment (Feely and Gibson, 1984).
1.2.5. Drug interactions
The pattern of drug interactions with CLB is complex and shows great inter-
individual variability. CLB can either increase or decrease the levels of
phenobarbital, phenytoin, carbamazepine and valproate (Dalby, 2004). It can lead to
worsening of side effects with these drugs, when it increases their levels. The
concentration of CLBis generally lower and that of NDCBis higher in patients with
inducer comedications. However, there are also reports of raised CLB concentration
with phenobarbital, carbamazepine and phenytoin (Wang, etal., 1993). Alcohol and
cimetidine significantly increase the levels of CLB (Dalby, 2004).
1.2.6. Uses
Patients of all ages, aetiologies and seizure types have responded to CLB.Patients
with non-convulsive status startle seizure, Lennox-Gastaut syndrome and alcoholic
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withdrawal symptoms have responded well to CLB (Dalby, 2004). However, very
few studies have used CLB as monotherapy. It has been used effectively in CBZ
resistant epilepsy and in benign childhood partial epilepsy. It has been reported that
CLB is the drug of choice in intermittent usage such as acute epilepsy, in cluster
seizures, in serial seizures and as prophylaxis (e.g. on days when it’s important to
avoid seizures suchastraveling, taking examinations, interviews, etc.) (Dalby, 2004).
The main drawback of CLB is the potential to develop tolerance. As mentioned
above, the incidence of tolerance varies among studies. There is a good correlation
between the dose and plasmaconcentration of CLB,but there is large inter-individual
variability (Guberman,et al., 1990; Bardy, et al., 1991). Polymorphisms involved in
drug targets, metabolising enzymes, distribution or elimination processes could be
responsible for this. Identification of these polymorphisms could enable usto identify
patients susceptible to tolerance, and prescribe the right dose for patients, avoiding
adverse effects.
1.3. Vigabatrin
Vigabatrin (VGB) is known as a designer molecule since it was synthesized as a
structural analog of GABAto specifically inhibit the GABA-T, thus increasing the
levels of GABA in the brain (Lewis, 1989). GABA is the major inhibitory
neurotransmitter in the brain, and GABA-T metabolises GABA in the brain and
tissues of the body (Lippert, et al., 1977) . VGB wasfirst introduced in the UK in
1989. VGBis a racemic mixture of R- and S+ enantiomers. Only the S+ enantiomer
is biologically active (Duncan, 1994).
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1.3.1. Mechanism of action
VGB forms a covalent bond with GABA-T andspecifically inhibits GABA-T in a
non-competitive fashion. It increases the levels of brain GABA in rodents and
humans (Lippert, et al., 1977). This inhibition peaks 3-4 hours after administration
and is maintained for at least 24 hours. Magnetic resonance spectroscopy showedthat
in clinically used doses, VGB increased the concentration of GABA by 200% in
epilepsy patients (Rothman,et al., 1993). Glutamic acid decarboxylase (GAD), the
enzyme which synthesizes GABA, is decreased in vivo (Jung, et al., 1977). This
might be the consequence of negative feedback of the raised brain GABA
concentration. VGB also increases B-alanine (a substrate of GABA-T). Since the
whole enzyme activity is lost, other substrates of GABA-T can accumulate.
(Schechter, et al., 1984; Menachem,et al., 1988). This is further proof that VGBis a
non-competitive inhibitor of GABA-T.
1.3.2. Pharmacokinetics
VGBhasa favorable phamacokinetic profile. It is almost completely absorbed from
the gastrointestinal tract, attaining a peak plasma concentration in 2 hours. Its half life
is 5-8 hours in adults and almost 5.5 hours in children. The half life is slightly
reduced in the presence of antiepileptic inducer co-medications (Browne,et al.,
1987). It has a large volumeofdistribution (0.8L/kg) in the body. The concentration
of VGBin brain is 10% ofthat in the blood (Menachem,et al., 1988). VGB is mainly
excreted by the renal route. Therefore patients with renal impairment and elderly
patients experience a slowerrate of elimination (Browne,et al., 1987).
4]
1.3.3. Metabolism.
VGBis hardly metabolised in theliver and its protein bindingis negligible. It is
eliminated relatively unchanged in the urine. Two minor metabolites that constitute
less than 5% of the drug are detected in the urine (Durham,etal., 1993).
1.3.4. Drug interactions
No drugs appear to have a pharmacokinetic or pharmacodynamic effect on VGB.
VGB can reduce the levels of phenytoin by 20-30%. It does not induce the
metabolism of phenytoin. The mechanism ofthis interaction is not known. There are
no other significant drug interactions (Duncan, 1994).
1.3.5. Adverse drug effects
Sedation, dizziness and headache are the most common adverse affects. These
symptomsareusually self-limiting. By gradually increasing the dose to 3gmsper day
over 5 weeks, these symptoms can be avoided. Allergic skin reactions are rare
(Duncan, 1994).A literature review of the double blind placebo controlled clinical
trials of VGB as add on therapy for refractory partial epilepsy revealed that patients
treated with VGB had a higher incidence of depression and psychosis (Levinson and
Devinsky, 1999).
It is now established that VGB can cause peripheral bilateral concentric visual field
defects (Eke,et al., 1997; Wild, et al., 2007). The nasalfield is affected more than the
temporal field (Krauss, et al., 1998; Miller, et al., 1999). Although it wasinitially
thought that only peripheral visual field defects result from the use of VGB,central
retinal changes have also been reported. They include colour vision disturbances, and
reductions in contrast sensitivity and visual acuity (Eke, et al., 1997; Krauss,et al.,
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1998; Nousiainen, et al., 2000a; Nousiainen, et al., 2000b). Electrophysiological
studies have also demonstrated defects in both the outer and innerretina at the level
of the Miiller cells (Coupland, et al., 2001). The severity can vary from mild to
severe. Males and smokers have a higherrisk of developing vigabatrin-induced visual
field defects (VVFD). Though there were conflicting reports on the risk factors for
VVED,Wild et al.(2007) in a prospective study, showed that VVFD wasassociated
with duration and mean dose of VGB therapy (Wild,et al., 1999; Wild, et al., 2007).
VVFD has an insidious onset. The earliest period at which VVFD has been
documented in complex partial seizures is 11 months. VVFD appears on an average
after 5.5-8 yrs treatment on VGB (Ovation Pharmaceuticals, 2007).
1.3.6. Uses
VGBhas been demonstrated to be effective in a wide range of patients with different
types of epilepsies. Significant (more than 50%) seizure reduction was seen in 60-
70% patients treated with VGB for complex partial seizures. In addition, 8% of
patients with complex partial seizures refractory to anticonvulsantslike barbiturates,
phenytoin, carbamazepineand valproicacid, attained seizure freedom (Loiseau,etal.,
1986; Bruni, et al., 2000). It is the drug of choice for infantile spasms (Chiron,etal.,
1990; Chiron,et al., 1997).
Howeverafter the report of VVFD in 1997, this drug is only prescribed to patients
refractory to other AEDs (Eke, et al., 1997; James, et al., 2009). Regular retinal
function assessment and visual field testing is recommended during the treatment
period. Polymorphismsin the pharmacodynamic or pharmacokinetic machinery could
lead to the development of adverse effects. Identification of these polymorphisms
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could enable clinicians to prescribe this drug safely to patients who are not
susceptible to adverse effects and at the same time responsiveto this drug.
1.4. Pharmacogenetics
Individuals respond to drugs in different ways. In some individuals, a desiredresult is
seen. In others, there may be no effect, while in the remainder, untoward effects
develop. Age, sex, disease, environmental factors and co-administration of other
drugs, can influence the response characteristics. Genetics can be an important factor
determining variability in drug response and development of adverse drug reactions
(Pirmohamed and Park, 2001). This has lead to the development of the branch of
science called phamacogenetics, a study of how genetic differences influence the
variability in patients' responses to drugs, and determines drug efficacy and safety for
individual patients (Ameen, et al., 2002). Genetics can affect the metabolism,
disposition and elimination of drugs, as well as drug targets and accessory pathways
involved in their mechanism of action. Thus, pharmacogenetic variation can be
divided into two categories depending on the processes involved:
1. Pharmacokinetics, in which the genetic variants in drug transporters and
metabolizing enzymes can result in the variation in the distribution and
elimination of drugs.
2. Pharmacodynamics, in which genetic variation in drug targets or target
pathwaysalters the effect of the drug. The drug targets or target pathways can
be receptors, ion channels, enzymes, immune molecules, transducer and
regulatory proteins.
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The number of studies that have investigated genetic risk factors in disease far
exceeds those examining the variants in drug response and the development of
adverse drug reactions. The completion of the human genomeproject provided an
impetus to pharmacogenetics research. Since then, numerous papers have explored
genetic factors affecting drug response, toxicity and efficacy. With the development
of genome wide approaches, data availability and technologies, the term
pharmacogenomics was introduced in 1997 (Meyer, 2004; Brockméller and
Tzvetkov, 2008). Pharmacogenomics explores the role of the entire genomein both
disease susceptibility and drug response, in an attempt to identify specific genes that
are associated with diseases and varied drug response. Pharmacogenomics differs
from pharmacogenetics in three ways:
(a) Genetic drug response profiles: Pharmacogenetic studies investigated the
association of one or a few SNPs involved in one gene or a few candidate genes.
This usually focused on pharmacokinetic genes. Thus, identification of variation in
drug metabolizing enzymescould lead to selection of appropriate drugs at the correct
dose. However, there are 3-12 million SNPs in the human genome which can
contribute to variable drug response. Pharmacogenomics envisages identifying the
genetic drug responseprofile in individuals.
(b) Gene expression profile: Pharmacogenomics also allows the analysis of the
expression of genes in the human genomein an attempt to investigate the relative
contributions of environmental and genetic factors to varied drug responses and
diseasestates.
(c) Drug development: Pharmacogenomicsalso allowsthe identification of all genes
and all protein products that will help in elucidating the factors causing, modifying or
contributing to disease states. This results in the recognition of genes and proteins
45
involved in the pathogenesis of diseases, which could serve as novel drug targets
resulting in alleviation or prevention of disease symptoms (Meyer, 2004). Currently
pharmacogenetics and pharmacogenomics are used interchangeably in the public
domain, which could lead to confusion.
1.4.1. Genetic variations in human genome
Whatare the genetic variations affecting drug response and disease status? SNPsare
the most commongenetic variations. The approximate frequency of SNPs is one in
every 300-3000bp, accounting for approximately 3-12 million SNPs. This constitutes
<1% of the 3.2 billion base pairs (bp) of the haploid genome (Meyer, 2004;
International HapMap Consortium, 2005). Most of the pharmacogenetic studies have
used SNPs to explore variable drug responses. Around 1000,000 insertions and
deletions are also present in the human genome. Variable number of tandem repeat
(VNTR) also add to the genetic variation. For example, an association was found
between a 16 aminoacid repeat (48 bp) in the dopamine receptor gene and catatonic
schizophrenia (Kaiser, et al., 2000). The human genomeproject revealed that there
are around 1500 large genomic segments in variable copy numbers (International
HapMap Consortium, 2005).
Heritable changes in gene expression can also occur without any change in DNA
sequence, as in epigenetics (Eckhardt, et al., 2006). Three interacting processes are
important in epigenetics: DNA methylation, modification of histones in chromatin
and RNA mediated regulation of gene expression (Peedicayil, 2008). DNA
methylation can affect the level of expression of genes and this could contribute to
variable drug response.
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Table 1.4. Different types of inter-individual variations in human genome.
 Genetic Abbreviati Description Frequency in
variation on human
genome
Single SNP Typically two different nucleotides 12,000,000
nucleotide (biallelic SNPs) at one defined
polymorphism position, but morerarely alsotriallelic
variants occur.
Insertion InDel Deletions (or insertions, depending on > 1,000,000°
/Deletion the allele frequencies) of between 1 to
1000 nucleotides. More frequent are
deletions of one or three basepairs.
Varying VNTR Microsatellites, also termed short > 500,000°
numberof tandem repeat (STR) polymorphisms
tandem repeats are typically tandem repeats of two,
three or four nucleotides, but repeats
up to ten nucleotides in length may
also beclassified in this group.
Minisatellites are VNTR
polymorphismsin which 10-100
nucleotides are repeated in variable
numbers. Repeated segments often do
not have exactly identical sequences.
VNTRswith larger repeat units (100—
1000 bp) are termedsatellites.
Copy number CNV Inheritable deletion or multiplication > 1500 loci
variation of DNA segments larger than 1 kb. covering
Currently, about 1500 CNVs 12% of the
distributed through all chromosomes genome
are known;estimated to cover 12% of
the human genomelength.
Epigenetic and somatic variations of the human genome
Cell karyotype
and somatic
mutations
DNA
methylation
Typically in tumours where DNA
recombination and repair machineries
are damaged, but also in some
inherited diseases.
Methylation of the cytosine residues
of CpG repeats (known as CpG
islands) of DNA transmitted through
generations. Methylation of CpG
islands located in the promoter region
of the genes causing down-regulation
usually.
> 20% of all
genes
a - based on databases and publications (International HapMap Consortium, 2005).
Adopted from (Brockmdller and Tzvetkov, 2008).
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What are the possible functional effects of these variations? The above mentioned
genetic variations could occur in any part of a gene. Depending onthe position in the
gene, this genetic variation could alter the function of the genes. Figure 1.5. shows
the various parts of a gene and the predictive functional effects of the genetic
variations in each of these parts (BrockmGller and Tzvetkov, 2008).
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Figure 1.5. The effect of SNPsin various part of the gene
Adapted from Brockmoller and Tzvetkov, 2008.
1.4.2. History of pharmacogenetics
Pharmacogenetics has a rich history. Its development is closely related to the
advancesin the field of human genetics and genomics, molecular pharmacology and
modern drug therapy. The major developments of pharmacogenetics are depicted in
Figure 1.6.
1850 to 1910: Duringthis time, physiological chemists ascertained that drugs and
exogenous chemicals are metabolised by the human body. In the 1860s, Mendel
discovered the fundamental laws of heredity. Unfortunately, his findings were not
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appreciated until 1900 when they were re-discovered. In 1870s, Ehrlich and Langley
proposed that drugs mediate their actions through receptors. These three discoveries
laid the foundation for pharmacogenetics (Weber, 2001).
1910 to 1950: During this time, scientists gained insight into the important findings
mentioned above. Archibald Garrod and William Bateson from England and Leucien
Cuenot in France proposed that genetics played a vital role in the metabolism of
exogenous substances. Archibald Garrod, from his observation of patients, with
alkaptonuria, and porphyria caused by sulphonal, identified the genetic predisposition
to alkaptonuria. He proposed the concept of chemical individuality and thought that
enzymesdetoxify or metabolize drugs and other exogenous chemicals (Weber, 2001).
He elegantly laid down the principles of pharmacogenetics, when he said, “Even
against chemical poisons taken by mouth, or by other channels, there are some means
of defence. Every active drug is a poison, when taken in large enough doses; and in
somesubjects, a dose, which is innocuousto the majority of people,has toxic effects,
whereas others show exceptional tolerance of the same drug. Some chemical poisons
are destroyed in the tissues, provided that the dose given be not too large, and others
are combined up with substances to hand, and so rendered innocuousandgotrid of”
in his book ‘The Inborn Factors of Disease’ (Garrod, 1931). Despite his insight into
genetic basis of drug metabolism, N. H. Snyder conducted the first pharmacogenetics
study. A.L.Fox was trying to synthesize a sugar substitute. He noted that people
reported that phenylthiocarbide had a bitter taste while others opined that it had
‘slight taste’ or "taste of sand" (Fox, 1932). In a large study of 800 families, Snyder
showed that taste blindness was an autosomal recessive disorder and its frequency
varied among populations of different ethnic origins (Snyder, 1932). This study
heralded the era of pharmacogenetic studies.
49
  
Gregor Mendelestablishes rules of heredity.
 
 A
 
 
(1900-1913) William Bateson popularizes
Mendelian inheritance, discovers linkage and
introducesthe term ‘genetics’.  A 
 
Snyderestablishes the monogenic inheritance
oftaste blindness for phenylthiocarbamide and
documents‘racial’ differencesin its incidence
  
 
Association ofprimaquine-induced hemolysis
with glucose-6-phosphate- dehydrogenase
deficiencyin erythrocytes
A
  
 Vogel coins the term ‘pharmacogenetics’
A
A  
 
Kalowpublishes the first monograph on
pharmacogenetics, Pharmacogenetics —
Heredity and the Response to Drugs   
(1975-1979) Smith (London) and
Eichelbaum (Bonn)andtheir co-workers
independently discover the
debrisoquine/sparteine polymorphism of
drug oxidation
A
 
 
Description of the polymorphism of
mephenytoin hydroxylation by Ktipfer and
Wedlund
A
 
 
PCRallowsgenetic sequencesto be amplified
exponentially.
 A
 
(1988-1990) Gonzalez and Meyercollaborate
to clone CYP2D6and characterize the genetic
defect of the debrisoquine/sparteine
polymorphism
 A   
1866
1875
1900
1902
1932
1953
1956
1957
1959
1960
1962
1967
1975
1980
1984
1985
1987
1988
 Vv  
Francis Galton describes the concept of
comparing pairs of monozygotic and dizygotic
twinsto distinguish genetic and environmental
factors.
 Vv  
(1902-1909) Archibald Garrod developsthe
concept of “chemicalindividuality”
(1953-1954) Bonicke and Reif, and Hughes
describe slowandrapid acetylation of
isoniazid
 
KalowandStaron characterize serum-
cholinesterase deficiency in a subject
Motulsky conceptualizes that
inheritance might explain main
individual differences in the efficacy
and toxicity of drugs
  (1957-1970) Twin studies indicatepolygenic influences on thepharmacokinetics of numerous drugs
 Vv  
Evansestablishes the genetic control of
isoniazid acetylation
 
(1967-1973) Sjéqvist and his co-
workersestablish that the metabolism of
tricyclic antidepressants is under genetic
control
 Vv  
Discovery of the genetic polymorphism of
thiopurine-methyltransferase (TPMT) by
Weinshilboum and Sladek
 
 v  
First nomenclature ofthe P450-supergene
family. 50
 
 
 
 
 
 
 
 
 
 
   
 
     
 
 
 
 
 
 
 
 
  
 
    
Heim and Meyer publishthefirst allele-Thefirst issue ofthe journal Pharmacogenetics ,| specific pharmacogenetic genetest for
is published. 1990 "| CYP2D6
Blum, Grant and Meyer purify N-
acetyltransferase- 1/2 (NAT1/2) and clone 4 1991
the respective genes as well as the mutations
ofNATZ that cause the acetylation Johansson, Ingelman-Sundberg and Bertilsson
polymorphism. _| discoverthat stable gene amplifications of
1993 *| CYP2D6causethe ultrarapid-metabolizer
phenotype
Cloning and characterization ofCYP2C19, Bi
whichcauses the mephenytoin polymorphism, ~ 1994by Goldstein. A committee (Vatsis and co-workers) offers
a nomenclature for NATalleles
1995 >) Krynetzki and co-workers publish the first
mutations of the TPMT gene, from which a
DNAtestis derived.
The term pharmacogenomicsfirst appears in LS
theliterature. i 1997 A nomenclature website for the human
cytochrome P450 (CYP)allele is established
by an international committee.
The first comprehensive pharmacogenetics 1999 >
knowledge base, the ‘PharmGKB’ web A public/private collaboration, the “SNP
site, is constructed on the basis of the Consortium’, provides public information on
NationalInstitute of Health 7 genomic diversity
Pharmacogenetics Research Network. a 2000
A draft of the human genome sequenceis
The human genomesequenceis (almost) 2001 >| published.
completed.
Start of the ‘HapMap’project for building
a map ofhaplotype blocks. ¢ 2003
The Federal Drug Administration issues Characterization of >1.8 million SNPs by the
draft guidelines for submission of SNP Consortium.
pharmacogenetic data with new drug 2004 >
applications.  
   a   
Figure 1.6. Shows the major developmentsin the history of pharmacogenetics.
Adopted from Meyer, 2004.
1950 to 1990: Pharmacogenetics was established as a discipline during this period.
New techniques emerged to accurately measure enzymeactivities, drug metabolites
and drug responses. Genetics also advanced tremendously during this period. The
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double helix structure of DNA was unraveled, human chromosomeswere visualized
and the biological importance of protein polymorphism was recognized. This
provided an excellent opportunity for pharmacologists to study the heritable patterns
of metabolism and response to several drugs. By the end of the decade, spanning
1950 to 1960, there were three examples of genetically determined adverse drug
reactions to drugs (Meyer, 2004).
During World War 2, it was observed that 10% of African American soldiers
developed hemolytic crisis when administered primaquine. This was rare among
Caucasian soldiers (Clayman,et al., 1952). Later studies proved that this was due to
Glucose-6-phosphate dehydrogenase (G-6PD) deficiency which affected red blood
cell (RBC) metabolism (Carson, et al., 1956). The same genetic defect caused
hemolysis in some people who consumed fava beans. Pythagoras recognized this in
500 BC (Nebert, 1999). Another paradigm example for pharmacogenetics is
prolonged apnoea, up to one hour, from succinylcholine. Altered kinetics in the
pseudocholinesterase enzyme, due to genetic variants in the gene which metabolizes
succinylcholine were found to be responsible (Lehmann and Ryan, 1956). Family
studies showed that pseudocholinesterase deficiency is an autosomal recessivetrait
(Kalow and Staron, 1957). Though a well studied phenomenon,it took 40 years to
prove that peripheral neuropathy in some patients due to isoniazid, an anti
tuberculous drug, was due to a polymorphism in its metabolizing enzyme, N-acetyl
transferase (Grant, et al., 1992; Vatsis, et al., 1995). Prior family studies had revealed
that this trait is autosomal recessive (Evans,et al., 1960).
Arno Motulsky recognized the importanceof the above findings. In his seminal paper
- 'Drugreactions, enzymes and biochemical genetics', Motulsky described the genetic
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basis of adverse reactions to primaquine, succinylcholine and barbiturates. He
explained “how hereditary-gene controlled enzymatic factors determine why, with
identical exposure certain individuals become sick, where as others are not affected”
(Motulsky, 1957). This paper formed the foundation of phamacogenetics. This
sparked the interest from many quarters. In 1959, Friedrich Vogel in Heidelburg
Germany coined the term pharmacogenetics (Vogel, 1959). In 1962 in his monograph
‘Pharmacogenetics: Hereditary and its response to drugs’, Kalow reviewed all the
articles exploring the genetic effects of drug response (Kalow, 1962). It is also
important to note that in 1956, the book "Biochemical Individuality” had a chapter on
variability in the response to drugs (Williams, 1956). By 1990, 100 monogenic
polymorphic traits in pharmacogenetics had been reported. The majority of these
polymorphisms were reported in drug metabolizing enzymes. A community of
researchers interested in pharmacogenetics was developing. Thefirst international
conference on pharmacogenetics was held at the New York Academy of Sciences in
1967 (Meyer, 2004).
1990-2000: The technical advances in molecular genetics in the 1990s lead to
cloning, sequencing and site directed mutagenesis to study the organization and
composition of genes. Currently although the sequence variability in genes is
becoming known,howthis relates to variability in drug response is being explored.
The paradigm for the study of pharmacogenetics has also changed. In the last
century, pharmacogenetic studies started with the phenotype and were followed by
studies of genetic variation. Thus, the earlier pharmacogenetics studies investigated
the association between genetic variations in the genes involved in pharmacokinetic
processes - so called ‘low hanging fruit,’ rather than those coding for drug targets
(Weber, 2001).
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2000-Present: In this century, many studies start with the genotype and are followed
by an analysis of the phenotype. Pharmacogenetic studies are also increasingly
focusing on the genes for drug targets. For example, Lynch et al. (2004) and Paez
et.al. (2004) demonstrated that in patients with somatic gain of function, the response
to geftinib was better, secondary to mutations in the epidermal growth factor receptor
in non-small lung cell carcinoma. This was the first study to demonstrate the
influence of somatic cell mutations to drug response, and this is now increasingly
being investigated.
The focus of pharmacogenetic studies is shifting to polygenic variation in both
pharmacodynamic and pharmacokinetic processes. In many cases, pharmacokinetic
genetic variation alone is unable to explain the variance in phenotypes. A classical
example is warfarin. Warfarin is the most commonly prescribed anticoagulant in
Europe and North America. In spite of the dosing being monitored by INR,there is a
wide variation in warfarin doses and manypatients develop bleeding, an important
and common adverse drug effect. Warfarin acts on vitamin K epoxide reductase
complex subunit 1 (VKORC1) preventing coagulation of blood.It is metabolized by
CYP2C9. Many studies have shownthat the SNPs in VKORC1 account for 15 to
30% of the variation in dose requirement, while those in CYP2C9 are responsible for
6 to 18 % of the variability in warfarin dosing (Rieder, et al., 2005; Wadelius, etal.,
2005; Sconce, et al., 2008). This showsthat in the case of warfarin, pharmacokinetic
and pharmacodynamic pathwaysare important in determining drug dose.
1.4.3. Where are we now?
Manygenetic association studies have appeared over the last decade. A major issue
however is that very few have been replicated. In fact, in 2002, only 6 out of 166
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putative genotype-phenotype association studies could be replicated after at least 3
attempts (Hirschhorn,et al., 2001). There are many possible reasons reported for the
problems encountered in replication (Hirschhorn, et al., 2001; Ioannidis, et al., 2001;
Ioannidis, 2003):
(a) Publication bias: The risk estimates in small studies are subject to large variation
and usually only large studies with positive results are published.
(b) Weak genetic effects and lack of power: A large sample size is required to
demonstrate a minor effect by genetic variants of complex diseases. Many
pharmacogenetic studies have small numbers of patients and are likely to be under-
powered.
(c) Population stratification: The minor SNP allele frequencies vary among
populations. So if the study population includes subjects from different ethnic
groups, like Caucasians, Africans, and Asians, the sample size may not be adequate
to detect the effect of SNPs that have variable frequencies in the populations.
(d) Heterogeneity in classification of phenotypes across studies. Poor phenotyping is
commonin manystudies.
(e) Different LD patterns between populations or different SNP markers between
studies.
(f) Gene-gene or gene-environmental interaction modifier genes can also influence
drug response.
(g) Regional population ethnic differences.
(h) Another functional variant linked to the allele under study.
(i) Unequivocal genotype is defined as the assignment of a genotype byscientific
investigators without any room for error. It is becoming increasingly difficult to
assign an unequivocal genotype. Allelic heterogeneity, locus (non-allelic)
a
heterogeneity, large number of genes contributing to a trait, genocopy and
synonymous mutationsthat unpredictably alter the trait can makeit difficult to assign
an unequivocal genotype (Nebert and Vesell, 2004). New discoveries about the
human genome further make it difficult to assign a genotype. Walsh et al. (2006)
showedthat 12% of the patients tested negative for breast cancer | early onset gene
(BRCA 1) and breast cancer 2 early onset gene (BRCA 2) SNPs, in a vast array of
DNAtests. However, these patients had gene rearrangements not included in the
DNAtests.
Risch and Merikangas (1996) raised concerns aboutthe ability of linkage studies to
detect genes of modest effect or lower penetrance, which is the case in complex
diseases. They proposed that genome wide association studies that tested all
candidate genes, and perhapsall genes in the genome, would have greater power to
detect genes of modest effect. The first ever genome wide association study (GWAS)
was published in 2002, where an association was drawn between Lymphotoxin-a
gene and myocardialinfarction. 92,788 gene SNP markers were tested in this study
(Ozaki, et al., 2002). By the end of 2007, two dozen GWAShad been reported and
manyofthese had beenreplicated (Nebert, et al., 2008).
Overall, the quality of pharmacogenetic studies has been steadily improving. There
have been many studies that have now proven the association between genetic
variants in drug metabolizing enzymes and drug transporter genes and
pharmacokinetics of at least one drug, and havealso been replicated. 10% of the new
drugs introduced into the market today carry pharmacogenetic information in their
labels. More and more pharmacogenetic tests are being approved by the Food and
Drug Administration (FDA) and are available commercially. However, translating
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pharmacogenetic principles to clinical practice remains a challenge (Swen,et al.,
2007).
1.4.4. Translation of pharmacogeneticsinto the clinic
There are various challenges in translating pharmacogenetics into clinical practice as
shown in Figure 1.7 (Swen,et al., 2007):
(1) Lack of scientific evidence for improvement in patient care by
pharmacogenetic testing.
There is a paucity of large powered genotype-phenotype association studies. Most of
the currently available studies are under powered to detect real associations. In
addition, many of these are single dose studies done in healthy volunteers. These are
inadequate since the pharmacokinetic or pharmacodynamic processes are altered in
the patients on chronic treatment. Therefore, the findings from these studies cannot
be used as a basis for adopting pharmacogenetic tests in clinical practice. Moreover, a
large proportion of the studies have not explored the association of genotypes and
clinical endpoints like efficacy or adverse drug reactions. They have explored the
effects of genotypes on the pharmacokinetic parameters of the drugs. The wide
variation in pharmacokinetic parameters maynottranslate into clinical effects.
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Figure 1.7. Different phases & associated challenges on the road to clinical
implementation of pharmacogenomics. PGx — Pharmacogenetics. Adopted
from (Swenetal. 2007)
For instance, a wide variation exists in the plasma levels of nortryptyline among
patients with mutant alleles of CYP2D6. However, even an increase of 10 fold in
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drug levels from the population norm doesnot necessarily result in toxicity (Swen,et
al., 2007).
(2) Selection of clinically relevant pharmacogenetic tests
Some genotype-phenotype associations might be true and replicable. However, their
clinical relevance is questionable. For example, the variation in CYP2D6that results
in the ultra-rapid metabolizer (UM genotype)status is relatively rare in the Caucasian
population. The UM genotype results in reduced levels of 5-hydroxytryptamine
receptor (SHT3 receptor) antagonists such as tropisetron and ondansetron reducing
efficacy causing more nausea and vomiting (Kaiser, et al., 2002; Kim,et al., 2003).
Howeversince the prevalence of the UM genotypeis lower amongst Caucasians, the
number of patients needed to genotype in order to prevent one patient from
unwarranted nausea and vomiting is 50 (McLeod, 2002). This is economically not
viable and hinders the implementation of this pharmacogenetic test (Maitland, etal.,
2006).
(3) Diagnostic test criteria for pharmacogenetic testing
A diagnostic test should be able to predict the outcomeof drug treatment. It should be
sensitive and specific. Drug response is a complex process. Pharmacokinetics,
pharmacodynamics and environmental factors can contribute to this. A diagnostic test
for single polymorphisms may only account for part of the variability of drug
response. The diagnostic test criteria for pharmacogenetics tests should be mentioned
to evaluate the clinical usefulness ofthis test.
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(4) Information on cost effectiveness and cost consequences of pharmacogenetic
testing
The health insurers will require more information on cost effectiveness of
pharmacogenetics diagnostic tests to reimburse routine tests. There are very few cost
effectiveness evaluations of pharmacogenetic tests. However, there is little
information about which pharmacogenetic tests predict adverse drug reactions or
effects, and the cost of genotyping is decreasing. Even though cost effectiveness
analysis has not been done for all pharmacogenetic tests before being used in the
clinic, any information mayaid clinical use of these tests in the future.
(5) Guidelines directing the clinical use of pharmacogenetic test results.
Very few pharmacogenetic studies exist, which recommend dose adjustments
according to genotype. Warfarin dose adjustments that are recommended based on
polymorphisms in VKORC1 and CYP2C9,and height of patients are an example, but
are still limited by the fact that the effectiveness of dosing algorithms has not been
tested in clinical settings.
(6) Improved acceptance for pharmacogenetic testing.
It took seven years before the use of the Calvert formulae to optimize the dose of
carboplatin becameroutine. In contrast, testing for human epidermal growth factor
receptor 2 (HER2/NEU) over expression was made mandatory by the regulatory
authorities to prescribe trastuzumab (for the treatment of breast cancer) within a year.
This testing was advocated by the company that manufactured the drug andbypatient
advocacy organizations. It is possible that if regulatory agencies recommended
testing prior to prescribing the drug and this in turn is supported either by
pharmaceutical companies or by patient organizations, or both, this will expedite the
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process of clinical updates of pharmacogenetic testing. However, the critical issue is
the weight of evidence to support genotyping before prescription.
Various stakeholders need to work together to aid this translation into clinical
practice. This should include the biotechnology and the analytical industry, the
pharmaceutical industry, the research institutions, funding agencies, regulatory
agencies, clinicians and patients. Each of these stakeholders has important individual
and collective roles in developing and executing the clinical application of
pharmacogenetics. Fast, reliable and affordable assays for routine pharmacogenetic
testing should be developed by the biotechnology and analytical industry. The
response of industry to pharmacogenetics tests has been reserved (Swen,et al., 2007).
A 2001 report stated that investments to develop a drug would be reduced by 300
million US dollars and by 2 years, if pharmacogenetic testing is used in the
development of drugs (Tollman, et al., 2001). The FDA is encouraging voluntary
pharmacogenetic data submission. European agencies for evaluation of medicinal
products and FDA have issued a joint procedure for the voluntary submission of
pharmacogenetic data
(http://www.emea.europa.eu/pdfs/general/direct/pr/FDAEMEA.pdf). Funding
agencies should be more willing to fund clinical trials involving pharmacogenetics.
The reimbursement authorities or companies should be willing to pay for
pharmacogenetictests, taking into consideration the medical events they can prevent.
Physicians and clinical pharmacists have to be educated on the usage of
pharmacogenetictests. Patients and patient advocacy groups have an importantrole
in implementing pharmacogenetics (Swen, et al., 2007). We are far away from
implementing pharmacogenetic tests for CLB and VGB. Polymorphismsspecific to
patient response, dose and adverse drug reactions are being investigated (Seo,etal.,
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2008). Once they are established, the aforementioned hurdles have to be surpassed to
bring pharmacogenetic tests specific for CLB and VGBinto clinical practice.
However, these drugs are not widely used now.
1.5. Aims of the thesis
In view of the points discussed above, for VGB, the hypothesis tested in this thesis
was that variation in the ABAT gene, which encodes GABA-T enzyme may
modulate GABA-T enzyme activity, and thereby predispose to the visual field
defects. For CLB, the hypothesis being tested was that variability in the metabolism
of CLB maylead to variation in pharmacokinetics, and drug response parameters.
In orderto test these hypotheses, the objectives of this thesis were to
1)
2)
3)
4)
5)
6)
7)
Develop a GABATactivity assay using platelets as a non-invasive source
of human material.
To identify putative functional SNPs in the ABATgene.
To assess the genotype-phenotypecorrelation of SNPs in the ABAT gene
and the activity of GABA-Tin platelets.
To assess GABA-Tactivity in patients who developed visual field defects
and compare them with patients without visual field defects despite prior
exposure to VGB.
To develop a HPLCassay to measure the plasma concentrations of CLB
and NDCB.
To correlate the known SNPsin the CYP2C/9 gene with the dose of CLB,
plasma concentrations of CLB, NDCBandtheirratios.
To identify the predictors of efficacy, tolerance and propensity to develop
adverse drug reactions to CLB.
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Chapter 2
GABA transaminase — characterisation ofphenotype-
genotyperelationship
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2.1. Introduction
GABA-T is involved in the catabolism of the main inhibitory neurotransmitter
GABA.It is ubiquitous in distribution, with the highest expression in liver, brain,
pancreas and kidney, moderate expression in prostate, testis and thyroid and low
expression in heart, ovary, adrenal gland, mammary gland and placenta (De Biase,et
al., 1995; Jeon, et al., 2000). It is also present in platelets (White, 1979) and hair
follicles (Armijo, 1989). GABA-T is a a2 homodimer with 472 amino acids in each
subunit. These subunits are intertwined with pyridoxal phosphate cofactor close to
the subunit interface. The subunits are made of2 identical monomers (De Biase, et
al., 1995; Storici, et al., 1999) (Figure 2.1).
Vigabatrin
Pyridoxal phosphate 
Figure 2.1. Shows the 2 identical monomers of GABA-T with vigabatrin
bound to the active sites and its co-factor pyridoxal phosphate
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The activity of GABA-T is known to vary. Berrettini et a/ (1982) reported that
genetic factors could play a major role in determining platelet GABA-T activity. The
4-aminobutyrate aminotransferase (ABAT) gene encodes GABA-T enzyme. It is
located on the short arm of chromosome 16 at 13.2 pter. It has 3 transcripts which
code for the same protein (Tsuji, et al., 2010). ABAT deficiency is associated with
psychomotorretardation, hypotonia, hyperreflexia, lethargy, refractory seizures, and
electroencephalograph (EEG) abnormalities.
ABATis also a polymorphic gene, with variants that could affect GABA-T activity.
To the best of my knowledge, there have not been any studies looking into the
effects of SNPs on GABA-Tactivity.
Platelet GABA-T has previously been used as a model for brain GABA-T. This is
because they have comparable kinetic properties, molecular properties and
pharmacology (White and Sato, 1978; White, 1979; White and Faison, 1980;
Rimmer, et al., 1988) Therefore I have used platelet GABA-T to investigate the
functional effects of SNPs on brain GABA-Tactivity.
There are many methodsto estimate GABA-Tactivity (Pitts, et al., 1965; Gonnard,
et al., 1973; Jung, et al., 1977; White, 1979). The spectrophotometric method
described by Schousboeet al. (1973) is simple, cost effective and does not involve
radioactivity. Therefore, this method was standardisedin platelets.
The aimsof this chapter were to
1. To standardise a simple, reproducible and cost-effective assay for platelet
GABA-T.
2. To select putative functional SNPs in the ABATgene.
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a To genotype these SNPs in healthy volunteers.
4. To correlate genotype to the activity of platelet GABA-T in healthy
volunteers.
2.2. Methods
2.2.1. Materials
Optiprep was purchased from Axon Lab AG, Le Mont-sur-Lausanne, Switzerland.
All the other chemicals used for the experiments mentioned in this chapter were
purchased from Sigma Aldrich, Poole, England. ABI PRISM 7000® was used to
perform real time polymerase chain reaction (PCR). The absorbance of
acetylpyridine (dihydronicotinamide adenine dinucleotide -coenzyme Q reductase)
NADHwas measured by Bio-Tek FL600 fluorescence micro plate reader.
2.2.2. Study population
DNAwasextracted from the blood of 32 healthy volunteers of Asian and Caucasian
origin. Ethical approval was obtained from the Capenhurst Independent Research
Ethics Committee, Bromborough Wirral. Blood was drawn from these healthy
volunteers for the GABA-T assay and genotype estimation, after obtaining written
informed consent. The study population was limited to this numbersince there were
only these many individuals in the department who consented to donate blood.
Forthe estimation ofthe allelic frequency of selected SNPs, DNA of 107 individuals
from the DNA bank in our lab (healthy Caucasian controls which have been
anonymised) was also used with the above mentioned healthy volunteers. Ethical
approval wasobtained from the ethical committee mentioned above.
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2.2.3. Platelet isolation
GABA-Tactivity has previously been shownto be reduced after food (Berrettini, et
al., 1982; Sherif and Ahmed, 1995). Therefore, I collected fasting venous blood
samples in tubes containing ethylenediaminetetraacetic acid (EDTA-100mM)as an
anticoagulant (150 ul for 10ml). To optimise the platelet isolation method, GABA-T
activity in platelets was estimated under the following conditions. Platelets were
isolated (a) soon after blood collection, (b) from plasma, after allowing the blood to
stand for 2hrs, and (c) 2 hrs after adding dextran. Dextran was added to help
sedimentthe blood cells.
Platelet isolation was undertaken using the density gradient method described by
Bagameryetal. (2005). OptiPrepTM wasreconstituted according to the instructions
of the manufacturer to obtain a 1.063 gm/ml solution. In a 15 ml centrifuge tube, 5
ml of plasma waslayered over 5 ml of the 1.063 gm/mlsolution and centrifuged at
350 x g for 15 min as shownin Figure 2.2. In order to avoid disturbance to the
banded material, the rotor was allowed to decelerate without the brake. The platelet-
containing band, extending into the density barrier from just above the interface was
harvested (subsequent to the removal of the clear plasma layer). This platelet rich
layer was centrifuged at 10,000 x g at 4°C. The supernatant was discarded and the
pellet from 30ml of blood was re-suspended in 500.1 of buffer (pyridoxal phosphate
(0.2mM), 2-aminoethylisothiouronium bromide hydrobromide (AET) (1mM), pH
7.2). This was sonicated for 3 cycles of 10s each on ice at 20% efficiency. The
platelets obtained were aliquoted and stored at -70°C till the GABA-T activity was
measured.
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2.2.4. GABA-Tassay standardisation
2.2.4.1. GABA-T activity
The activity of GABA-T in the platelet preparations was measured using a
spectrophotometric method with GABAasa substrate described by Schousboeetal.
(1973). The GABA-T assay consisted of a coupled assay, as shown in Figure 2.3.
The first step is the rate limiting reaction. GABA-T converts GABA to succinic
semialdehyde, during which o-ketoglutaric acid is converted to glutamic acid. The
glutamate formed in the first reaction is converted to a-ketoglutaric acid by
glutamate dehydrogenase in the presence of acetylpyridine NAD+. Acetylpyridine
NADHis also formed and is measured at 340nm.
350 X g for 15 min
at 20°C
ed
Platelet rich plasma
Blood   
 
Equal volumeof
Optiprep
WBCs
RBCs
 
Figure 2.2. Schematic diagram showing plateletisolation using OptiPrep™
as the density gradient
The volume of the first reaction was optimised to 100pl. 20u1 of the platelet
preparation was added to 20ul of potassium phosphate buffer (pH=8, 50mM). A
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mixture of 20u] of 1OmM a- ketoglutaric acid, 1ul of 100UM AET,20 pl of 50mM
GABAand 0.20 ul of 20uM pyridoxal phosphate were prepared. This was added to
the platelets and the volume made up to 100 ul with water. The mixture was
vortexed for 10s and then incubated at 37°C in a shaker for 30 min. Blank samples
were incubated with sodium phosphate buffer instead of the platelets. The reaction
was terminated by the addition of 2u! of 100uM aminooxyacetic acid and placing
the reaction tubes on ice. The second reaction mixture contained 60u1 of 50mM
potassium phosphate buffer (pH=8), 30u1 of 25mM hydrazine, 6y1 of ImM
aminooxyacetic acid, 30ul of 750mM acetyl-pyridine-NAD+, and 2ul of 1.3
units/ml glutamate dehydrogenase. The volume was made up to 300u1 with water.
This was addedto thefirst reaction. After a short vortex, the reaction was run for 90
min at room temperature and the optical density measured at 340nm. A schematic
representation of these two reactions is shown in Figure 2.3. Here I am measuring
acetylpyridine NADHproducedasa result of reduction of acetyl pyridine NAD+.
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GABA Succinic semialdehyde
HOOC-CH,-CH,-CH,-NH, HOOC-CH,-CH,-C20
H
GABA-T
Os HHOOC-CH,-CH,-C-COOH HOOC-CH,-CH,-C-COOH
NH,
a — Ketoglutaric acid Glutamic acid
AcetylpyridineNADH Glutamate Acetylpyridine
340 nm dehydrogenase NAD +
Figure 2.3. Shows the schematic representation of GABA-T assay
The protein concentration in the platelet samples was measured by the Bradford
reaction (Bradford, 1976). GABA-T activity was expressed as nm/mg/ml
(nanometre/milligram/ml) of protein. Various concentrations (0.2, 0.4, 0.6, 0.8 and
Img/ml) of bovine serum albumin (BSA) were prepared in a platelet buffer
(pyridoxal phosphate (0.2mM), AET (2-aminoethylisothiouronium bromide
hydrobromide) (1mM, pH 7.2)) mentioned above. The samples for protein estimation
were diluted (1/10, 1/20, 1/40) in platelet buffer. 20 pl of the above mentioned
solutions were aliquoted on to a 96 well plate. 250 wl of Bradford reagent was added
to each well. The plate was read on a spectrophotometer at 570 nm. The
concentration of the protein in samples were calculated from the protein
concentration in the BSA.
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2.2.4.2. Assessmentofstorage on GABA-Tactivity
Platelets were isolated using the above method mentioned in section 2.2.3, and stored
at -70°C. Once platelet preparations were taken out of -70°C freezer, they were
always kept on icetill used for the assay. After one week of storage, GABA-T
activity was measured and was comparedto that of platelets stored for one day.
2.2.4.3. Measurement ofGABA-Tactivity using a 96 wellplateformat
Theinitial reaction volume (during standardisation) for the first reaction was 1,100u1
while that of second reaction was 1000uI. The optical density was measured at
340nm bya spectrophotometer. Since it is more cost effective to set up reactions in
small volumes, I standardised the reaction volume to 100u] and 300ul, for the first
and second reactions, respectively. The assay was read on a 96-well plate by a Bio-
Tek FL600 fluorescence micro plate reader at 340nm of absorbance and compared to
that done in a larger volume.
2.2.4.4. Assessmentofthe optimum time requiredfor the 1”reaction
Thefirst reaction in the GABA-Tassayis the rate limiting reaction. To estimate the
optimum time required for thefirst reaction, the reaction was stopped at 10, 20, 30,
40, 50, 60, 70, 80 and 90 min. After the second reaction, the OD was checked and
comparedfor all these assays at the different time points.
2.2.4.5. Effect ofthawing on platelet GABA-Tactivity
GABA-Tactivity was determined at 30, 60, 90, and 150 min after taking the platelets
out of the -70°C freezer. Platelet preparations were always kept on icetill they were
used for the GABA-T assay. This gave me an indication of the optimum timeat
whichtheplatelets are active after removal from the -70°C freezer.
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2.2.4.6. Inhibition ofGABA-Tactivity by vigabatrin (VGB)
Platelets were incubated with VGB for 10 min (Jacob, et al., 1990) . GABA-T
activity was then assessed as outlined above. Various concentrations (314M- 3mM)of
VGBwereusedto attain a dose response curve.
2.2.5. Prediction of putative functional SNPs in the ABAT gene
SNPs were selected from public databases like dbSNP
(http://www.ncbi.nlm.nih.gov/sites/entrez), Ensemble
(http://www.ensembl.org/index.html) and UCSC (http://genome.ucsc.edu/) with the
help of SNP prediction software programs, PupaSNP (Conde, et al., 2004) and
SNPper (Riva and Kohane, 2004). The inclusion criteria used were (a) location of the
SNP (exons, promoter region, exon-intron boundary, 3’untranslated region, 5’ UTR),
(b) minorallele frequency > 5%, (c) population (Caucasian), (d) presence of SNP in
conserved regions of the gene. Sequencesofat least 100 bp and a percentidentity of
at least 70% that match in alignments of sequences between two species were
considered as conserved region. SNPsin this region could alter the function of the
gene (Loots, et al., 2000) and (e) function. SNPs are knownto alter the function of
the gene products-proteins. They could increase (Sim, et al., 2006) or decrease the
activity of enzymes (De Morais,et al., 1994).
2.2.6. Genotyping
All samples were genotyped using the TaqMan allelic discrimination assays
according to the manufacturer’s instructions on the ABI PRISM 7000® platform.
TaqMan chemistry (Figure 2.4) was used for allelic discrimination. Briefly, an
oligonucleotide was constructed consisting of a reporter fluorescent dye on the 5’ end
and a quencher dye on the 3’ end. Whenthe probeis intact, the energy from the
72
fluorescent dye flows to the quencher dye by a phenomenon named fluorescence
resonance energy transfer (FRET). In the presence of a target sequence, the 5’
nuclease activity of the Taq DNA polymerasecleaves the annealed probe, separating
the reporter dye from the quencherresulting in fluorescence of the reporter dye. This
fluorescence can be measured and quantified. More reporter dye is cleaved from its
probe resulting in an increase in fluorescence with each cycle of the PCR. This
fluorescence is proportional to the amount of PCR product.
In allelic discrimination PCR assays, a specific fluorescent dye labeled probe was
used for each allele. The probes contained the 6-FAM and VIC dyes,to differentiate
the amplification of the two alleles. During PCR, each probe annealed to the
complimentary sequence between the forward and reverse primers. Taq DNA
polymerase only cleaved the hybridized probes. The reporter dye was cleaved from
the quencherdye. The fluorescent signal generated by the PCRreaction indicated the
allele present in the sample, as demonstrated in Figure 2.5.
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Genotyping was done without knowledge of the GABA-T activity status of the
volunteers. All of the reactions were done in the presence of negative controls. 10%
of the samples (positive controls) for each SNP were genotyped twice and checked
for any discrepancies. These positive controls were randomly selected for each allele
of a SNP.
Each 20ul reaction contained 10u1 of TaqMan® Universal PCR master mix, |ul of
TaqMan® pre-designed SNP genotyping assay, 1.5ul of DNA and 7.51 of water.
The conditions used for the PCR were 50°C for 2 min, 95°C for 10 min and 40 cycles
of 95°C for 15 sec and 60°C for 1 min.
2.2.7. Genotype- phenotypecorrelation
GABA-Tactivity was ascertained in 32 healthy volunteers of Asian and Caucasian
origin. These healthy volunteers were genotyped for the 5 selected SNPs in ABAT
gene. Their genotype wasthen correlated with their GABA-Tactivity.
2.2.8. Statistical analyses
All the statistical tests were performed using SPSS software (SPSS 16.0). Paired
Student’s t test was used to compare the GABA-Tactivity of platelets stored for one
day and for a week. p value < 0.05 denoted that there wasa significant difference in
GABA-Tactivity of platelets under these conditions.
The GABA-Tactivity in platelets when the assay was done in large volume (2,100
ul) was compared to that when the assay was done on a 96-well plate in a smaller
volume (400ul) by unpaired Student’s t test. A p value of < 0.05 was considered
statistically significant.
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One way analysis of variance (ANOVA)wasused to compare the means of GABA-T
activity at different time points to determine the optimum time required for the first
reaction, which is the rate limiting reaction. A p value of < 0.05 implied that there
was a significant difference in GABA-T activity at the different time points
compared.
Theeffect of thawing onplatelet activity was assessed acrossthe different time points
using one way ANOVA.A p value of < 0.05 indicated that there wasa statistically
significant difference in GABA-Tactivity in the various groups analysed.
The GABA-Tactivity of each of the VGB exposed platelet groups was compared to
that without VGB treatment using one way ANOVA. Bonferroni correction for
multiple testing was applied. A statistically significant difference in GABA- T
activity was indicated by a p value < 0.05.
H-W equilibrium principle defines a hypothetical situation in which there is no
change in the gene pool (frequencies of alleles), hence no evolution. The allele
frequencies were calculated. By using the H-W equilibrium equation, p+ 2pq + gq =
1, where p is the frequency of the dominant allele and q is the frequency of the
recessive allele, an expected number of people having a particular genotype
(homozygous major, heterozygous or homozygousrecessive) can be calculated. The
chi-squared test compares the expected and observed counts and states whether there
is a significant difference between the two (p value < 0.05).
Genotype-phenotype correlation was undertaken by one-way ANOVA using the
SPSSsoftware (SPSS 16.0). Bonferroni correction for multiple testing was done. A p
value < 0.05 wastakento bestatistically significant.
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2.3. Results
2.3.1. GABA-Tactivity is dependent on platelet isolation method
Platelets were isolated (a) soon after blood collection, (b) from plasma, after allowing
the blood to stand for 2hrs, and (c) 2 hrs after adding dextran, and later GABA-T
activity was determined. The technique described in section 2.2.4.1 has previously
been used to measure the activity of brain GABA-T.Forthe first time, I used it to
measure platelet GABA-T activity. Modifications were made to elucidate the
optimum activity of platelet GABA-Tactivity. There was no significant variation in
GABA-Tactivity in platelets isolated from blood soon after collection and from
plasmaafter 2hrs. Contrast microscopy revealed the platelets were contaminated with
RBCs whenisolated from blood soon after the collection. In contrast, there was no
RBC contamination of platelets when isolated from blood treated with dextran, but a
significant decrease (p < 0.05) in GABA-Tactivity was observed, as shown in Figure
2.6. No RBCswere foundin platelets isolated from the plasma.
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Figure 2.6. GABA-T activity using platelets isolated by different methods.
Each experiment was performed 6 times and GABA-T activity was
ascertained 6 timesin triplicate. There was a significant (ANOVA) decreasein
GABA-T activity when platelets were extracted from blood to which dextran
was added. The results represent the mean value of 6 experiments with the
error bars representing the standard error of the mean (SEM).
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2.3.2. GABA-Tactivity is not affected by storage
The GABA-Tactivity in platelets was estimated immediately (next day) and after
one week of storage at -70°C. There was no significant difference (p > 0.05) in
GABA-Tactivity as shownin Figure 2.7.
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Figure 2.7. Shows the GABA-T activity of platelets isolated the next day (0
week) and after one week. GABA-T activity was ascertained 6 times in
triplicates at O and 1 week. Results represent the mean value of 6
experiments with the standard error of mean (SEM).
2.3.3. GABA-Tactivity using a miniaturised assay
Nosignificant difference (p > 0.05) in activity of GABA-T was observed when
measured using a spectrophotometer and by a Bio-Tek FL600 fluorescence micro
plate reader on a 96 well plate, as shown in Figure 2.8.
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Figure 2.8. Shows the GABA-T activity of platelets read on a 96 well plate.
The activity was ascertained 6 times each by a spectrophotometer and by a
Bio-Tek FL600 fluorescence micro plate reader at 340nm. Each GABA-T
activity assay was donein triplicate. Results represent the mean value of 6
experiments and the error bar represents the standard error of mean (SEM).
2.3.4. Optimum time required for the first reaction.
Thefirst reaction is the rate limiting reaction. There was nosignificant difference in
optical density whenthefirst reaction was stopped at any of the time points assessed
(10-90 min), as shownin Figure 2.9. The volumeofthe first reaction was 100 ul.
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Figure 2.9. shows GABA-Tactivity whenthefirst reaction was stopped at 10-
90min. The experiment was repeated 4 timesintriplicates. Results represent
the mean value of 4 experiments and the error bar represents the standard
error of mean (SEM).
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2.3.5. GABA-T activity after removal from the freezer
GABA-Tactivity was checked 30, 60, 90, 150 min after taking the platelets out of the
-70°C freezer. The platelet samples were kept on ice until used for the estimation of
GABA-T activity. There was nostatistically significant decrease in GABA-T
activity until 150 min, as demonstrated in Figure 2.10. There was a downward trend
in activity, most pronounced at 150 min, although this did not reach statistical
 
   
 
           
significance.
%
°5 0.145o = 0.14EE 0.135 1 I
BE 0.13 |BE 0.125 ]3s 0.12
a 0.115
a 0.11 + T T T T 1
o 30 60 90 120 150
Timein min   
Figure 2.10. Shows GABA-Tactivity of platelets measured 30-150 min after
taking the platelets out of the freezer. This experiment was done 3 timesin
triplicates. Results represent the mean value of 3 experiments and the error
bar represents the standard error of mean (SEM).
2.3.6. Inhibition by vigabatrin (VGB)
Dose-dependent inhibition of platelet GABA-T activity was observed as shownin
Figure 2.11. VGB at 3mM concentration produced statistically significant (p <
0.011) difference in GABA-T activity when compared to the platelets not treated
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with VGB,after correction for multiple comparisons. However complete inhibition
of platelet GABA-Tactivity was not achieved even at 3mM. The GABA-Tactivity
with other concentrations of VGB wasnotsignificantly different from that without
VGB.
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Figure 2.11. Showsinhibition of GABA-T activity by various concentrations of
vigabatrin. This experiment was performed six times in triplicates. Results
represent the mean value with the standard error of mean (SEM). 3mM of
vigabatrin concentration produced a statistically significant (ANOVA, after
correction for multiple comparisons) difference in GABA-T activity when
comparedto the platelets not treated with vigabatrin.
To summarise, the conditions used for GABA-T activity assay for the rest of the
experiments were as follows: platelets were isolated and stored for one week before
GABA-T activity was estimated. GABA-T activity was ascertained within 30
minutes of taking it out of the -70°C freezer. This assay consisted of 2 reactions. The
first one was the rate limiting reaction for 30 min and the second reaction was
performed for 90 minutes. The volumeofthe first reaction and secondreactions were
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100and 300ul, respectively. This assay was read on a 96 well plate by a Bio-Tek
FL600 fluorescence micro plate reader at 340nm of absorbance.
2.3.7. Putative functional SNPs predicted in ABAT
Table 2.1 shows the putative functional SNPs predicted in ABATusingthecriteria
mentioned in the methods section. Out of 745 known SNPs in ABAT (dbSNP), 5
were selected for genotyping. As seen in Figure 2.12, these were present in different
locations on the gene.
 
5' UTR a LTRrs1345300 rs1641003 rs1641022
| "| —t ——+
rs1731017 rs1079348
Figure 2.12. A schematic representation of selected SNPs mapped on to
ABATgene.Theblue blocks represent the exons.
Table 2.1. Putative functional SNPs in ABAT to genotype
 
Position in Aminoacid
ONE ID Chromosome 16 Alleles change Type Mak
rs1731017 8747455 (-) T/C Q/R NS-ESE 0.4
rs1641022 8776277 (+) A/C V/V S-ESE 0.439
31079348 8780957(+) TIC ay 0242oundary
rs1641003 8742317 (+) C/T upstream 0.225
rs1345300 8671929 (+) C/T 0.192
 (NS —Non synonymous, S — Synonymous, ESE — Exon splice enhancer, MAF -
minorallele frequency).
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2.3.8. Allelic frequency of the selected SNPs
Figure 2.13 shows anallelic discrimination plot representative of the genotyping
performed. The allelic frequencies of the selected SNPs were ascertained by real
time PCR. Table 2.2 below showstheallelic frequencies of the above SNPs in my
study population. All the SNPs were in H-W equilibrium (Table 2.3). The allele
frequencies were comparableto that in dbSNP.
Alielic Discnmination
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Figure 2.13. An example ofallelic discrimination plot of rs1731017 using real
time PCR technology by ABI PRISM 7000 Sequence detection system. The
homozygous wild type (GG genotype) is represented as blue diamonds,
heterozygotes (GA) as green triangles and the homozygous mutant (AA) as
blue diamonds. NC is negative control.
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Table 2.2. Allelic frequency of genotyped SNPs in ABAT
 
dbSNPSNP No. ofindividnals “mr alleles Major allele: Minorallelefrequency frequency frequency
1s1731017. 139 A: 0.400 G: 0.600 0.400
181641022 139 A: 0.439 C: 0.561 0.439
131641003 139 C: 0.225 T: 0.775 0.225
1s1079348 138 C: 0.242 T: 0.758 0.242
1s1345300 137 C: 0.192 T: 0.808 0.192
 
Table 2.3. Demonstrates that the SNPs were in Hardy-Weinberg equilibrium
(as shownbythe X°test)
SNPid Genotype Observed No. of Expected No. of peoy x? p value
GG 50 50
rs1731017 GA 67 66 0.004 0.998
AA 22 22
TT 67 79
1s1079348 TC 59 50 2.906 0.234
CG 13 8
TT 90 89
rs1345300 TC i) 43 0.893 0.64
CC 8 >
TT 91 82
rs1641003 TC 43 48 1.128 0.569
CC 4 6
CC 55 43
rs1641022 CA 64 68 2.359 0.307
AA 20 26
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2.3.9. Genotype phenotype correlation
The GABA-T activity was estimated in 32 healthy volunteers. The results were
expressed as nm/mg/ml protein. This was correlated to the genotype of 5 SNPs. No
association was observed between GABA-T activity and SNPs rsl641022,
rs1079348, rs1641003 and rsl1345300 (Figure 2.14). An association was found
between GABA-Tactivity and SNP rs1731017. The homozygous GG individuals had
significantly lower activity than AA (p=0.011) or GA (p= 0.001) individuals as
shown in Figure 2.15.  1s1731017 is a nonsynonymous SNP leading to a
glutamine/arginine (Q/R) amino acid changeat position 56 of the GABA-T enzyme.
BO17 and BO18 wereoutliers (Figure 2.14 and 2.15). Both genotyping and GABA-T
activity were estimated three times in these individuals. To the best of my knowledge
an association of SNPs and GABA-Tactivity has not been reportedearlier.
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Figure 2.14. Correlation of GABA-T activity in 32 healthy volunteers with
different SNP genotypes - rs1641022, rs1345300, rs1641003 and rs1079348.
The Y axis represents GABA-T activity and X axis the genotype of healthy
volunteers. No association was found between GABA-Tactivity and any of
these SNPs.Individuals BO18 and BO17 areoutliers.
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Figure 2.15. GABA-T activity in 32 healthy volunteers with different
genotypes for the SNP rs1731017. Y axis represents the GABA-T activity and
X axis the genotype of healthy volunteers. GABA-T activity of healthy
volunteers with GG wassignificantly lower than AA & GA. Genotypes AA &
GA did not affect GABA-T activity. Individual BO18 wasan outlier.
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2.4. Discussion
Platelets are discoid cells produced by megakaryocytes in the bone marrow. They are
released into blood by the fragmentation of the megakaryocyte cytoplasm. Theirlife
span is 9-10 days after which they are replenished (Rodgers, 1999; Camacho and
Dimsdale, 2000). Platelets are mainly involved in haemostasis. They have been used
as a model for serotonin transport in the brain (Paasonen, 1968; Lingjaerde, 1969).
They also contain uptake mechanisms for many amino acid transmitters including
GABA,glutamate, aspartate and glycine, similar to those present in the CNS (Zieve
and Solomon, 1968; Mangano and Schwarcz, 1981; Hambley and Johnston, 1985).
Indeed, platelets have been used to explore the etiopathogenesis of many
neuropsychiatric diseases (Mangano and Schwarcz, 1982; Ferrarese, et al., 1999;
Ferrarese, et al., 200la; Ferrarese, et al., 2001b; Ferrarese, et al., 2001c). The
characteristics of platelet GABA-T are similar to those of brain GABA-T. The
kinetic, molecular and pharmacological properties of these enzymes are comparable.
They are both inhibited by VGB and other inhibitors and they have the same
substrates. However, platelet GABA-T activity is much lower than that of the brain
GABA-T (White, 1979; White and Faison, 1980; Sherif, 1994). It has been proposed
that platelet GABA-T activity can be used as a model of brain GABA-T activity
(Arteaga, et al., 1993; Sherif, 1994). For this reason, I used platelets as a model
system to assess GABA-Tactivity.
I have described the standardization of a GABA-T assay in platelets. This is a
spectrophotometric method, hence not as sensitive as radiometric assays or gas
chromatography—mass spectrometry (GC-MS). This assay is a coupled reaction in
that it involves two reactions and the product of one reaction is the substrate of the
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second reaction. This assay thus measures the GABA-Tactivity indirectly. As shown
in Figure 2.3, this assay measures the NADH formed not succinic semialdehyde. In
my experiments, the GABA-Tactivity did not significantly decrease over time. This
could be dueto the fact that the rate of formation of NADH maynotbe equal to the
rate of formation of succinic semialdehyde. There could be a lag time for the
formation ofNADH.Also coupled reactions can give higher values when the enzyme
concentration is less as in the case of estimation of creatinine kinase activity
measured by coupled reaction (Dinovo, et al., 1973). Also there was nosignificant
difference in GABA-Tactivity when the time of the first reaction, which is the rate
limiting reaction was changed from 10-90 min. In a coupled reaction, for example in
the reaction in Figure 2.3, if the measurement ofNADH hasto be a direct measure of
the GABA-T activity, the velocity of glutamate dehydrogenase enzyme should
approach infinity and the reaction should be irreversible (Dinovo,et al., 1973). This
is hardly the case in most of the reactions conducted in the laboratory. Time is
required to achieve steady state concentration of the intermediate products; thus the
acetylpyridine NADH formed may beless than succinic semialdehyde formed. The
second reaction is a reversible reaction, further reducing the concentration of
acetylpyridine NADH.
There are no in vitro studies exploring the effect of VGB on humanplatelets.
However, the IC50 values of VGB for neuronal GABA-T vary from 89- 200M
(Gram,et al., 1989). I used concentrations between 34M — 3mM of VGBto inhibit
platelet GABA-T. This concentration is well above the concentration of VGB
achieved in healthy volunteers taking 1 g, 2 g and 4 g doses of VGB. At these doses
of VGB, the GABA-Tactivity was 43%, 30% and 21%, respectively compared with
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the mean control value (Rimmer, et al., 1988). VGB, a specific inhibitor of GABA-T
however was not able to totally abolish platelet GABA-T activity in the assay
reported here. While other studies (Rimmer, et al., 1988; Arteaga, et al., 1992) have
been able to reduce the platelet GABA-Tactivity by around 70-75%, my experiments
could only decrease this by 50%. This could be due to the above mentioned reasons
or it may suggest that the GABA-Tassay is not specific. In the assay described, I
have measured the amount of acetylpyridine NADH formed (Figure 2.3). Platelets
contain NADHasa part of their redox regulation in platelet adhesion (Seno,et al.,
2001; Arthur, et al., 2008), and the assay may also be measuring this NADH.It is
known that platelets contain GABA, glutamic acid and glutamate dehydrogenase
(Oset-Gasque, et al., 1986). So even before the start of the assay, acetyl pyridine
NADHcould be formed, which is also measured by the assay. Additionally platelets
were treated with VGB for only 10 min — it is possible that greater GABA-T
inhibition could have been achieved with a longer incubation. Despite these possible
limitations, VGB did inhibit GABA-T activity in this assay suggesting that GABA —
T is definitely present in platelets. All platelet samples from healthy volunteers were
treated similarly. Therefore, though not an ideal assay, conclusions can be drawn
from these experiments.
Platelet isolation requires 3-4 hrs. Ascertaining the GABA-T activity takes another3-
4 hrs. Usually the GABA-Tactivity of platelets from 6-8 individuals is assessed at
the same time. Henceplatelet isolation and estimating the GABA-T activity on the
same day is not economical in terms of time, effort and resources. Therefore, I
checked the GABA-T activity of platelet samples after storing at -70°C for a week.
As shown in Figure 2.5, the GABA-T activity was maintained after a week of
storage.
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Next I scaled down the reaction volumes, since it is cost effective and less time
consuming to perform the GABA-Tassay. This reduction did not affect the GABA-T
activity as seen in Figure 2.6. Potassium phosphate buffer was used instead of the
Tris-HCL used by Schousboeetal. (1973). I used phosphate buffer since Tris buffers
inhibit GABA-T activity. Tris forms a complex with pyridoxal phosphate, the
cofactor essential for the functioning of GABA-T. This reduces the amount of
pyridoxal phosphate available for the activity of GABA-T (White and Sato, 1978).
The GABA-Tactivity in platelets varies considerably across species (Sherif, et al.,
1993). As mentioned earlier, GABA-T enzymeis widely distributed in the CNS and
other body tissues. GABA-Tactivity is higher in the grey matter than in the white
matter (Sherif, et al., 1992a). This enzyme is present in both neurons and theglia.
However most of its activity is in the neurons (Bedoya, et al., 1988; Larsson and
Schousboe, 1990). In rats, an increase in GABA-Tactivity was reported with age and
sex. Male rats showed 15-25% higher activity than females (Aoyagi, et al., 1990;
Sherif, et al., 1991). In humans, no age or sex related changes in brain orplatelet
GABA-Tactivity have been reported (Berrettini, et al., 1982; Armijo, et al., 1989;
Arteaga, et al., 1993; Sherif, et al., 1992b). There is no seasonal or diurnal variation
in GABA-T activity in a single individual, though great inter-individual variability
exists (Rimmer,et al., 1988; Bolton, et al., 1989). It has also been shown that GABA-
T activity decreased significantly when platelets were isolated after a meal
(Berrettini, et al., 1982). Therefore, I used fasting blood for platelet isolation to
determine the GABA-Tactivity in healthy volunteers.
Kinironset al. (2006a) used a tagging methodto identify putative functional SNPs in
the ABAT gene. I used the criteria mentioned above (2.2.5) to identify putative
functional SNPs in the ABAT gene. All the SNPs genotyped were in H-W
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equilibrium. These SNPs included SNPs in the 5’ UTR region, coding and intronic
regions (Table 2.1). The synonymous SNP rs1641022 is close to the active site at
position 329 while rs1641022 and rs1731017 are predicted to be exon splicing
enhancers (ESE) according to the software programs I used in selecting the SNPs.
ESE sequences are present in the exons and they are involved in constitutive and
regulated splicing (Blencowe, 2000). Variation in these sequences could lead to exon
skipping and defective alternate splicing. SNPs in the intronic regions could also
affect RNA splicing (Brockméller and Tzvetkov, 2008). All these SNPs were in
highly conserved regionstoo.
There are no studies to date, which have lookedinto the association between GABA-
T activity and SNPs in the ABATgene.I lookedat the correlation between GABA-T
activity and selected SNPs in 32 healthy volunteers. Studies have shown GABA-T
activity varies in different types of epilepsy (Arteaga, et al., 1993; Rainesalo,et al.,
2003). Twin studies have demonstrated that GABA-Tactivity may be determined by
genetic factors (Berrettini, et al., 1982). It has been proposed that genetic factors play
a major role in determining GABA-Tactivity (Berrettini, et al., 1982; Rainesalo, et
al., 2003) . For the first time, I showed an association between GABA-Tactivity and
SNP rs1731017. VGBacts by inhibiting the GABA-T enzyme. SNP rs1731017 is a
non synonymous SNP whichresults in a Q/R amino acid change in the GABA-T
enzyme. Though this SNP is not near to any of the active sites in the primary
structure, the SNP is not far from the active site in its tertiary structure as seen in
Figure 2.16. This could potentially affect the activity of GABA-T.
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Figure 2.16. Showing the SNP rs1731017 in GABA transaminase enzyme.
Only one subunit of this enzyme is shown which consists of 2 identical
monomersrepresentedin blue and red colours.
In mystudypopulation, according to H-W equilibrium equation (p2+q2+2pq = 1),
the minor allele frequency should be at least 0.4 to have five individuals who are
homozygous for the minor allele. Then I could look at the association between
homozygous minorallele, homozygous majorallele, heterozygous, and the GABA-T
activity. Among the SNPsselected, only rs1731017 and rs1641022 had a minorallele
frequency above 0.4. To detect association between the other SNPs and GABA-T
activity a larger study population is required. Therefore, | cannot conclusively say
that there is no association between other SNPs genotyped and GABA-Tactivity.
Clearly, there is a necessity to look at variants affecting genes, which are involved in
the pharmacokinetics and pharmacodynamics of VGBin a large patient population.
This could help us identify SNPs which predispose to VVFD, and help us develop a
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screening test to prescribe this highly effective AED in selected patients (Coppola, et
al., 1997; Mitchell and Shah, 2002), whowill benefit from this drug, especially the
paediatric patients with infantile spasms. I have established that variation at SNP
rs1731017 affects the activity of GABA-T. The next step will be to investigate
GABA-Tactivity in VVFD patients and compare it to that of patients who have
normalfieldsin spite of being treated with VGB.
95
Chapter3
Estimation ofGABA-Tactivity in patients with
vigabatrin-inducedvisualfield defects
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3.1. Introduction
VGB,an antiepileptic drug, with a similar structure to GABA (Figure 3.1) has been
used in the treatment of complex partial seizures (Coppola, et al., 1997; Cramer, et
al., 1999; Satishchandra,et al., 1999; Coppola, 2004) and infantile spasms (Aicardi,
et al., 1996; Appleton, et al., 1999; Mitchell and Shah, 2002) since 1989 in more
than 60 countries (Hisama,et al., 2001). However Ekeet al. (1997) reported three
patients who developed peripheral visual field loss after taking VGB (Figure 3.3).
Figure 3.2 shows the normal isopter positions in the peripheral visual field
(Niederhauser and Mojon, 2000). When comparedto Figure 3.2, all the patients had
loss of peripheral visual field (Figure 3.3). Their central visual field was intact. All
three patients had tunnel vision. Their vision and the peripheral visual field
constriction did not improve after stopping VGB.
3.1la 3.1b
BON HN COOH
GABA Vigabatrin
Figure 3.1. Showing the structures of GABA (3.1a) and Vigabatrin (3.1b)
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Figure 3.2. Normal positions of the isopters. The average positions + 2
standard deviations are plotted. (Niederhauser,et al., 2000)
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al. 1997).
centre), 38 monthsafter start of vigabatrin treatment (case 3, bottom) (
top), 28 monthsafter start of vigabatrin treatment (case 2,
Eke et
treatment(case 1
Figure 3.3. Goldmann visual fields 37 months after start of vigabatrin
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VGBcauses VFD in approximately 30-50% of patients. The VVFD consists of
bilateral constriction of the peripheral visual field. The nasal field is usually
extensively affected (Wild, et al., 1999; Lawden, et al., 1999; Gross-Tsur, et al.,
2000; Gross-Tsur, et al., 2002). The severity can be mild to severe; however VFD
does not affect the routine activities of the majority of patients. There are also
reports of mild to moderate involvement of the central retina (Krauss, et al., 1998;
Nousiainen, et al., 2000b; Manuchehri, et al., 2000). They include colour vision
disturbances, and reductions in contrast sensitivity and visual acuity (Eke, et al.,
1997; Krauss, et al., 1998; Nousiainen, et al., 2000a; Nousiainen, et al., 2000b).
Electrophysiological studies have also demonstrated defects in both the outer and
inner retina at the level of the Miiller cells (Coupland, et al., 2001). VVWFD has
unique electroretinogram findings (Nousiainen, et al., 2000a). Males have a two-
fold greater risk of developing VVFD (Wild, et al., 1999; Hardus, et al., 2000a;
Hardus,et al., 2000b). Evidence for the association between VVFD and duration of
treatment and dose of VGB has been contradictory (Wild, et al., 1999; Lawden,et
al., 1999; Manuchehri, et al., 2000; Newman,et al., 2002; Kinirons, et al., 2006b).
However,a recent large prospective cohort study reported that male gender, duration
and dose of VGBarerisk factors for the development of VVFD (Wild,et al., 2007).
VVFD has an insidious onset. The earliest period at which VVFD has been
documented in complex partial seizures is 11 months. VVFD appears on an average
after 5.5-8 yrs treatment with VGB (Ovation Pharmaceuticals, 2007).
The exact aetiology of VVFD is not known. Possible explanations include direct
toxicity of GABA (Hosking and Hilton, 2002) or VGB(Sills, et al., 2001) to the
retina, ischaemia in the retina caused by GABA (Hosking and Hilton, 2002),
abnormal visual fields associated with complex partial seizures (Hisama, et al.,
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2001) and an idiosyncratic reaction to VGB (Newman,etal. 2002; Best, et al., 2004;
Kinirons, et al., 2006; Wheless, et al., 2007). Although the mechanism of
development of VVFD is not known, the site of injury appears to be the retinal
ganglion cells (Best and Acheson, 2004; Wheless,et al., 2007).
In chapter 2, I described the validation of a platelet GABA-T assay. In initial
studies, this assay was used in healthy volunteers with known common
polymorphisms. However, it is important to note that investigation of healthy
volunteers only allows an assessment of common polymorphisms, and one cannot
rule out the presence of rare mutations in the ABAT geneitself or in other genes
which may control its activity. In view of this, the purpose of this chapter was to
investigate the activity of GABA-T in platelets taken from patients who had been
prescribed VGB and (1) who developed VVFD and compare them to (2) patients
without the visual field defects. In effect, although I had previously utilised a
genotype to phenotype approach, in this chapter, I reverted to the conventional
paradigm of using a phenotypic assay to identify differences in the activity of a
candidate enzyme.
The aim of this chapter was:
To estimate and compare GABA-T activity in patients who developed
VVEDandin patients who did not develop VVFD.
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3.2. Methods
3.2.1. Materials
Optiprep was purchased from Axon Lab AG, Le Mont-sur-Lausanne, Switzerland.
All the other chemicals used for the experiments mentioned in this chapter were
purchased from Sigma Aldrich, Poole, England.
3.2.2. Subjects
This study was a sub-study of the multicentre study — “Pharmacogenetics of GABA-
ergic mechanisms of benefit and harm in epilepsy: a retrospective study of genetic
and environmental factors determining potential harm from vigabatrin therapy”.
This was a collaborative project by Charing Cross Hospital, the National Hospital
for Neurology and Neurosurgery, the Sanger Institute and the University of
Liverpool. The patients for this study were selected from the patients recruited
from the above mentioned main study. Patients over the age of 12 with any type of
epilepsy, who took VGBforat least 12 months, were included in this study. Patients
who are blind or partially sighted (non-VGB aetiology) or having significant
learning difficulties were excluded from this study. Fresh blood was required for
this study. Therefore, only patients from Walton Centre for Neurology and
Neurosurgery, Liverpool were recruited. Out of 358 patients recruited for the main
study only the first 14 who agreed to participate in the study were recruited, since
this was a pilot study. This could introduce selection bias of patients. However, the
mean age and duration of VGB therapy of these 14 patients (51.57yrs, 5.39
respectively) did not significantly differ from the patients in the main study (49.12
yrs, 6.01 yrs, unpublished data). 93.3 % of patients had partial seizures similar to
this pilot study (92.8%).
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Four experts looked at the visual fields (this comprised of three ophthalmologists
and one vision scientist). Visual fields were assessed by Humphrey Field Analyzer,
by three consultant neuro-opthalmologists separately who wereblindedto all clinical
information. A database managerentered their diagnosis in a database.If there was a
disagreement on the results, the issue was discussed with the fourth person acting as
chairperson until the problem is resolved (i.e. they agree upon one definition).
Patients were assignedto the following categories by neuro-ophthalmologists:
e Normal
e VGBassociated defect: Either binasal or generalised field constriction with
normal fundoscopic examination
e Abnormal non VGBrelated: Hemianopic/ Central field defects
Unreliable: Patients who exhibit responses greater than the standard accepted
criteria for normality (>20% fixation losses, >33% false negative responses,
>33% false positive responses) on visual field assessments.
e Inconclusive: Patients whose fields manifest so high a degree of threshold
variability within test and between tests to render accurate interpretation of
the field impossible.
Powercalculations were not done, as this was a pilot study. Only 14 patients from
Walton Centre for Neurology and Neurosurgery, Liverpool agreed to enter this pilot
study. These 14 patients with epilepsy were treated with VGB. Noneof the patients
was on VGBatthe time of recruitment, even those who did not have any evidence
of VVFD. Seven ofthe patients had VGBassociated defect and seven of them had
normal visual fields. University College London/ University College London
hospital Committees on the Ethics of Human Research (Committee A) approval was
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obtained for this study and a written consent was obtained from all the patients
recruited for this study.
The demographic characteristics of the patients in this study are given below (Table
3.1). Fourteen patients who had been treated with VGB were recruited for this
study. The duration of treatment of VGB was longer in patients who developed
VVEDbutthis was notsignificantly different from those patients without the VVFD
(Table 3.1). The ages of the patients in the two groups were similar, but there was
discordance in the gender ratios between the two groups, although this was not
statistically significant because of the small numbersstudied.
Table 3.1. Showing the demographic characteristics of patients recruited for
this study
 
Visual field not Visual field
affected affected p value
Numberof Males 1 4 0.094
Numberof females 6 3
Age 56 + 11.045 47.14+ 9.616 0.136
Seizure type
Partial 6 7 0.299
General 1 0
Duration of
vigabatrin
Mean(yrs) 3.85 + .95 6.93 + 1.25 0.072
Range(yrs) 1.17-6.17 1.67-11.17
 
3.2.3. GABA-Tactivity
Blood samples were collected from patients 2hrs after food. Platelets were isolated
as mentioned above. GABA-Tactivity of the platelet samples was estimated, as
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described in chapter 2. Bradford method (Bradford, 1976) was used to estimate the
protein concentration (see chapter 2). GABA-Tactivity was expressed as nm/mg/ml.
GABA-Tactivity values decreases significantly after food (Berrettini, et al., 1982).
Because of logistical difficulties, it was not possible to get fasting blood samples
from patients. Therefore, initial experiments were conducted in one healthy
volunteer to determine the effect of food on GABA-Tactivity. A fasting blood
sample and a blood sample after 2hrs of food consumption were collected from the
healthy volunteer. Plasma wasseparated andplatelets isolated, and GABA-Tactivity
measured as described above and in chapter 2.
3.2.4. Statistical analyses
The Chi-squared test (for comparisons of the categorical data) and Student’s t-test
(for comparisons of continuous data) were used to compare the distributions of
demographic characteristics among patients with and without VVFD. The
categorical data were sex and epilepsy syndrome, and the continuous data were age
and duration of treatment. A p value of < 0.05 was considered significant.
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3.3. Results
3.3.1. GABA-Tactivity
It is reported that food affects GABA-T activity (Berrettini, et al., 1982). It was not
possible to collect fasting blood samples from patients. Therefore, GABA-T activity
was estimated in fasting blood samples and in 2 hr postprandial blood samples from
one healthy volunteer. There was no significant difference in GABA-T activity
between the fasting samples and those taken after 2 hours of food intake (Figure
3.4), in the healthy volunteer.
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Figure 3.4. GABA-T activity(expressed as nm/mg/ml) in platelets on the Y-
axis, using blood from one fasting healthy volunteer and blood withdrawn 2
hrs after food intake. This experiment was done3 timesin triplicates on one
individual. Results represent the mean value with the error bars representing
the standard error of mean (SEM).
106
3.3.2. GABA-Tactivity in patients
There wasa significant difference (p = 0.002) in GABA-Tactivity between patients
with and without VVFD (Figures 3.5 and 3.6). The mean GABA-Tactivity in
patients with VVFD was 0.012 + 0.003 nm/mg/ml compared to 0.025 + 0.002
nm/mg/mlin those without the VVFD.
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Figure 3.5. GABA-T activity (nm/mg/ml) in patients with and without
vigabatrin-induced visual field defects. GABA-T activity in each sample was
estimated at least 3 times in triplicate and the mean value was used. The
error bars denote the standard error of mean (SEM). Statistical analysis was
performed by Student’st test.
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Figure 3.6. The values of individual patients are shown in the scatter
diagram. Although there was some overlap in the individuals, a clear
distinction can be seen between patients with and without VVFD. Also
indicated on the figure are those patients who are males(red circles) and
those who are females (blue diamonds). Within the group with VVFD,there
was nodifference in activity between males and females (mean values for
males and females were 0.12040.01 and 0.113+40.01 nm/mg/ml
respectively).
3.4. Discussion
This study has demonstrated a statistically significant difference (p value = 0.002)in
GABA-Tactivity between patients with VVFD when compared to patients without
VVED,with the GABA-Tactivity being significantly lower in patients with visual
field defects. To the best of our knowledge, this is the first time this has been
demonstrated in patients with VVFD. I used the method described in chapter2 to
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estimate GABA-T activity, which is not the ideal method to estimate GABA-T
activity, as mentioned in chapter 2. Nevertheless, since all the samples were treated
uniformly, I could still draw some conclusions that have to be repeated in a larger
trial, preferably a prospectivetrial.
Although the duration of VGB treatment in patients who developed VVFD was
longer than in those who did not develop VVFD,this wasnotstatistically significant
(p value = 0.072). Manystudies, including a recent prospective study by Wild etal.
(2007), have shown that VVFD is seen in patients who are treated with VGB for an
average of 5.5-8 yrs. The lack of a statistically significant correlation between
VVED and the duration of treatment in this study is probably due to the small
sample size. The crucial issue is whether those individuals without VVFD, i.e.
controls, might have gone on to develop the visual field deficit. Clearly it is
impossible to be sure about this given the retrospective nature of the study, and our
data does need to be replicated in another cohort. A numberof studies including
Wild et al. (2007) have reported that VVFD is more prevalent in males than in
females. In our study, I had more males in the group with VVFD; this was again
related to the availability of patients locally, and ideally it would have beenbetterif
the patients were truly sex-matched. This is something that needs to be tackled in a
replication cohort, which unfortunately I could not do because of time constraints.
Nevertheless, it is important to note that there was no difference in the GABA-T
activity in males and females with VVFDas demonstrated in Figure 3.6.
Previous studies have shown that GABA-Tactivity decreases after food (Berrettini,
et al., 1982). However, it was difficult for us to be able to test the patients while
they were fasting, and I therefore estimated the platelet GABA-T activity 2 hours
109
after food. I did not find a significant difference in GABA-Tactivity at this time
when compared to the GABA-T activity estimated in platelets from fasting blood.
This contradicts the findings of Berrettini et al. (1982); the reasons for this are
unknownbut may have been dueto differences in assay sensitivity or dietary factors.
It is important to note that other studies which have explored platelet GABA-T
activity in epilepsy patients did not use fasting blood samples (Arteaga,et al., 1993;
Kumlien, et al., 1995; Rainesalo,et al., 2003).
Our finding that GABA-Tactivity is significantly reduced in VVFD patients when
compared to patients with normal visual fields is novel and highly interesting.
GABA-Tactivity has been evaluated in epilepsy (Sherif and Ahmed, 1995). In our
study there was no significant difference in the epilepsy type among patients with
VVEDandthose without VVFD. The GABA-Tactivity of the patients in our study
was lowerthan healthy volunteers estimated in chapter 2. Some of the studies have
also reported lower GABA-T activity in patients with epilepsy (Rimmer,et al.,
1988) when compared to healthy controls. Some have reported higher GABA-T
activity in patients with partial epilepsy (Arteaga,et al., 1993; Kumlien, et al., 1995)
when compared to healthy controls. However, other studies found no significant
difference in GABA-T activity between partial epilepsy patients and healthy
volunteers (Rainesalo, et al., 2003). Sex, age and seizure frequency did not affect
GABA-Tactivity. Generalised epilepsy syndromeshavea predisposition to occurin
families (Kinirons,et al., 2008). That is, there is a genetic predisposition. GABA-T
activity in monozygotic twins also shows a strong correlation (Berrettini, et al.,
1982). Thus genetic factors are known to affect GABA-T activity, and the inter-
patient variability observed in this study that might be due to this. All our patients
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with and without VVFD except one, had partial epilepsy and were thus well
matched.
The demonstration of a reduction in GABA-T activity in patients with VVFD has to
be contrasted with the lack of correlation between most of the SNPs that were
studied in chapter 2 (except one). However, the SNP (rs1731017) which was
functionally active has not been shown to be a predisposing factor for VVFD
(Kinirons, et al., 2006a). Kinironset al. (2006a) measured the visual field of patients
using the Goldmann test, which is a manualtest. Since this is a subjective test, even
with utmost care to avoid unreliable visual fields, variation in the measurement of
visual fields can happen. Rosset al. (1984) reported a 14% variation in repeated
visual field testing in individuals with normal visual fields. The visual field of the
patients in this study was assessed by Humphrey Field Analyzer, where thetestis
computerized. However, this too has a subjective nature which canlead to variable
test results.
Clearly the approach taken by the above study (Kinirons, et al., 2006a), and in
chapter 2, was to investigate common genomic variants (minor allele frequency
more than 5%). From the data presented, it seems unlikely that commonvariants in
the ABAT genepredispose to VVFD unless the effect size is very small. Given our
finding of a difference in GABA-T activity between patients with and without
VVED,I cannot exclude the possibility that more rare variants, either individually or
in combination, predispose to VVFD. This hypothesis can only be examined by
direct sequencing of the gene, which is on-going at present. In effect, although the
prevailing hypothesis in association studies has been one that common variants
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cause commondiseases, there is now increasing interest in the commondisease-rare
variant hypothesis.
The site of injury in VVFDis thoughtto be the peripheral retina. But recent studies
have shownthat both central and peripheral retinal areas may be involved (Krauss,
et al., 1998; Nousiainen, et al., 2000a; Nousiainen, et al., 2000b; Manuchehri, etal.,
2000). However, the question remains as to what is causing injury to the retina. The
exact cause or the mechanism is still not known. GABA-T is involved in the
catabolism of GABA. If GABA-Tactivity is reduced, this could lead to an increase
in GABAin the retina. When VGBis administered, the level of GABA wouldrise
even more. This could reduce ocular perfusion and glucose metabolism, possibly
through ischemia ofthe retina (Hosking and Hilton, 2002) . If this hypothesis is true,
our patients with lower GABA-T activity may have a greater propensity to develop
VVEDthan their counterparts with higher GABA-Tactivity. I did not assess the
effect of VGB on the GABA-Tactivity of these patients. In any follow-on study the
activity of VGB would haveto be assessed along with the GABA-Tactivity assay to
explore the effect of VGB on GABA-Tactivity in patients who developed VVFD
and those whodid not. However, Hisamaetal. (2001) have shownthat there was no
change in the GABA levels in patients treated with VGB with VVFD when
compared with patients on VGB with normal visual fields, though only three
patients with VVFD werestudied. However, since GABAis retino-toxic (Izumi,et
al., 2004), there could be a threshold above whichit inducesretinal injury. Izumi et
al. (2004) showed that acute exposure of the retina to VGB in presence oflight
causes retinal injury in rats, while VGB alone did not cause retinal injury. The
retina was intact when exposed to GABAin presenceor absenceoflight. However,
all of these were acute studies. By contrast, Jammoulet al. (2009) demonstrated that
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chronic VGBtreatment of rats and mice maintained in 12/12hr night and dark cycles
impaired retinal function and causedretinal injury, while rats kept in darkness had
similar findings as the control group not treated with VGB.
They also observed that VGB toxicity could be mediated by taurine deficiency.
They demonstrated taurine deficiency (67%) in the animals, which had VGB-
inducedretinal toxicity. Taurine replacement in food reduced the features ofretinal
VGBtoxicity in both rats and mice. Theclinical relevance of these findings was
evaluated in infants with infantile spasms on VGBtreatment. All these patients had
significantly lower levels of taurine when compared to their age matched controls.
One of the patients had normal taurine concentration before starting VGB.
However, after 15 months of treatment with VGB, taurine was undetectable in
plasma (Jammoul, et al., 2009). The mechanism of VGB reducing taurine is not
clear. GABA could be the culprit again, being a natural substrate of taurine
transporters; it could compete with taurine for transport (Debler and Lajtha, 1987).
VGBcould have a direct action on taurine uptake and release - an explanation for
the photo-toxicity to photoreceptors, while GABA was phototoxic only in the
presence oflight (Jammoul,et al., 2009). Future studies examining the cellular and
molecular mechanisms of VGB induced taurine deficiency and photoreceptor
degeneration is required for a better understanding of the aetiopathogenesis of
VVED.From the abovediscussion, it is clear that many factors could be involved in
the development of VVFD.
In summary, I have identified lowered GABA-T activity in the platelets of patients
with VVFD when comparedto patients without VVFD. A limitation of our study is
the small numbers of patients studied, and this finding therefore needs replication in
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a large set of patients, preferably in a prospective study. An alternative way of
validating this phenotypic finding may be through the demonstration of rare variants
in the ABATgene — this workis currently on going.
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Chapter4
Development and validation ofan assay to
simultaneously determine clobazam andits active
metabolite N-desmethylclobazam by HPLC
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4.1. Introduction
CLBis a 1, 5-benzodiazepine synthesised in 1972 (Weber,et al., 1972). It has been
used successfully to treat many types of epilepsies especially carbamazepine (CBZ)
resistant epilepsy. NDCB, the most important and active metabolite of CLB is
formed by the action of CYP2C19 on CLB. Drug inducers can increase the activity
and drug inhibitors inhibit the activity of CYP2C19 (Dalby, 2004). During long
term treatment, NDCB accumulates in the body reaching almost 10 times the
concentration of the parent drug (Caccia,et al., 1980; Haigh, et al., 1987) . This may
contribute to the efficacy and toxicity of CLB. The concentration of CLB is
proportional to the dose in an individual patient but exhibits great inter-individual
variation. However the concentration of NDCBis not proportional to the CLB dose
but also exhibits great inter-individual variation (Guberman,et al., 1990; Bardy,et
al., 1991). Therefore simultaneous estimation of CLB and its metabolite NDCB may
be useful for several reasons: (a) to assess compliance; (b) to determine the ratio
between the parent drug and the active metabolite as a marker of CYP2C19 activity;
(c) to assess inter-individual variability in CLB: NDCB ratio; (d) to relate this
variability to genotype; and (e) to assess the possible relationship between
CLB/NDCBlevels and adverse drugeffects.
There are various techniques described for the quantification of CLB and NDCB.
These include radiochemical techniques, fluorometry (Stewart, et al., 1979), mass
spectrometry, gas chromatography (Badcock and Zoanetti, 1987) and HPLC
(Scholten, et al., 1980; Brachet-Liermain, et al., 1982; Ratnaraj, et al., 1984; Dusci
and Hackett, 1987; Gazdzik, et al., 1989). In radiochemical techniques, the measured
radioactivity represents the total amount of drug, including its metabolites. In
fluorometry, the metabolites also contribute to the signal generated to measure the
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quantity of the drug. Mass spectrometry, gas chromatography and HPLC are more
specific methods (Rupp,et al., 1979). HPLC is less laborious, simple and more cost
effective than gas chromatography. For instance, the analyte requires derivatization
and hasto be vaporized in gas chromatography (Proen¢a,et al., 2004).
The main advantages of HPLC over gas chromatography are lower temperatures
during analysis that reduces the probability of isomerization of double bonds, and the
possibility of collecting fractions for further analysis (Czauderna and Kowalczyk,
2001). HPLC and liquid chromatography-mass spectrometry (LC-MS) have largely
replaced gas chromatography from the bio/drug analytical scene. Mass spectrometry
is more sensitive and selective than HPLC, but expensive. There are a number of
HPLC methods published for the simultaneous estimation of CLB and NDCB
(Brachet-Liermain,et al., 1982; Ratnaraj, et al., 1984; Zilli and Nisi, 1986; Dusci and
Hackett, 1987; Gazdzik, et al., 1989; Streete, et al., 1991). Some need a large
volumeof plasma (1ml) for the estimation of the analytes (Brachet-Liermain, etal.,
1982; Ratnaraj, et al., 1984; Dusci and Hackett, 1987). Other HPLC methodsare
cumbersometo perform (Scholten, et al., 1980; Ratnaraj, et al., 1984) and some use
diethyl ether which is inflammable (Brachet-Liermain, et al., 1982; Tomasini,et al.,
1985; Dusci and Hackett, 1987). I tried replicating the method published by Streete
et al. (1991). I could not procure the internal standard (IS) they used, in spite of
contacting the manufacturer. Though other chemicals were used as internal
standards, adequate resolution of the peaks of the analytes and ISwas not achieved.
Therefore, I chose to develop an alternative simple, sensitive, reproducible and cost
effective reverse phase gradient HPLC method to analyse CLB and NDCB
simultaneously in patient samples.
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The aim of this chapter wasto:
To develop and validate a novel, sensitive, reproducible, rapid and simple reverse
phase HPLC methodfor the simultaneous estimation of CLB and NDCB.
4.2. Methods
4.2.1. Reagents and chemicals
NDCB was a kind gift from Centaur Chemicals Pvt. Ltd, Mumbai, India. HPLC
grade acetonitrile (ACN) and methanol were purchased from Fisher Scientific
(Loughborough, UK) and ammonium acetate from VWR Laboratory Supplies (Poole,
UK). CLB, diazepam, Tris-base, chloroquine, primaquine, clozapine and
dichloroethane were purchased from Sigma-Aldrich (Poole, UK).
Blank plasma was purchased from the blood bank. This was stored at -20°C. Water
from a water purification system (Purelab Option, Elga labWater, High Wycombe,
UK)wasused throughout the experiments.
4.2.2. Equipment
The HPLC system used consisted of a Dionex P680 pump, a Dionex ASI-100
automated sample injector, a Dionex UVD170U variable wavelength detector set at
235nm wavelength and a computer with Dionex Chromeleon® (version 6.70) data
acquisition software.
Separation of CLB and NDCBwasinitially attempted using a thermo 5um, 150*4.6
mm Hypersil® BDS C18 column. However, the results of this method were not
satisfactory, and therefore a gradient method was developed for the separation of
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CLB and NDCB. A Waters, Nova-pak®, C18 (4u, 3.9x150 mm) column wasused in
this method.
4.2.3. Sample preparation
Prior to extraction, the calibrators, quality controls (QCs) and samples were taken out
from the freezer and allowed to thaw completely. They were vortexed (2 seconds
(sec) and centrifuged (1000 rpm for Imin). All calibrators, QCs and samples were run
in duplicate. The standard curves for CLB (25, 50, 100, 200, 500ng/ml) and NDCB
(200, 400, 800, 1600, 4000 and 8000ng/ml) were prepared by diluting 1000ng/ml
CLB and 8000ng/ml NDCB, with drug free plasma in a 10ml labeled glass tube.
500ul of each test sample and QC samples were transferred into a 10ml labeled LSL
glass tube. 250ul of Tris buffer (0.8M, pH 10.9) and 25ul of the [Sat 20,:.g/ml were
added to each test tube, followed by 6ml of 1, 2-dichloroethane. Diazepam was the
ISused for the gradient method. Clozapine, chloroquine and primaquine were
experimented as internal standards by the isocratic method. Each tube was then whirl
mixed for a minute, followed by rota mixing for 10 min. These tubes were
centrifuged (4000 rpm) for 10 min. The supernatant was then discarded carefully by a
Pasteur pipette. Great care was taken to avoid shaking and therefore contamination
with the lower clear layer. This lower clear layer was transferred into another clean
identically labeled 10ml LSL tube, which was dried under a stream of nitrogen gas in
a water bath at 30°C. The residue was re-suspended in 100ul of ammonium acetate
50mM (pH 5), which is a part of mobile phase, vortexed (2 sec), centrifuged (1000
rpm for lmin) and transferred to an auto sampler vial. 30ul of the sample was
injected into the column. A summary ofthis procedure is shownin Figure 4.1.
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Extraction Procedure
500 uL (Standard, QC or sample)|
Tris buffer — 250 uL (0.8M, pH 10.9)
+
Diazepam (IS) —25u1 at 20u:g/ml in methanol
+
1,2 Dichloroethane — 6mL|
Whirl mixed- 20 sec
rota mixing- 10 min
Centrifuge- 4000 rpm for 10 min|
Transfer the top layer of cloudy liquid into a tube (This is discarded)
Transfer 5 ml of clear organic phase (the layer below)into a clean tube.
Evaporate till dry under constant flow of nitrogen, whilst held in a water bath at
a0CG. |
Once dry — reconstitute the residue in the tube with 100 yl of ammonium
acetate 50mM (pH5), whichis part of the mobile phase
Vortex — 20 sec
Centrifuge-2000 X g for 2 min.
Transfer 100 wl in to HPLC vial.
Inject 30 pl on to the column.
Figure 4.1. Summary of the extraction procedure used to isolate clobazam
and N-desmethylclobazam from plasma
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4.2.4. Preparation of stock solutions
Stock solutions of CLB, NDCB, diazepam, clozapine, primaquine, and chloroquine
(1mg/ml each) were prepared by dissolving the appropriate amount of the compound,
in HPLC grade methanol. Thesestock solutions were stored at 4°C. Every 6 months
fresh stock solutions were prepared for use.
4.2.5. Preparation of calibrators, quality controls and internal
standard
The stock solutions of CLB and NDCBwerediluted by drug free plasmato obtain a
concentration of 1000ng/ml and 8000ng/ml respectively. On the day of the
experimental setup, the different points (calibrators) on the standard curve for CLB
(25, 50, 100, 200, 500ng/ml) and NDCB (200, 400, 800, 1600, 4000 and 8000ng/ml)
were prepared by diluting 1000ng/ml (CLB) and 8000ng/ml (NDCB)with drug free
plasma.
The QCs were constituted by diluting the stock solutions (Img/ml) of CLB and
NDCBwith drug free plasma. Three QCs of CLB were 70, 300 and 762.15ng/ml and
that of NDCB were 600, 2000 and 6097.56 ng/ml. They were called low quality
control (LQC), medium quality control (MQC) and high quality control (HQC),
respectively. They were selected as follows: The LQC was 5-10% of the maximum
concentration of CLB and NDCBonthestandard curve; the MQC was 25-30% ofthe
maximum concentration of CLB and NDCBonthe standard curve; and HQC was 75-
80% of the maximum concentration of CLB and NDCBonthe standard curve. All
these were stored in aliquots of 1.2ml at -20°C. For daily use, 20pg/ml of diazepam
(IS) was prepared from a lmg/ml stock solution, and was used as the internal
standard.
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4.2.6. Chromatographic conditions
Initially, a modification of the method described by Streete et al (1991) was used.
This was a reverse phase isocratic HPLC method. The mobile phase at pH 5.5
consisted of 1 litre acetate buffer (made by adding 50 ml of 1M sodium hydroxide
(NaOH)and 58 mlof 1M acetic acid and making up the volume to 1L with distilled
water) and 580 ml of ACN. The flow rate was 1 ml/min. To summarise, the mobile
phase concentration and pH werealtered in an attempt to obtain peaks with good
resolution and properties for CLB, NDCB andthe IS. Clozapine, primaquine and
chloroquine were tried as IS. The molecular weight and structures (Figure 4.2) of
these compounds were similar to that of CLB and NDCB. The pH of the mobile
phase was altered from 8-3.6, by adding glacial acetic acid. The concentration of
ACNin the mobile phase was changed from 5%- 40%.
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Figure 4.2. Chemical structures of clobazam (CLB), N-desmethylclobazam
(NDCB)andthe drugstried as internal standards
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Since the above method did not produce peaks (of the IS, CLB and NDCB) with
good resolution, a gradient method was developed for the quantification of CLB and
NDCB.Various mobile phase gradients (Tables 4.1 A-C) were used to obtain peaks
(CLB, NDCB,IS) of good resolution. Primaquine, clozapine and diazepam were used
as IS. Finally, diazepam was selected as the IS for this method. CLB, NDCB and
diazepam (IS) were eluted from the Waters column by a gradient mobile phase
(ammonium acetate 50mM, ACN + 0.05%formic acid, pH 5) at a flow rate of
Iml/min. The gradient program used is shown in Table 4.1C. The eluant from the
column was monitored at 235nm. The column was maintained at a temperature of
21°C during the run. A summary ofthe optimal conditions for the analysis is given in
Table 4.1C and Table 4.2.
Table 4.1. An outline of the mobile phase gradient programs consisting of
ammonium acetate 50mM (pH=5)and acetonitrile (ACN) buffer to elute clobazam
and N-desmethylclobazam. Program C gave peaks with good resolution and
properties and was used to estimate the levels of CLB and NDCBinall patient
 
samples.
A
Time (min) Ammoniumacetate ACN+ 0.05%Formic
50mM (pH=5) acid (%)
(%)
0 10 90
10 100 0
15 10 90
20 10 90
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B
 
 
Time (min) Ammoniumacetate ACN + 0.05%Formic
50mM (pH=5) (%) acid (%)
0 20 80
10 100 0
15 20 80
20 20 80
hs
Time (min) Ammonium acetate ACN+ 0.05%Formic
50mM (pH=5) (%) acid (%)
0 30 70
10 100 0
15 30 70
20 30 70
Table 4.2. HPLC characteristics for the gradient run of reverse phase HPLC
 
Column Chromatograph Detector Auto Integration
wavelength sampler
preparation
Guard Flowrate: 235 nm Injection Data
column: 1 ml/min Volume:30 pl handling:
Thermo®, Run Time: Dionex
Column Saver 20 minutes Chromeleon!
Column: =
Waters, Nova- Peak
pak®, C18 measurement:
4um, 3.9x150 Area
mm
Temperature:
21°C
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4.2.7. Method validation
This assay was validated for accuracy and precision for both CLB and NDCB.
Accuracy is a measure of how close one can get to the true value with the assay
method. It was evaluated by calculating percentage bias [% bias; [(measured
concentration-nominal concentration)/ nominal concentration] x 100]. The precision
is the measure of how close the data values are to each other from a number of
measurements under the same analytical conditions and is generally expressed in
terms of the percentage coefficient of variation (CV%) [(Std. Deviation /mean) x
100]. Inter-assay and intra-assay accuracy and precision were evaluated from low
quality control (LQC), medium quality control (MQC), and high quality control
(HQC) samples. To determine intra-assay accuracy andprecision, 6 replicate sample
analyses were performed on one run. Inter-assay accuracy and precision was
determined over a period of 6 separate days. 6 runs of standard curves and QCs were
done on these days. The percentage bias and %CV were estimated for these runs.
Accuracy and precision, determined at each concentration level, should not exceed
15%, except for LQC, where it should not exceed 20% (FDA, 2001). Thelinearity of
the method wasevaluated overthe concentration range of 25-1000ng/ml for CLB and
200-8000ng/ml for NDCB.
The upper limit of quantification was set as the top point on the standard curve. The
lower limit of quantification was defined as the lowest concentration that produced a
peak with peak to noise ratio more than 3, where the peak area ratio had a CV% less
than 20%. The lowerlimit of detection was taken as the lowest concentration which
produced a peak whoseheight is three times the background noise (FDA, 2001).
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4.2.8. Stability and recovery
Previous studies have reported the stability of CLB and NDCB under various
conditions (Streete, et al., 1991; Rouini, et al., 2005). Patient samples received in our
lab underwent centrifugation at 2600 X g and the resulting plasma was stored as
aliquots of 1.2-1.8mls, at -20°C until analysed. These samples were completely
thawed before being processed for HPLC analysis (as mentioned above for the QCs
and calibrators). It is important to check whether the samples are stable under these
conditions. So the QCs- LQC, MQC and HQC were analyzed in duplicates on 3
separate occasions to determine the plasma concentrations of CLB and NDCB under
the 4 different storage conditions (stored at -20°C, left at room temperature for 48 h
prior to analysis, subjecting samples to three freeze-thaw cycles and storage for 7
daysin the refrigerator at 4 °C prior to analysis).
Recovery (extraction efficiency) of CLB and NDCBafter the liquid—liquid extraction
was determined by comparing peak areas of each compound in extracted plasma to
those of non-processed standard solutions. QCs - LQC, MQC and HQC of CLB and
NDCBwereusedfor this. Six replicates of each of the QCs on 3 different occasions
were done. For the liquid-liquid extraction, drug free plasma was spiked with CLB
and NDCBto obtain the QCs, as mentioned above. 500,of the calibrator/QC/patient
plasmais taken and processed and reconstituted in 100 pl of mobile phase. For direct
injections, 500 pl of each of the QCs in methanol was dried with liquid nitrogen and
reconstituted in 100 pl of mobile phase. Percentage recovery was calculated by
evaluating the resulting peaks.
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4.2.9. Data analyses
The peaks were integrated using Dionex Chromeleon™. The peak areas of the
standards or QCsor samples, and that of the IS were used for further calculations. A
calibration/standard curve wasconstructed using peak area ratios (PAR) (peak area of
CLB or NDCB/peak area of IS) of the calibrators by applying linear regression
analysis using Microsoft Excel, 2003 (Microsoft, USA). All concentrations of
unknownsand QCswerethen calculated from their PARsagainstthe calibrationline.
One-way analysis of variance (ANOVA) with Bonferroni correction was used to
assess the stability of CLB and NDCB under the following conditions: stored at -
20°C, left at room temperature for 48 h prior to analysis, subjecting samples to three
freeze-thaw cycles and storage for 7 days in the refrigerator at 4°C prior to analysis.
A p value < 0.05 indicated a significant effect of the treatment/storage condition on
the stability of CLB and NDCB.
Percentage recovery of CLB and NDCB wascalculated as follows: (peak area of
CLB or NDCBextracted from plasma / peak area of CLB or NDCB from direct
injection) x 100.
4.2.10. Measurement of clobazam and N-desmethylclobazam in
patient samples
The gradient method outlined above was used to determine the concentration of CLB
and NDCBinepilepsy patients. These patients were recruited from different centers
in UK (see chapter 5 for details of ethics and consent procedures). Blood samples
were collected in a 9 ml (EDTA) tube. Plasma was separated by centrifugation at
128
2600 X g for 20-30 minutes. Aliquots (1.2 -1.8ml) were stored at -20°C until
analyzed.
4.3. Results
4.3.1. Detection & chromatography by the isocratic reverse phase
HPLC method
CLB, NDCB,clozapine, chloroquine, and primaquine were detected by UV-HPLCat
235nm.
4.3.1.1. Detection by the isocratic method
In spite of changing the assay conditions - pH of the buffer, constitution of the buffer
and the column, I was unable to attain good separation between CLB, NDCB and
clozapine, chloroquine, and primaquine (the internal standards) used. The results can
be summarised as follows:
(1) The peak of chloroquine wasclose to the injection peak when the conditions were
adjusted to get the peaks of CLB and NDCB(Figure 4.3 A). If the concentration
of ACN wasincreased to shift the peak of chloroquine to the right, then the
retention times of CLB and NDCBwere more than 20 minutes (Figure 4.3 B). If
the retention times of the drugs are more than 20 min, the run time will be longer,
consuming more mobile phase and the numberof patient samples, which could be
analysed, will be less.
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Figure 4.3. Chromatogram showing chloroquine used as internal standard
under the isocratic HPLC conditions. 1 = Clobazam, 2 = N-
desmethylclobazam, 3 = Chloroquine.
In the case of clozapine and primaquine, though resolution was obtained under some
of the conditions tried (Figure 4.4 A & 4.5 A), when CLB, NDCBand these drugs
were extracted from plasma, the resolution of the peaks disappeared (Figure 4.4 B &
4.5 B). With primaquine, there was a significant peak fronting, which was due to
impurities in the compound (4.5 C). These impurities are produced during the
manufacture of primaquine andare present in the product I purchased (Dongre,etal.,
2008).
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 18.4
4.3.2. Detection & chromatography by the gradient reverse phase
HPLC method
CLB, NDCB, diazepam, clozapine and primaquine (Figure 4.2) were detected by
UV-HPLC at 235nm over a total run time of 20min. With the program shown in
Table 4.1 A, CLB and NDCBdid notelute in 20 minutes (Figure 4.6 A & 4.6 B),
while with the program shownin Table 4.1B, CLB did not elute in 20 min (Figure
4.6C). The peak of clozapine wastoo close to that of NDCBandfailed to give good
resolution (Figure 4.7 A). With the gradient program shownin Table 4.1C, the
impurity in primaquine was separated; however, the blank plasma had peaks with
similar retention times as primaquine (Figure 4.7 C). Drug free plasma did not
interfere with the peaks of CLB, NDCB, clozapine (Figure 4.7 A) and diazepam
(Figure 4.8 A-C). The typical retention times were 8.29, 7.5, 10.71, 10.30, 7.10 and
6.25 min for CLB, NDCB,diazepam, clozapine and primaquine respectively, using
the gradient program shownin Table 4.1C.
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4.3.3. Assay validation
Six standard curves and QC samples(in duplicate) were performed for the validation
of this assay. The standard curves used for the quantification of CLB and NDCB
were linear over the concentration range of 100-1000ng/ml and 200-8000ng/ml,
respectively. They were adequately described by a non-weighted linear regression.
Correlation coefficient (r°) for all validation standard curves was above 0.999.
Examples of standard curves used to determine CLB and NDCB concentrations are
shownin Figure 4.9.
The upperlimit of quantification wasset as the top point on the standard curve. It was
1000ng/ml for CLB and 8000ng/ml for NDCB. The lower limit of quantification of
CLB was 12.5ng/ml and that of NDCB was 25ng/ml. The lowerlimit of detection of
CLB was 5ng/ml and that ofNDCB was 15ng/ml.
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Figure 4.9. Plots of standard curves to determine the concentration of (A)
clobazam and (B) N-desmethylclobazam
Intra and inter-assay accuracy and precision of CLB and NDCB were evaluated by
assaying quality control samples at three concentration levels (LQC, MQC, and
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HQC)(Tables 4.3 and 4.4). Intra and inter-day coefficients of variation were less than
7% for both CLB and NDCB.Theintra and inter assay accuracy (% bias) for all QC
concentrations wasless than 6% for both CLB and NDCB.
Table 4.3. Intra-assay precision and accuracy of the low (LQC), medium
(MQC) and high (HQC) quality control samples of clobazam and N-
desmethylclobazam as measured by the HPLC method (n=6).
 
Roma Messured Precision AccuracQC Level conc. conc. (ng/ml) (CV %) 0, has”
(ng/ml) Mean(SD) 7 °
LQC 70 71.84 (3.33) 4.632 2.767
Clobazam MQC 300 290.76 (10.39) 3.572 -2.612
HQC 762.19 790.15 (45.64) 5.776 -4.384
LQC 700 719.37(17.62) 2.448 0.043N-
desmethyl MQC 2000 1947.77(69.64) 3.58 2.612
clobazam 5939HQC 6097.56 5830.23(305.01) 5.231
 
Table 4.4. Inter-assay precision and accuracy of the low (LQC), medium
(MQC) and high (HQC) quality control samples for clobazam and N-
desmethylclobazam as measured by the HPLC method (n=6)
 
QC Nominal cone.(ng/ml) Precision Accuracy. ; a oy LsLevel (ng/ml) Mean(SD) (CV%) % bias
LQC 70 62.759 (4.30) 6.855 -4.599
Clobazam MQC 300 296.976 (17.63) 5.935 -1.008
HQC 762.19 783.025(42.10) 5.377 2.734
LEC 700 677.059 (39.53) 6.850 -3.824
N-desmethyl Qc 2000 1866.259 (105.21) 5.637 -6.687
clobazam HQC 6097.56 5731.981(330.72) 5:710 -5.995
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Simultaneous quantification of CLB and NDCB wasperformed in patient samples
using this method. Chromatogramsof samples from two patients are shown in Figure
4.10.
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Figure 4.10. Chromatograms representing samples taken from two patients
who were on clobazam. IS is the internal standard used (diazepam).
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4.3.4. Stability and recovery
Concentrations of QCs obtained at various storage conditions are shown in Table 4.5
and Table 4.6. ANOVA wasused to compare the QCsafter storing at -20°C, leaving
the samples at room temperature for 48h prior to analysis, subjecting samples to
three freeze-thaw cycles and storage for 7 days in the refrigerator at 4°C prior to
analysis. There was no significant difference between QCsat a p value < 0.05. That
is subjecting the QCs to these conditions did not affect the concentration of CLB or
NDCB.
Table 4.5. Comparison of the QCs(low quality control (LQC), medium quality
control (MQC) & high quality control (HQC)) of clobazam when analysedin
duplicate on 4 separate occasions. Data are expressed as mean
concentration in ng/ml + standard deviation and analysis was performed with
one wayanalysis of variance with Bonferroni correction (p < 0.05). There was
no significant difference between the QC’s across the different storage
conditions within each category (LQC, MQC & HQC).
 
Storageconditions ULQC(70ng/ml) MQC(300ng/ml) HQC(762.19ng/ml)
Stored at-20°C 66.244 + 1.62 293.485 + 8.00 770.073+ 45.93
Room
temperature for 76.4904 76.49 301.764+ 12.74 756.854+ 30.17
48 hrs
Three freeze- 49gg4 + 2.63 313.8264 22.37 778.535+ 34.08thaw cycles
Tdaysat4°C  69.504+ 10.61 302.103+ 14.67 727.987 62.3|
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Table 4.6. Comparison of the QCs (low quality control (LQC), medium quality
control (MQC) & high quality control (HQC)) of N-desmethylclobazam when
analysed in duplicate on 4 separate occasions. Data are expressed as mean
concentration in ng/ml + standard deviation and analysis performed with one
way analysis of variance with Bonferroni correction (p < 0.05). There was no
significant difference between the QC’s across the different storage
conditions within each category (LQC, MQC & HQC).
 
Storageconditions LQC(700 ng/ml) MQC(2000ng/ml) HQC(6097.56ng/ml)
Stored at-20°C 607.832 + 21.85  1938.314+ 122.36 5671.598 + 405.59
Room
temperature for 617.794 + 32.65 2020.386 + 19.68 5763, 191 = 317.78
48 hrs
Three freeze-thaw 647.511 + 29.14 1979.913 + 46.77 5868.172 + 106.54cycles
7 days at 4 °C 665.571+ 9.43 2010.264 + 28.30 5924.070 + 232.85
 
Recovery of CLB and NDCB wasabove 90% for the 3 concentrations (LQC, MQC
and HQC)checked as demonstrated in Table 4.7.
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Table 4.7. Percentage recovery from plasma at 3 concentrations,( low quality
control (LQC), medium quality control (MQC) & high quality control (HQC)
LQC- 70ng/ml, MQC-300ng/ml and HQC-762.19ng/ml of clobazam, and LQC-
700 =ng/ml, MQC-2000ng/ml and AHQC-6097.56ng/ml of N-
desmethylclobazam, in duplicates on 3 different occasions, calculated by
comparing peak areas of directly injected drug solution and drug that was
extracted from plasma by a liquid-liquid extraction method. Data are
expressed as mean concentration in ng/ml + standard error of mean (SEM).
 
Percentage recovery (%)
Drug LQC MQC HQC
Clobazam 96.49 +0.04 95.64 + 0.03 94.67 + 0.038
N-desmethyl- 95.34 +0.034 94.67 + 0.03 95.92 + 0.038
clobazam
 
4.4. Discussion
I have described a novel HPLC method for the quantification of CLB and NDCB
simultaneously, which is sensitive, accurate, precise, reproducible, cost effective and
simple. I initially attempted to set up a method in the lab using a modification of the
method described by Streete et a/.(1991). At least two columns and different
analytical conditions were utilised using isocratic conditions, but the assay could not
give goodresolution of the peaks of the analytes andIS.
Since I was unable to procure methoxycarbamazepine which was used as the [Sin
previousstudies (Streete, et al., 1991), other structurally related compounds such as
clozapine, chloroquine and primaquine were tried as internal standards. But the
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isocratic method failed to separate these drugs from CLB or NDCB,as shown in
Figures 4.4 and 4.5. This could be due to the fact that all these drugs have similar
structures to CLB and NDCB(Figure 4.2). It is understood that the drugs/chemicals
to be used as IS should have comparable physicochemical characteristics (Wieling,
2002). Their molecular weights should also be close to each other. All these
compounds also demonstrated significant absorbance at 235 nm which was the
wavelength used in this method to detect CLB and NDCB.In view of these initial
findings, a decision was made to develop a gradient HPLC method for the estimation
of CLB andits active metabolite NDCBin patient plasma.
Formic acid was used as a peak modifier in the gradient reverse phase HPLC method.
Very low concentrations of an additive to the mobile phase can improvethe partition
characteristics of the analytes by coating the stationary phase with the additive or
additive plus water. This leads to rapid equilibration of the analytes between the
mobile phase and stationary phase leading to peaks with better characteristics
(Wieling, 2002). Various gradient protocols were used (Table 4.1). Even with the
gradient method used (Table 4.1 C), good resolution of clozapine was not achieved
(Figure 4.7 A). The gradient method howeverdid separate the impurity in primaquine
(Figure 4.7 B), but four samples of blank plasma obtained from the blood bank
showed a peak with similar retention time as primaquine (Figure 4.7 C). For these
reasons, primaquine and clozapine were rejected as an IS. Other compounds
structurally related to CLB could be investigated as IS. However dueto lack oftime,
this was not possible. Therefore, with due considerations of the problems
encountered with the other compoundstested as IS, I decided to use diazepam as the
IS. Diazepam gave good peak resolution from CLB and NDCB (Figure 4.8 A-C.),
with good peak properties. A disadvantage of using diazepam asanISis thatit is
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used in status epilepticus, but not as first line treatment. In addition, it can also be
used in chronic epilepsy, although this is uncommon. Diazepamalso has anti-anxiety
properties, but National Institute for Health and Clinical Excellence (NICE)
(http://www.nice.org.uk/nicemedia/pdf/CG022NICEguidelineamended.pdf) does not
recommend diazepam as the drug of choice for anxiety. Therefore, I felt that the
chance of patients being on this drug was small, and therefore its use as an IS was
warranted.
Various HPLC techniques have been described for the quantification of CLB and
NDCBas mentionedin the introduction to this chapter. The HPLC method described
here uses only 500u1 of plasma. The extraction procedure used is simple and based on
that reported by Streete et al. (1991). It is a single step liquid-liquid extraction. The
procedure is simplified by substituting a filtering step mentioned in Streete ef al.
(1991), with centrifugation, which is much easier and faster to perform. This method
gave pure chromatogramswithout any interfering peaks,i.e. it was able to extract the
pure drug and its metabolite, as shown in Figures 4.8 A-C. The advantage here is that
it enabled us to analyse 40-50 samples per day (24hrs).
Plasma wasseparated from the blood samples and stored in -20°C until analysed. On
the day of analysis, the samples were thawed fully before analysis. This procedure
did not affect the stability of CLB and NDCB, with recovery being above 90%,
which is an improvement on previous methods (Dusci and Hackett, 1987; Streete, et
al., 1991).
A minimum of six assays were prepared and analysed to obtain mean values for
calibration (standard curve points) and QC analysis. This compensates for the
variation in the preparation of stock solutions, calibrator points and QCs. The assay
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performance was monitored by the QCs. The accuracy of this HPLC method in
quantifying CLB and NDCBwas between 4 and 7% whichis within acceptable limits
(FDA, 2001). The inter-assay and intra-assay precision did not exceed 7 and 6%,
respectively. This is comparable with some studies (Tomasini, et al., 1985; Kunicki,
2001) and better than others (Pistos and Stewart, 2003).
In patients, the concentrations of the drug and metabolites show wideinter-individual
variation (Guberman, et al., 1990; Bardy, et al., 1991). Given current clinical
practice in the use of CLB, most epilepsy patients will be on other AEDs. These
drugs could be both inducers (phenytoin, phenobarbitone, carbamazepine) or
inhibitors (valproic acid) of CYP2C19, and thereby alter the levels and the ratio of
CLB and NDCB.Genetic factors could also have a similar effect. Therefore, it is vital
that the assay can detect and quantify a wide range of concentrations of CLB and
NDCB.The range of CLB and NDCB,used in the various HPLC methods, reported
in literature varied as well, ranging from <200ng/ml to 896ng/ml for CLB and
<500ng/ml to 7,058ng/ml for NDCB. The range of concentrations on the standard
curves wascarefully selected after considering the reported plasma concentrations of
CLB and NDCBin patients on CLB (Brachet-Liermain, et al., 1982; Dusci and
Hackett, 1987; Streete, et al., 1991; Knapp,et al., 1999; Kunicki, 2001). Thus the
standard curve utilised had 6 points ranging from 25-1000ng/ml for CLB and 100-
8000ng/ml for NDCB.
Since CLB is used as an adjunct in the treatment of refractory epilepsy patients
(Dalby, 2004), these patients will be on other AEDs.Ideally, I should have explored
whether the peaks of other AEDsinterfere with that of CLB. However, dueto lack of
time, I could not dothis.
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In conclusion, a simple, fast, sensitive, reproducible HPLC method with good
accuracy andprecision for the quantification of CLB and NDCB wasdeveloped and
validated. This method was used to estimate the concentrations of CLB and NDCBin
patient samples, the full results of which are presented in chapter5.
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Chapter 5
The impact ofCYP2C19polymorphismson the
metabolism ofclobazam,its efficacy and toxicity
148
5.1. Introduction
CLB, a 1,5-benzodiazepine (Figure 5.1 a) is acclaimed for its better potency and side
effect profile than its predecessors - the 1,4 benzodiazepines (e.g. diazepam-Figure
5.1 b). The shift of the nitrogen from position 4 to position 5 in the heterocyclic ring
(as shownin Figure 5.1) is responsible for its better anticonvulsant properties and less
sedative and muscle relaxant properties (Dichter and Brodie, 1996). NDCB, the
major metabolite of CLB has a longer half-life than the parent drug. It attains 8-10
times higher steady-state concentrations than CLB, thereby exerting an important
influence on efficacy and the development of adverse drug effects (Fielding and
Hoffmann, 1979; Greenblatt, et al., 1981).
5.l.a 5.1. b
; yAH3C~ 7 4 0 HC N5 |N
cl Cl
Figure 5.1. Chemical structures of anti-convulsants (a) clobazam and (b),
diazepam
Despite its established efficacy, CLB remains under-used because of concerns
regarding development of adverse drug effects and tolerance (Shorvon, 1998). Side
effects due to CLB have been reported in 20 to 85% ofthe clinical trials, but only
around a third of these were significant leading to change in dose or termination of
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treatment (Koeppen, et al., 1987). Drowsiness is the most common adverse effect
reported affecting around 26% of patients followed by dizziness (7%), dry mouth
(3%), headache (2.1%), constipation (2.1%) and nausea (1.6%) (Koeppen, 1985;
Shorvon, 1995).
There is preliminary evidence suggesting that genetic variation in CYP2C/9 affects
the metabolism, efficacy and adverse effects of CLB (Seo, et al., 2008). CLB is
primarily metabolized to its active metabolite NDCB by CYP3A4 and CYP2C19 in
humans. NDCBis later converted to 4-hydroxy nor-clobazam mainly by CYP2C19
(Giraud, et al., 2004). The concentration of CLB and NDCB showsgreat inter-
individual variation (Guberman, et al., 1990; Bardy, et al., 1991). Co-medications
that are inducers or inhibitors of CYP3A4 and CYP2C19are partially responsible for
this. Since CLB is converted to NDCB, primarily by CYP3A4 and CYP2C19,
inducers or inhibitors could decrease or increase the levels of NDCB respectively
(Kosaki, et al., 2004; Seo, et al., 2008). The SNPs in CYP3A4are unlikely to
contribute substantially to inter individual variability in CYP3A4activity due to their
limited functional significance or low allelic frequency (Lepper, et al., 2005). In
addition, the serum concentrations of NDCB in patients who are not on treatment
with CYP3A4 inducers are not predictable by CLB dosealone.
Many polymorphisms in CYP2C/9 affect the function of CYP2C19. CYP2C19*2
and CYP2C19*3 decrease the activity of CYP2C19 (De Morais, et al., 1994;
Poolsup, et al., 2000). Based on CYP2C/9 genotypes, individuals can be divided in 3
sub groups namely: homozygous extensive metabolizers (EMs —CYP2C19 *1/*1),
heterozygous extensive metabolizers (CYP2C19 *1/*2 or CYP2C19 *1/*3,
CYP2C19 *2/*3) and poor metabolizers (PMs- CYP2C19*2/*2, CYP2C19 *3/*3,
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CYP2C19 *2/*3) (Gardiner and Begg, 2006). While the majority of SNPs inhibit the
activity of CYP2C19, CYP2C19*17 increases CYP2C19 activity (Sim,et al., 2006).
The frequency of PMs varies in different populations. It ranges from 13 to 23% in
Asians and 1-8% in Caucasians (Gardiner and Begg, 2006). CYP2C19*2 and
CYP2C19*3 account for 85% of Caucasian PMs and 99% of Asian PMs(De Morais,
et al., 1994); i.e, in the remaining patients, other mutations may be important.
CYP2C19*2 (1rs4244285)allele is a single base pair mutation (guanine to adenine) in
exon 5 of CYP2C19 (De Morais, et al., 1994). This results in an aberrant splicesite
that changes the reading frame of the mRNA and a premature stop codon 20 base
pairs downstream. Another SNP (rs4986893) (G to A) in position 636 of exon 4 of
CYP2C19 (CYP2C19 *3) also produces a premature stop codon. Thus both of these
SNPscreate a truncated non-functional protein (De Morais, et al., 1994). The allele
CYP2C19*17 contains 2 SNPs -806C>T (rs12248560) and -3402C>T in the S’
flanking region of CYP2C19 gene. CYP2C19*17 binds nuclear proteins and
facilitates increased gene expression in mice (Sim,et al., 2006). Hence CYP2C19*17
could increase the metabolism of drugs metabolized by CYP2C19.
It is known that CYP2C19 genotype is a major determinant of NDCB concentration
(Kosaki, et al., 2004; Giraud, et al., 2004; Seo, et al., 2008). There are very few
studies, which explored the impact of CYP2C/9 on the metabolism, efficacy and
development of adverse drug effects to CLB. Two of them were conducted in
Japanese patients (Kosaki, et al., 2004; Seo, et al., 2008). Only one study looked at
the effect of CYP2C19 genotype on metabolism of CLB in Caucasian population
(Giraud,et al., 2004). Since the polymorphisms vary among populations,it is
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essential to explore the effect of CYP2C/9 genotype on NDCB concentration,
efficacy, tolerance and adverse effects in a Caucasian population to identify genetic
factors predisposing to efficacy and development of adverse drug effects.
Furthermore, previous studies have beenretrospective. In this chapter, I have used a
prospective cohort of patients to study how CYP2C19 polymorphisms affect the
response to CLB. Prospective studies have the advantage as they allow the collection
of accurate data on seizure frequency, adverse effects, tolerance and collection of
blood for the estimation of CLB and its metabolite at the same time points as the
reporting of efficacy or adverse effects. This theoretically should enable better
correlation between genotype, concentration of CLB and NDCB, efficacy and
adverseeffects.
Therefore, the aims of this study were to
1. To estimate the NDCB and CLBconcentration in patients recruited in the
prospective study.
2.  Tocorrelate CYP 2 C/9 genotype to
a. Concentration ofNDCB
b. Concentration of CLB
c. Maintenance dose
d. Efficacy
e. Adverse effect
f. Tolerance.
g. Treatmentfailure
3. To identify factors affecting efficacy of CLB
4. To identify factors affecting tolerance to CLB
5. To identify factors affecting development of adverse reactions to CLB
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5.2. Methods
5.2.1. Study population
This study was a part of the multicentre study — “Pharmacogenetics of GABAergic
mechanisms of benefit and harm in epilepsy”. This study (CLOPS-Clobazam
Prospective cohort Study) is a prospective multicentre study involving an established
networkofclinicians collaborating in multicentre clinical trials (Marson,et al., 2007).
Theinclusioncriteria of the patients were:
Patients with continued seizures despite current treatment with between 1 and 3
conventional AEDs (carbamazepine, valproate, lamotrigine, phenytoin, topiramate,
levetiracetam, gabapentin). Patients who may have been treated previously with
AEDsnotin this list will also be included.
a. Patients have been on their existing combination of AEDsfor at least 3 months.
b. Addition of CLB to existing AED regime or switch of one of current AEDs for
CLBisclinically indicated.
c. Any epilepsy syndrome(generalized, localization-related, unclassified).
The exclusioncriteria of the patients were:
d. Significant learning disability
e. Patient and/or relatives unable to maintain a seizure diary.
Information on age, sex, ethnic group, seizure frequency over the previous 3 months,
seizure types, aetiology of epilepsy, AEDs taken at time CLB started, number of
AEDstried before CLB, learning difficulty, and neurological signs was collected,
whenthe decision was made to administer CLB. The data on other AEDs taken were
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used for analysis involving co-medications; data on neurological signs was used to
make a diagnosisofpatients.
Patients were recruited from different centres for this prospective cohort study. A
blood sample was taken at recruitment for DNA. Efficacy was defined as at least
50% reduction in seizure frequency when compared to baseline seizure frequency,
after 3 months of CLB treatment. The recruiting physician recorded baseline seizure
frequency, after consulting the patients on the occurrence of seizures in the 3 months
prior to treatment with CLB. Since the patients maintained diaries, the information
provided by them can be trusted. Responders were defined as patients who achieved
50% reduction in seizure frequency after 3 months of CLB treatment, when compared
to baseline seizure frequency (seizure frequency before starting CLB). The
definition of tolerance has been controversial. Loscher and Schmidt (2006) have
defined tolerance as any conversion from a responsive status (more than 50% seizure
reduction) to a non responsive status. For this study, if the seizure frequency of a
patient was reduced to 50% at any time during the 12 month follow up period and
later on increased to above 50%, that patient was considered tolerant to CLB.
Patients entered the cohort on the date that the decision to add CLB is made, with
time set to zero for analyses when the first CLB tablet was taken. All the patients,
except those who stopped CLB treatment, were followed up for 12 months.
Outcomesincluded (1)Time to withdrawal of CLB (a) for any reason (b) dueto side
effects (c) due to inadequate seizure control and (d) combination of b and c. The
information gathered from above (a-d) wasused toascertain the relationship between
treatment failure and genotype. (2) Seizure control - Seizure frequency per monthat
3, 6, 9, and 12 months was compared to baseline seizure frequency. (3) Adverse
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effects -This was assessed using the Liverpool Adverse Events Profile which was
completed by patients at baseline, 3, 6, 9 and 12 months (Baker, et al., 1995). For my
thesis, only drowsiness, dizziness and weight gain were analysed. If any patients
developed any of these adverse effects, during the 12 month follow up period, they
were included in the analysis.
Patients were followed upat 3, 6, 9 and 12 months for data on seizure frequency and
drug withdrawal data, AED treatment, blood for CLB levels and the Liverpool
Adverse Events Profile. The last CLB dose taken by patients was either on the
previous night (20.00-22.00 hrs) or in the morning (7:00- 9.00) of blood collection.
Blood samples were collected in the morning or afternoon. The time at which the
blood samples were taken was not recorded. These blood samples were used to
ascertain the concentrations of CLB, NDCB and NDCB/CLBratio and to check
compliance. NDCB/CLB ratio was used as a phenotypic indicator of CYP2C19
activity.
5.2.2. Measurement of clobazam (CLB) & N-desmethlylclobazam
(NDCB)levels
The concentration of CLB and NDCB was measured using the methods described in
chapter4.
5.2.3. Selection of SNPs in the CYP2C19 gene
SNPs were simultaneously selected from public databases and websites such as
CYP450 allele nomenclature website (http://www.cypalleles.ki.se/), _dbSNP
(http://www.ncbi.nlm.nih.gov/sites/entrez), UCSC (http://genome.ucsc.edu/),
Ensemble (http://www.ensembl.org/index.html) and HapMap
(http://www.hapmap.org/), with the help of SNP prediction software programmes
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PupaSNP (Conde, et al., 2004) and FastSNP
(http://fastsnp.ibms.sinica.edu.tw/pages/input_CandidateGeneSearch.jsp). The
characteristics of the SNPs were: (a) location of the SNP (exons, promoter region,
exon - intron boundary, 3’untranslated region, 5’ UTR), (b) minorallele frequency
more than 5%, (c) population (Caucasian), (d) presence of SNPs in conserved regions
of the gene (Loots, et al., 2000) and (e) function (kindly refer to chapter 2).
The potential effects of these SNPs were explored using software programs Polyphen
(http://genetics.bwh.harvard.edu/pph/) & SIFT
(http://www.blocks.fherc.org/sift/SIFT.html). Both these programs predict possible
effects of an amino acid substitution on protein function. Polyphen can also predict
the effect of an aminoacid substitution on protein structure. In an attempt not to omit
any deleterious SNPs and to represent most or all common variation, I utilised the
tagging SNP strategy using HapMap data to select SNPs. HapMap contains high
density SNP data that covers the entire genome of population of Europe, African and
Asian ancestry. Linkage Disequilibrium (LD) can be quantified using Haploview.
This allows us to generate tagging SNPs whichpredict the rest of the SNPs in a gene
or across the genome. The SNP data on CYP2C/9 genes were downloaded from the
HapMap website. Haploview (r’ = 0.8, 2kb upstream of the gene) was used to
identify tagging SNPs in CYP2C19 genes
(http://www.broadinstitute.org/haploview/haploview-downloads#DOWNLOAD). A
literature search was also performed to identify any SNPs that were reported to affect
the function of CYP2C19. The nonsynonymous SNPsidentified from all of the above
websites and programs were examined by Polyphen and SIFT to predict the effect of
any amino acid substitution on protein structure. A final list of SNPs selected for
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genotyping wasbasedontheselection criteria mentioned earlier, with emphasis onits
knownfunctionalrole or potential to alter the activity of CYP2C19.
5.2.4. Genotyping
All samples were genotyped using the TaqMan allelic discrimination assays
according to the manufacturer’s instructions on the ABI PRISM 7900HT Fast Real-
Time PCR System platform. Genotyping was done without knowledgeofthe clinical
data or the concentrations of CLB and NDCB.All of the reactions were done in the
presence of negative controls. 10% of the samples (positive controls) for each SNP
were genotyped twice and checked for any discrepancies. These positive controls
were randomlyselected for each allele of a SNP. Each Sul reaction contained 2.5ul of
TaqMan® genotyping master mix, 0.25ul of TaqMan® pre-designed SNP
genotyping assay, |ul of DNA and 1.251 of water. The conditions used for the PCR
were 50°C for 2 min, 95 °C for 10 min and 40 cycles at 95 °C for 15 sec and 60 °C
for | min.
5.2.5. Statistical Analyses
Descriptive statistics were used to describe the demographic characteristics of the
patients participating in this study - age, sex, type of epilepsy, weight and co-
medications. Chi-square tests (for comparisons of categorical data) were used to
compare the demographic characteristics, pharmacokinetic and pharmacodynamic
data among the CYP2C/9 genotypes. Correlation between dose and (a) concentration
of CLB, (b) concentration of NDCB,and (c) the ratio of NDCB/CLB concentration
was estimated using the Pearsonscorrelation coefficient. If an association was found
between the ratio and more than one of these factors, a multiple regression analysis
was planned.
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The correlations betweenefficacy, tolerance and adverse drug effects, and predictors
were explored. The predictors tested were genotype, epilepsy type, NDCB/CLB
concentration, and baseline seizure frequency. Chi-square test was used to compare
the distribution of genotypes and epilepsy types and unpaired t-test was used to
comparethe baseline frequency and NDCB/CLBconcentration among:
1. Responders and non responders
2. Patients who developed tolerance and those whodid not
3. The patients who developed adverse drug reactions and those who did
not.
The parameters used to measure efficacy of CLB were:
1. Seizure frequency reduction to 50% after 3 months of CLB treatment
2. Seizure freedom at 3 months.
A logistic regression was performed including the variables significantly associated
with efficacy, tolerance and adverse drug reaction. Kaplan-Meier analysis was done
to estimate whether there is a significant difference in the mean time to treatment
failure to occur among the various genotypes of SNPs- rs4244285, rs12248560 and
rs11568732. The analyses which involved multiple comparisons were corrected by
Bonferroni’s correction.
158
5.3. Results
5.3.1. Study population
This prospective study included 120 Caucasian patients with epilepsy. The mean age
and body weight were 40.48 + 1.19 (range: 18-73 years) and 75.94 + 2.31 kg (range:
40-130.0 kg), respectively. In total, 9 patients (7.5%) had generalized seizures and
104 patients (86.67%) had partial seizures (Table 5.1). Body weight wasavailable in
only 67 patients.
Table 5.1. Demographic characteristics of patients in this study
 
Demographic characteristics Values
Age(years)
Mean 40.48+1.19
Range 18-73
Males 61
Females 59
Body weight (Kg)
Mean 75.94+2.31
Range 40-130
Epilepsy type
Partial epilepsy 104
Generalised epilepsy 9
Unclassified 7
 
71.6% of patients were on inducer or inhibitor antiepileptic co-medications, which
included inducers such as carbamazepine, phenytoin, phenobarbitone, primidone,
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oxcarbazepine and topiramate. Valproic acid (VPA) was the only CYP450 inhibitory
antiepileptic drug co-administered to these patients.
5.3.2. Selection of putative functional SNPs in CYP2C19
Characteristics:
Regions:other than intron & intergenic
Minorallele frequency: >5%, Caucasian, conserved
region of the gene
Websites used'
FastSNP PupaSNP
FastSNP PupaSNP rs4244285- synonymous
134244285 Haploview r$4986893-(MAF-cau-0)Hapmaprs3758581 UCSC rs4986894- Upstream
rs3758580 dBSNP rs3758581- Nonsynonymous
Cypsites rs1118809- downstream
Haploview and Hapmap
Looked at tagging SNPs too
vo V 
peneyEnymalsenr® OIsr SNPs Selected SNPs
+4 4244285- *2Polyphen Evaluatebased eeeSIFT on functionality rss7BESAO-Synenymons
rs3758581- Nonsynonymous
Ny a rs11568732- Promoter
Selection of SNPs ————> '°12248560~ "17, Promoter
rs4986893- *3, Nonsense
Figure 5.2. Shows the summary of the selection criteria used with the list of
SNPsselected to genotype (colured in green). SNPs selected by more than
one program is shownin blue.
The proven functional SNPs in the CYP2C/9 gene from the P450 allele nomenclature
web site are shown in Table 5.2. Only 3 SNPs had a minorallele frequency (MAF)
above 5%. These 3 SNPs (rs4244285, rs12248560 and rs3758581) were considered
for genotyping. The numberofpatients to be recruited for this study was 400. The
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MAFof SNPsshould be at least 5% to be detected in this numberof patients. In
addition, the lower the MAF of SNPs, the larger number of SNPs required to represent
the genetic variation across the genomic region. The CYP2C19 *3 polymorphism
(rs4986893) was also considered for genotyping taking into consideration its
functional importance as mentionedin the introduction.
Table 5.2. Proven functional SNPs in CYP2C19 from CYP2C719 allele
nomenclature web site (compiled from http:/Awww.ncbi.nlm.nih.gov/snp/;
http://www.cypalleles.ki.se/cyp2c19.htm).
 
 
  
Allele rs number Change in DNA Amino acid MAFin Effect on CYP2C19
name change Caucasian Activity
-* population
1
2& rs4244285 ** G681A (40b- 0.15 Decreases
21 DEL 643-682)
3 rs4986893 ** G636A W212X 0-0.50 Decreases
4 rs28399504 AlG MIV 0.01 Nil (in vitro)
5 rs56337013 C1297T R433W no data
6 G395A R132Q 0.01 Nil (in vitro)
7 19294T>A 0 Splicing defect
8 rs41291556 (T358C W120R 0.01 Decreased
transition in exon (in vitro)
3)
9 rs17884712 108296G.A R120H 0.01 Decreased(in vitro)
10 1s6413438 C101927T P227L 0 Decreased(in vitro)
1] G108278A R150H 0.03 Nil
(in vitro)
12 A30871C Stop491Cys f=0 No holoprotein (in
vitro)
13 R410C f=0 Unaltered activity
(in vitro)
14 T20829C LI7P f=0
15 A120824C I19L f=0
16 30871A.C R442C not known Japanese patients
17 rs12248560 ** 806C>T and 0.22 Increases
3402C>T
18& rs3758581,** A991G 0 Deleterious
19 other SNPs
20 rs4986893 G636A W212X 0 Decreases
22 rs3758581, AI9IG 1331V 0.051 Deleterious
other SNPs
23 rs3758581, A991G 1331V 0.051 Deleterious
other SNPs     Highlighted markers=higher frequency; ** SNPs considered for further selection
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Tagging SNPsthat cover genetic variation in the whole gene were selected by tagging
SNP strategy, using HapMapdata as shownin Table 5.3. The LD map of CYP2C/9 is
shown in Figure 5.3. rs4244285, rs3758580, rs10509676, rs4532967 and rs4986894
were in complete linkage disequilibrium (LD). rs4244285 is better known as
CYP2C19*2 and is associated with decreased catalytic activity of the enzyme (De
Morais, et al., 1994). Therefore rs4244285 wasselected. rs3758581 and rs11568732
are in LD, while rs3758580 and rs3758581 are very close together making it difficult
to genotype. Hence rs! 1568732 was given preference. rs12248560 is a promoter SNP
whichincreases the activity of CYP2C19 with a minorallele frequency of 21.8%. The
rest of the tagging SNPs werein the introns, which was one of our exclusion criteria.
In addition, I used software programs FastSNP and PupaSNP to predict putative
functional SNPs. Theresults are given in Figure 5.4. The final selection of SNPs was
thus made based on the selection criteria, giving credence particularly to their
functional implications (Figure 5.4).
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Table 5.3. Tagging SNPs in CYP2C79 identified by Haploview using Hapmap
 
data.
rsnumber Contig dbSNP_ Function MAFin Functional
Position allele — Region. Caucasian importance
population
rs4244285 15290142 G/A Synonymous 95 (40b-DEL 643-682)— exon 5 disrupts splicing site,
rs10509676 15271571 =A/T Intron 1
Synonymous
rs3758580 15351148 C/T - exon 7 0.15
1s4532967 0.15
1s4986894 15270891 =C/T 5' near gene 0.16
183758581 15351149. G missense ©XOM 9.05
rs11568732, 15270100 G/T 5' near gene 0.06
CYP2C19 *17,
15270183 C/T 5' near gene 0.22 increases therelapene activity of CYP2C19.
rs4917623 15358094 =—-C/T Intron 7 0.49
1s7916649 15283110 A/G Intron 1 0 .55
1s4388808 15284582 A/G Intron 3 0.19
1s4362080 15285915 A/G Intron 3 0.78
1s7088784 15289899 =A/G Intron 4 0.08
rs1322179 15323768 A/G Intron 5 0.08
1810786172 15329620 A/G Intron 6 0.36
 
Highlighted SNPs were includedin the list of SNPs to genotype
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FastSNP
1rS4244285
rs3758581
rs3758580   
Hapmap
rs4244285
rs4986894
rs3758580
rs11568732
rs12248560
rs3758581   
CYP2C19
allele
nomenclature
website
rs4244285
rs4986893
rs12248560   
PupaSNP
rs4244285
rs4986893
rs4986894
rs3758581
rs1118809
Selected SNPs
rs4244285- synonymous
rs12248560 - Promoter
rs11568732- Promoter
rs4986893 — Nonsense
Figure 5.4. Showing the SNPsselected by various programmesandthefinal
selection of SNPs
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5.3.3. Allele frequencies of the selected SNPs
Allelic frequency of the selected SNPs wasascertained by real time PCR. Thetable
below (5.4) showstheallelic frequencies in our study population. All the SNPs were
in H-W equilibrium. The allele frequencies were comparable to those in dbSNPas
proved by chi square test (Table 5.5). 5 patients were not genotyped either due to
inadequate quantity of blood collected or poor quality of DNA.
Table 5.4. Allelic frequency of genotyped SNPs in CYP2C19
 SNP genotyped No.of Minorallele Majorallele dbSNP
individuals frequency frequency Minorallele
1s4244285 115 A: 0.15 G: 0.85 0.15
rs 12248560 115 T: 0.25 C: 0.75 0.22
rs1 1568732 115 C: 0.08 A: 0.92 0.06
rs4986893 115 G: 0.00 A:1.00 0.00
 
Patients with the homozygous major allele, heterozygous and homozygous minor
alleles for rs4244285 (CYP2C19*2) were classified as homozygous extensive
metabolisers (EMs), heterozygous EMs and poor metabolizers (PMs), respectively
according to convention. For SNPs rs12448560 and rs11568732, the patients were
classified according to the total count of mutant allele(s): group 0, homozygous
majorallele; group 1, heterozygousallele; group 2, homozygous minorallele. Since
all the patients genotyped for rs4986893 belonged to group 0, this SNP was not
considered for further analysis.
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Table 5.5. Shows the SNPsin Hardy - Weinberg equilibrium (as shown by
 
the X?test)
Expected. Observed 2 PpSNPid Genotype No. ofpeople No.of xX value
people
1s4244285 GG 84 83
GA 27 30 0.004 0.948
AA 4 3
rs12248560 cc 65 63
TC 4244 0.000 1
TT 6 7
rs11568732 AA 98 98
AC 16 17 0.004 0.948
CC 1
 
The demographic characteristics of patients did not differ significantly when
stratified for the genotypes represented by the SNPs rs4244285 (Table 5.6). A
significantly larger percentage of patients with the homozygous minor allele
(rs12248560) received VPA (Table 5.7). However the numbers were small andit is
likely that it is a chance finding. There were more homozygous major males; more
heterozygous females, with an overall balance of the sexes (Table 5.8).
167
Table 5.6. Demographic characteristics of patients stratified by genotypesat
SNP 1rs4244285
 Parameters Homozygous Heterozygous Homozygous p value
Majorallele (n=26) Minorallele
(n=85) (n=4)
Age
Mean 41.54 + 1.45 39 + 2.46 34.25 + 4.82 0.4
Males 42 (49.4%) 14 (53.8%) 3 (75%) 0.6
Females 43 (50.6%) 12 (46.2%) 1 (25%)
Body weight 74.15 +2.64 82.13+6.01 70.50£13.50 0.4
Epilepsy type
Partial epilepsy 73 (85.9%) 23 (88.5%) 4 (100%) 0.2
Generalised 9 (10.6%) 0 0
epilepsy
Unclassified 3 (3.5%) 3 (12%) 0
Co-medications
Inducers 54 (63.5%) 18 (69.2%) 2 (50%) 0.7
Inhibitors 15 (17.6%) 1 (3.8%) 1 (25%) 0.2
 
Data is represented as mean + standard error of the mean (SEM) or as number of
patients (percentage)
** Body weight was available in only 67 patients. n= numberofpatients
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Table 5.7. Demographic characteristics of patients stratified by genotypesat
SNP rs12248560
 Parameters Homozygous Heterozygous Homozygous p
Major allele (CT) Minorallele value
(CC) (n=45) (TT)
(n=64) (n=6)
Mean 41.63+£1.71 39.514£1.79 4046.65
Males 37(57.8%) 18 (40%) 4 (66.6%) 0.14
Females 27 (42.2%) 27 (60%) 2 (33.3%)
Body weight
(Kg) 38 28 1 0.4
Mean 7843.24 72.3143.67 92
Partial epilepsy 54 (84.4%) 41 (91.1%) 5 (83.3%) 0.7
Generalised
epilepsy 5 (7.8%) 3 (6.6%) 1 (16.7%)
Unclassified 5 (7.8%) 1 (2.2%) 0
Co-medications
Inducers 40 (62.5%) 29(64.4%) 5 (83.3%) 5%
Poets 5 (7.8%)  10(22.2%) 2 (33.3%) 0.05
 Data is represented as mean + standard error of mean (SEM) or as number of
patients (percentage)
** Body weight of only 67 patients were available, n= number of patients,
Significant p values highlighted
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Table 5.8. Demographic characteristics of patients stratified by genotypesat
 
rs11568732
Parameters Homozygous Heterozygous Homozygous p value
Majorallele AC (n=13) Minorallele
(AA) (n=101) CC (n=1)
Age
0.6Mean + SE 40.28 + 1.27 43.69 + 4.52 46
Gender
Males 56 (54.5 %) 3 (23.1%) 0
; 6 7 0.053Females 45 (44.6%) 10 (76.9 %) 1 (100%)
Body weight
in Kg an (Teo 7 (68 + 1.69) 1 (66)
(mean + SEM )** ~~
Epilepsy type
Partial epilepsy 88 (87.1%) 11 (84.6%) 1 (100%)
0.9
Generalised 7 (6.9%) 2 (15.4%) 0epilepsy
Unclassified 6 (5.9%) 0 0
Co-medications
Inducers 65 (64.4%) 9 (69.2%) 0 0.4
Inhibitors 16 (15.8%) 1 (7.7%) 0 0.7
 Data is represented as mean + standard error of mean (SEM) or as number of
patients (percentage)
** Body weight of only 67 patients were available, n= numberofpatients.
The concentrations of CLB and NDCB were measured in 94patients, after 3 months
of CLB treatment. At the time of 6" month blood analysis, only 72 patients had
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completed 6 months of CLB treatment. Of these 72 patients, 3" month CLB
estimation was not done for 11 patients. The reasons include blood samplesarriving
very late and insufficient blood to extract plasma. In total, the concentration of
CLB and NDCBwasestimated in 120 patients. Seventeen patients were excluded
from analysis involving correlation of genotype of CYP2C19 to the
pharmacokinetics of CLB and NDCB,due to the following reasons: Genotype was
not done in 5 patients, CLB wasnot detected in 5 patients, 2 patients had interfering
peaks and onepatient refused to give blood. In the case of 2 patients, there was
insufficient blood to extract plasma. Two patients were on diazepam, and so could
not be included as diazepam was used as the ISfor the estimation of CLB and
NDCB. The mean (of 3" month and 6" month) of CLB dose, CLB concentration,
NDCBconcentration and NDCB/CLBratio were notsignificantly different between
the 3“ and the 6" month offollow up (Table 5.9). Therefore the mean of the 3" and
6° month, of CLB dose, CLB concentration, NDCB concentration and NDCB/CLB
ratio wasused in further analyses. In cases where the mean wasnot available, the 3“
or 6" month value (of CLB dose, CLB concentration, NDCB concentration and
NDCB/CLB) was used for analysis since there was no significant difference
between the ge 6" month and meanofthe two values.
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Table 5.9. Showing the comparison of pharmacokinetic parameters of
 
clobazam
rd_. 3% Month, 6"Month,  Meanof3" &  p valueCharacteristic 6 month,n=94 n=72 n=60
0.22 (3 m Vs 6m)
Clobazam 0.73 (3 m Vs
dose 15.4+0.61 17.7140.82 16.02+0.62 Mean)
(mg) 0.44 (6 m Vs
Mean)
0.27 (3 m Vs 6 m)
Clobazam 161.94 194.38 185.6 (fem) m Vs
concentration 10.89 16.90 15.45 1.00 (6m Vs
Mean)
1.00 (3 m Vs 6 m)
NDCB 997.54 1145.99+ 1189.96 enh” mvs
concentration 114.23 122.44 148.84 1.00 (6 m Vs
Mean)
1.00 (3 m Vs 6 m)
1.00 (3 m Vseee 8841.1 8.84+1.08 8.54+1.08 Mean)
1.00 (6 m Vs
Mean)
 
Data is represented as mean + standard error of mean (SEM), n= numberofpatients
p values after Bonferroni correction for multiple testing. Vs = versus
5.3.4. Association between CYP2C19 genotypes & clobazam
pharmacokinetics
The rs4244285 (CYP2C19*2) SNP genotype was associated with NDCB
concentrations, the concentration/dose (C/D) ratio of NDCB and the NDCB/CLB
concentration ratio, but there was no association with the CLB daily dose
(Table 5.10). The homozygous EMs, heterozygous EMs, and PM genotypes had a
greater impact on the concentration of NDCB than on CLB. The NDCB
concentration in PMs was5.75 and 4.48 times higher than in homozygous EMs and
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heterozygotes respectively. In addition, the EMshad significantly lower value of
NDCB/CLBratio than heterozygotes and PMs (Table 5.10).
Table 5.10. Association between the CYP2C19*2 (rs4244285) genotypes
and clobazam pharmacokinetics
 
 
 
Parameters Groups n Mean p value
CLB/CLB mg(ng/ml/mg) Homozygous 719 10.86+1.04 1(2 Vs 0)
majorallele (0)
Heterozygous 21 10.67+1.01 1 (1 Vs 0)
(1)
Homozygous 3 9.3043.59 1(2 Vs 1)
minorallele (2)
NDCB/ Homozygous 79 51.71+4.31 0.00 (2 Vs 0)
mg(ng/ml/mg) majorallele (0)
Heterozygous 21 63.08+7.01 0.71 (1 Vs 0)
(1)
Homozygous 3 304.30+86.03 0.00 (2 Vs 1)
minorallele (2)
CLB Dose Homozygous 83 16.62+0.66 1(2 Vs 0)
majorallele (0)
Heterozygous 22 16.02+1.00 1(1 Vs 0)
(1)
Homozygous 3 18.33+£1.67 1 (2 Vs 1)
minorallele (2)
NDCB/CLBratio Homozygous 719 8.27+1.09 0.00 (2 Vs 0)
majorallele (0)
Heterozygous 21 7.56+1.22 1 (1 Vs 0)
(1)
Homozygous 3 37.00£7.39 0.00 (2 Vs 1)
minorallele (2)
NDCBconcentration Homozygous 719 835.08+73.90 0.00 (2 Vs 0)
(ng/ml) majorallele (0)
Heterozygous 21 1072.21+154.79 0.54(1 Vs 0)
(1)
Homozygous 3 4798.6741129.3 0.00 (2 Vs 1)
minorallele (2) 6
CLB concentration Homozygous 79 167.35+13.67 1(2 Vs 0)
(ng/ml) majorallele (0)
Heterozygous 21 172.89417.53 1(.1 Vs 0)
(1)Homozygous 3 151.91452.38 1 (2 Vs 1)
minorallele (2)
p value (significance across groups). Significant p values are highlighted. Data
expressed as mean + standard error of mean (SEM). n= number of patients. Vs=
versus
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Figure 5.5. Shows the association of the CYP2C19*2 genotypes
(rs4244285) with the NDCB/CLB ratio. Each bar represents the mean +
standard error of mean (SEM) of each genotype.This is the result from 103
patients.
The CYP2C19*17 (rs12248560) genotype was associated with the CLB dose.
Patients who were homozygousfor the minor allele were on higher CLB doses than
heterozygous or homozygous major allele patients (p value = 0.086 and 0.012,
respectively). Other pharmacokinetic parameters, mentioned in the table below, were
not influenced by rs12248560 (Table 5.11).
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Table 5.11. Association between CYP2C19*17 rs12248560 genotypes and
clobazam and NDCBconcentrations
 
 
Parameter Genotype n Mean p value*
CLB Homozygous
concentration major 0.230 (2. Vs
(ng/ml) allele (0) 55 172.38414.98 0)
Heterozygous
(1) 42 174.03418.28 1(1 Vs 0)
Homozygous 0.227 (2 Vs
minorallele (2) 6 86.20422.29 1)
NDCB Homozygous
concentration major
(ng/ml) allele (0) 55 1159.03+158.46 1 (2 Vs0)
Heterozygous 0.222 ( 1 Vs
(1) 42 800.79+101.47 0)
Homozygous
minor
allele (2) 6 917.384224.94 1(2 Vs 1)
NDCB/CLBratio Homozygous
major 0.956 (2 Vs
allele (0) a) 9.8141.56 0)
Heterozygous 0.588 ( 1 Vs
(1) 42 7.0941.29 0)
Homozygous
minor 0.339 (2 Vs
allele (2) 6 14.2043.29 1)
Dose of CLB (mg) Homozygous
major 0.012 (2 Vs
allele (0) 64 15.54+.63 0)
Heterozygous 0.459 ( 1 Vs
(1) 45 17.14+.95 0)
Homozygous
minor 0.086 (2 Vs
allele (2) 6 22.50+2.81 1)
 
*Significant p values are highlighted. Data expressed as mean + standard error of
mean (SEM). n= numberofpatients. Vs= versus
rs11568732 had an impact on NDCB concentrations. The concentration of NDCB
was 1049.89+ 109.42, 693.14 + 94.16 and 432.24 ng/ml in groups 0, 1 and 2
respectively (Table 5.12). Since there was only one patient in group 2, a post hoc
test was not done after ANOVA. ANOVAalone did not show anysignificant
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difference between the groups. However, when group 2 was excluded and t-test
done, there was a significant difference in the concentration of NDCB between
groups 0 and 1. In addition, the mean ratio of NDCB/CLBconcentration was 8.87 +
0.99, 10.08 + 4.38 and 2.18 in groups 0, 1, and 2. ANOVAalone did not show any
significant difference between the groups. A t-test performed after excluding group
2 did not show significant difference between the means of the NDCB/CLBratio
in groups 0 and 1.
Table 5.12. Association between rs11567832 genotypes and clobazam
pharmacokinetics
Parameter Genotype n Mean p value
 
CLBconcentration
(ng/ml)
NDCB
concentration
(ng/ml)
NDCB/CLBratio
CLB dose (mg)
Homozygous
major
allele (0)
Heterozygous(1)
Homozygous
minor
allele (2)
Homozygous
major
allele (0)
Heterozygous(1)
Homozygous
minor
allele (2)
Homozygous
major
allele (0)
Heterozygous(1)
Homozygous
minor
allele (2)
Homozygous
major
allele (0)
Heterozygous(1)
Homozygous
minor
allele (2)
89
13
1
168.004 12.38
165.6329+ 24.98
201.63
1049.89+ 109.42
693.14 + 94.16
432.24
8.87 + 0.99
10.08 + 4.38
2.18
16.70+ 0.60
15.96 + 1.43
10
0.955
0.017!
0.745
0.472
Significant p values are highlighted. Data expressed as mean + standard error of
mean (SEM). 1- group 2 was excluded anda t-test done. n = numberofpatients
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The concentration of CLB wassignificantly lower in patients who were on enzyme
inducers (p value = 0.003) (Table 5.13). In addition, the dose of CLB washigher in
patients on inducers, but this was not significant. Co-medication with VPA, an
enzymeinhibitor, did not affect any pharmacokinetic parameters.
Table 5.13. The distribution of pharmacokinetic parameters in patients who
had inducers as co-medications (1) compared with patients who were not on
these co-medications(0)
 
Status of
Parameter Co- n Mean p value
medications
CLE soncenizahion 9 42 —-:221.38 422.83 0.003(ng/ml)
1 68 143.29+11.09
NDCEB concentration 0 42  -990.82+192.67 0.9(ng/ml)
1 69 1009.46+93.61
NDCB/CLBratio 0 42 6.47+1.29 0.06
1 66 9.80+1.156
CLBdose (mg) 0 44 14.71+0.81 0.1
1 76 16.77+40.85
 
Significant p value is highlighted. Data expressed as mean + standard error of mean
(SEM). n= numberofpatients
The mean concentration of CLB or NDCBdid not correlate with the mean dose of
CLB using Pearson’s correlation coefficient. Multiple regression was used to
identify predictors of the NDCB/CLB ratio. The variables tested were genotype
(rs4242285, rs12248560, and rs11568732), dose of CLB and co-medications.
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1s4242285 was the only predictive factor identified. The details of the model
obtained are shownin Table 5.14.
Table 5.14. The details of the multiple regression done for NDCB/CLBratio
 
Parameters of multiple regression Values
R square 0.100
F 11.280
P (using the stepwise method). 0.00
Predictor Variable rs4244285; 0=GG; 1=GA; 2=AA
Beta 5.654
P value 0.001
 
5.3.5. Association between CYP2C1/9 genotypes andtheefficacy of
CLB
A 50% or greater reduction in the seizure frequency when comparedto the baseline
before starting CLB therapy (responderstatus) was achieved in 55 (46.6%) patients,
while 17 (14.4%)of the total patients (118, see below) achieved seizure freedom. The
mean CLB daily doses in cases with 50% reduction in seizures (responders) and
nonresponders were 15.86 + 0.79 and 16.35 + 0.95 respectively (p = 0.7). Table 5.15
shows the responder rates for each genotype for rs4244285. Two subjects were
excluded from the analyses because their baseline seizure frequency was not known
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and 5 patients were not genotyped. The reasons were inadequate quantity of blood or
poor quality DNA.
The responders were more likely to possess the mutant allele(s) than the
nonresponders. All the patients who were PMs had 50% reduction in their seizures
when compared to baseline seizure frequency. It is notable that 50% of the PMs
achieved seizure freedom while only 10% of the homozygous EMs obtained seizure
freedom, with 27% of the heterozygotes achieving seizure freedom. However the
numbers are small. To summarise, the efficacy (seizure freedom and 50% reduction
in seizure frequency) was greater in the PMs than in heterozygous EMs who
demonstrated better efficacy than homozygous EMs.
Table 5.15. Efficacy of clobazam amongstthe rs4244285 genotypes
 
Efficacy Characteristic Yes No P value
50% reduction in seizures
Homozygous(83) 32 (38.55%) 51 (61.45%) 0.005
Heterozygous(26) 17 (65.38%) 9 (34.62%)
Homozygous minorallele (4) 4 (100%) 0
Seizure freedom
Homozygous(83) 8 (9.64%) 75 (90.36%) 0.014
Heterozygous(26) 7 (26.92%) 19 (73.08%)
Homozygous minorallele (4) 2 (50%) 2 (50%)
 Significant p value is highlighted. Data expressed as number of patients
(percentage)
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The SNPs rs12248560 and rs1 1568732 did not affect the efficacy of CLB. There was
no significant difference in the numberof patients who had 50% or greater reduction
in seizure frequency among the different genotypes for rs12248560 (p=0.499).
Seizure freedom at 3 months of treatment also showed a similar pattern (p =0.634).
The efficacy of CLB (50% reduction in seizure frequency (p=0.464) and seizure
freedom (p=0.914) wasnot associated with the different genotypes of rs1 1568732.
Logistic regression was used to predict seizure freedom from epilepsy type,
genotype (1rs4244285, rs12248560, and rs11568732), baseline seizure frequency,
dose of CLB, concentration of CLB and NDCB, ratio of NDCB/CLB. Only
1s4244285 was a significant predictor of seizure freedom. For every mutantallele of
1s4244285, the odds of seizure freedom (versus presence of seizures) increased by a
factor of 4.16 (Table 5.16 and 5.17).
Table 5.16. Shows the parametersof the logistic regression modelfor
seizure freedom
 Variables in the equation ©
B SE. Wald df Sig. ous
Step la rs4244285 1.42 0.48 8.88 1 0.01 4.16
Constant -2.07 0.36 32.47 l 1.21 0.13
Step 2b rs4244285 1.72 0.54 10.35 ] 0.00 5.61
Epilepsy_type 5.05 2 0.08
Epilepsy_type(d) 0.10 1.25 0.007 1 0.93 1.12
Epilepsy_type(e) 2.02 1.48 1.87 1 0.17 7.54
Constant -2.53 1.28 3.89 1 0.04 0.08
 
a. Variable(s) entered on step 1: rs4244285.
b. Variable(s) entered on step 2: epilepsy_type,d = partial epilepsy, e=
generalised epilepsy,
c. Stepwise procedure stopped because removing the least significant variable
result in a previously fitted model. B= regression coefficient
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Table 5.17. Shows the parameters of the logistic regression model for
seizure freedom
 
OmnibusTests of Model Coefficients
Chi-square df Sig.
Step 1 Step 9.30 1 0.002
Block 9.30 1 0.002
Model 9.30 1 0.002
Step 2 Step 4.46 2 0.107
Block 13.77 3 0.003
Hosmer and Lemeshow Test
Step Chi-square df Sig.
1 0 0 3.5E+308
2 0.140 3 0.987
 
A logistic regression model wasused to predict 50% or greater reduction in seizure
frequency from epilepsy type, genotype (1s4244285, rs12248560, and rs11568732),
baseline seizure frequency, dose of CLB, concentration of CLB and NDCB, and
ratio of NDCB/CLB. Only rs4244285 wasa significant predictor of 50% or greater
seizure reduction. For every mutantallele in rs4244285, the odds of 50% or greater
seizure reduction (versus non-reduction) increased by a factor of 3.8 (Table 5.18 and
5.19).
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Table 5.18. Shows the parametersof the logistic regression of 50% seizure
 
 
 
reduction
Variables
in the equation
B S.E. Wald Df Sig. Oddsratio
Step la 134244285 1.33 0.49 7.15 1 0.007 3.78
-0.35 0.23 2.18 1 0.139 0.70Constant
Step 2b 14244285 1.41 0.50 7.84 1 0.005 4.11
rs1 1568732 1.27 0.69 3.42 1 0.064 3.59
-0.52 0.27 4.17 1 0.041 0.59Constant
a. Variable(s) entered on step 1: rs4244285.
b. Variable(s) entered on step 2: rs1 1568732, B= regression coefficient
Table 5.19. Showing the parametersofthe logistic regression of 50%
seizure reduction
OmnibusTests of Model Coefficients
Chi-square Df Sig.
Step1 Step 8.80 1 0.003
Block 8.80 1 0.003
Model 8.80 1 0.003
Step 2 Step 4.11 1 0.042
Block 12.92 2 0.002
Model 12.92 2 0.002
Hosmer and Lemeshow Test
Step Chi-square df Sig.
1 0 0 3.48+308
7 0.946 2 0.62
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A Kaplan-Meier survival analysis was undertaken to explore the differences in
cumulative incidence of treatment failure in the genotypes of SNPs 1s4244285,
rs12248560 and rs11568732. Twenty five patients experienced treatment failure. 12
patients had inadequate seizure control, 2 patients had inadequate seizure control and
adverse effects, and 13 patients had unacceptable adverse effects to CLB. There
was nosignificant difference in the estimated mean survival time (treatment failure)
amongthe genotypes of these SNPs.
5.3.6. Association between CYP2C/9 genotypesandtolerance to
CLB
Baseline seizure data or seizure data of the aa 6", 9" or 12 month weren’t available
for 56 patients. Sixteen patients (33.3%) out of the remaining 48 patients developed
tolerance to CLB therapy. The incidence of tolerance did not differ among the
genotypes of any of the SNPs (rs4244285, rs12248560 and rs11568732) tested.
There was a significant difference (p = 0.023) in mean CLB daily doses in subjects
who developed tolerance than in those who did not (19.68 + 1.06 Vs 16.51 + 0.80
respectively). The NDCB /CLB ratio was significantly higher in patients who
developed tolerance (13.51 + 2.68) than in patients whostill responded to CLB (7.05
+ 1.04) (p value = 0.038). The NDCB concentration was higher in patients who
developed tolerance but this failed to reach significance (p value =0.055) (Table
5.20). In the 12 month follow up period after CLB wasstarted, 5 (31.2%) out of 16
patients did not respond to CLB once tolerance developed. The seizure data after
tolerance developed were not available for 4 patients. 43.75% (7/16) developed
tolerance by the timeofthe last follow up. Further data on seizure frequency were not
available.
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A logistic regression model was used to predict tolerance from epilepsy type,
genotype (rs4244285, rs12248560, and rs1 1568732), dose of CLB, concentration of
CLB and NDCB,ratio of NDCB/CLB. However none of these parameters were
identified as predictors for developing tolerance.
Table 5.20. Showing the distribution of pharmacokinetic parameters in
patients who developed tolerance (1) and patients who did not develop
tolerance (0).
 
Pharmacokinetic Degree of Mean P valueParameters tolerance
0 48 186.70+20.40 9376
CLBconcentration
1 16 157.38 + 25.49
0 48 929.12 4121.09 °°
NDCBconcentration
1 16 1553.16 + 425.03
0 46 7.06 + 1.04 O38
NDCB/CLBratio
1 16 =13.52+2.69
0 48 16.51 +0.81 0.023
Dose of CLB
1 16 19.69+ 1.07
 Meanis expressed as mean + standard error of mean (SEM). Significant p value is
highlighted. n= numberofpatients
5.3.7. Association between CYP2C/9 genotypes & adverseeffects to
CLB
For this thesis, the incidence of only drowsiness, weight gain and dizziness was
evaluated. The total incidence of adverse effects was 42.5%. The most common
adverse effect, experienced alone or in combination with others, was weight gain
(23.3%), followed by drowsiness (15%) and dizziness (14.1%). Only SNP
rs11568732 was associated with adverse effects (Table 5.21). The incidence of
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dizziness decreased with the mutantallele(s) for rs11568732 (p =0.043). However,
weight gain and drowsiness were not affected by this SNP. Only one patient had
homozygous minorallele and did not develop any adverse effects. This finding has
to be replicated in a larger study group to prove that this is not a chance finding.
The incidence of these adverse effects did not differ among the rs4244285 and
rs12248560 genotypes (Table 5.22 and 5.23).
Table 5.21. Association between rs11568732 genotypes and adverse
 
reactions
Adverse Homozygous Heterozygous Homozygous p-value
reaction Majorallele (1) (n=13) minorallele
(0) (7 101) (2) (n=1)
Drowsiness 15 (14.85%) 2 (15.38%) 0 0.9
Dizziness 15 (14.85%) 1 (7.69%) 0 0.04
Weight gain 24 (23.76%) 3 (23.08%) 0 0.9
 Significant p values highlighted; n= numberofpatients
Table 5.22. Association between rs4244285 genotypes and adverse
reactions
Adverse Homozygous Heterozygous Homozygous p-value
reaction EMS(0) (n=85) EMS (1) (n=26) minorallele
(2) (n=4)
Drowsiness 13 (15.29%) 3 (15.54%) 1 (25%) 0.8
Dizziness 12 (14.12%) 4 (15.38%) 1 (25%) 0.8
Weight gain 20 (23.53%) 7 (26.92%) 0 Oe
 n= numberofpatients
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Table 5.23. Association between rs12248560 genotypes and adverse
 
reactions
Adverse Homozygous Heterozygous Homozygous p-value
reaction Majorallele (0) (1) (n =45 ) minorallele (2)
(n =64 ) (n=6)
Drowsiness 10 (15.63%) 6 (13.33%) 1 (16.67%) 0.9
Dizziness 10 (15.63%) 6 (13.33%) 1 (16.67%) 0.9
Weight gain 15 (23.43%) 11 (24.4%) 1 (16.67%) 09
 n= numberofpatients
5.4. Discussion
To the best of my knowledge, this is the first prospective study conducted in
Caucasians exploring the impact of CYP2C/9 polymorphisms on the metabolism,
efficacy and adverse effects of CLB. An attempt has also been made to define the
covariates or predictors that influence the metabolism, tolerance and propensity to
develop adverse drug effects with CLB. I have documented an association between
CYP2C19*2 polymorphism and (a) NDCB concentration (b) NDCB/CLB dose and
(c) NDCB/CLB concentration. In addition, CYP2C19*2 had an impact on the
efficacy of CLB. However CYP2C19*2 did not influence the development of
tolerance and adverse drug effects to CLB. By contrast, rs12248560 (CYP2C19*17)
influenced the CLB dosein patients (p = 0.012), while rs11568732 was associated
with the development of dizziness. A multiple regression model for the ratio of
NDCB/CLB showed that CYP2C19*2 genotype wasthe only factor influencingthis
ratio. A logistic regression model for efficacy also predicted the same. In summary,I
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present novel data which show that CYP2C19 SNPs have an impact on the
metabolism, efficacy and toxicity of CLB.
Theselection of SNPs for genotyping is very important in candidate genestudies. I
feel that the criteria we used for SNP selection was optimal. I wanted to genotype a
set of SNPs, which capture the genetic variation in the CYP2C/9 gene andat the
same time produce an effect that has sufficient impact to be picked up in our study.
The minorallele frequency of the SNPs should be high enoughforthis (at least 5%).
Saito et al (2007) used a tagging SNP strategy and selected most of the SNPs (5/6)
that I considered (Table 5.3), to represent the 6 haplotypes of CYP2C/9 gene.
Therefore our genotyping strategy is likely to have been successful in covering the
genetic variation across the whole gene.
Our study population had Caucasian ancestry. This is important since heterogeneous
populations have different genotype frequencies, which might lead to spurious
results in genotype-phenotypecorrelations. All the subjects in this study were adults.
The Concentration/Dose (C/D) ratio of CLB in children wassignificantly lower than
adults, among the patients who were homozygous for the major allele of SNP
184244285, leading to doubtful results (Seo, et al., 2008). In our study, the
demographic characteristics were comparable among the genotypesfor all our SNPs
(Tables 5.6-5.8).
In our study, two blood samples were collected: one at month 3 and the second at
month 6 after starting CLB treatment. There was no significant difference between
the iad 6" and the mean of the two (NDCB/CLB concentration, NDCB
concentration, CLB concentration and CLB dose) (Table 5.9). For all the further
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analysis, we used the mean (of 3™ and 6" month) of these parameters, where
available.
The NDCBconcentration, C/D of NDCB and NDCB/CLBconcentration increased
as the rs4244285 minor allele increased. However, the only significant difference
was detected between the PMsand (a) heterozygous EMsand (b) homozygous EMs
(p =0.00). All the previous studies had demonstrated a significant difference in
NDCB/CLBratio among all 3 groups (Contin, et al., 2002; Kosaki, et al., 2004;
Parmeggiani, et al., 2004), or between homozygous EMs and heterozygous EMs
(Giraud, et al., 2004). However the concentration of NDCB was muchhigher than
CLB asreported in earlier studies. There was no significant difference in CLB
concentration across various genotypes of rs4244285, similar to recent studies
(Kosaki, et al., 2004; Seo,et al., 2008).
Patients with rs12248560 homozygous minorallele had significantly higher dose of
CLB (22.50mg) than the homozygous majorallele patients (14.80mg) (Table 5.10).
SNP rs12248560 increases the activity of CYP2C19. Theoretically patients with
homozygous minorallele should have a higher dose of CLB, which is evident in our
study. The concentration of CLB wasinsignificantly lower in homozygous mutant
allele group (group 2). In addition the concentration of NDCBis not significantly
higher in group 0 when compared to homozygous minorallele (group 2). Probably a
larger sample size might be able to confirm thesefindings.
There was only one patient with homozygous minor allele (group 2) of SNP
1s11568732. The patients in group 1 had significantly lower concentration of
NDCBand C/D ofNDCBthan group 0. Functional studies on this SNP haven’t been
done. Howeverit is only 83 bp (base pairs) upstream of rs12248560, which induces
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gene expression in mouse. In humans, rs12248560 is responsible for ultra rapid
metabolism of drugs metabolized by CYP2C19. This has been associated with lack
of response to some proton pumpinhibitors and anti depressants, due to an ultra
rapid clearance of these drugs (Sim, et al., 2006; Saito, et al., 2007). The hepatic
reporter expression by Sim et al (2006), to assess the effect of rs12248560 on
CYP2C1/9 included the region of SNP rs11568732. Therefore this SNP too could
increase the expression of CYP2C19. However the frequency of this SNP is only
6.1% (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11568732) in
Caucasian population while that of —_rs12248560 is 21.6%
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12248560). Functional
assays should be conducted to verify the function of rs11568732. If rs11568732
increases the activity of CYP2C19, the concentration of NDCB will be lower in
subjects with this mutant allele. Though only one patient had homozygous minor
allele, the NDCB concentration was 2.4 fold lower than group 0 and 1.6 fold lower
than group! patients (Table 5.12). It is interesting to note that the only patient with
minorallele did not have a mutantallele of CYP2C19*2 (1rs4244285). In addition the
ratio of NDCB/CLB concentration was more than 4 fold lower in the patients in
group 2 when compared to group 0. This adds further weight to our assumption that
rs11568732 could increase the activity of CYP2C19. However, conclusions cannot
be drawn from the findings in a single patient. Genotypes had lesser influence on
CLB concentration. This could be dueto the fact that CLB is metabolised to NDCB
by CYP2B6, CYP3A4 and CYP2C19 while NDCB is converted to 4’-
hydroxynorclobazam primarily by CYP2C19 (Giraud, et al., 2004).
46.6% of the subjects experienced reduction in seizures by 50% when compared to
that of the baseline. This is consistent with various studies including a multi centre
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study in Canada (Canadian Clobazam Cooperative Group, 1991). It is interesting to
note that all the patients with homozygous minorallele (group 2) of rs4244285
responded to CLB.In addition, 65.4% patients in the heterozygous group had 50%
reduction in seizure frequency compared to base line. This was higher than the
responders in the homozygous major allele group. This is consistent with other
studies (Seo, et al., 2008).
44.9% (44/98), 53.8% (7/13) and 100% (1/1) patients of group 0, 1 and 2 of
rs11568732, experienced 50% reduction in seizure frequency p = 0.464. A larger
sample size with more patients with homozygous minorallele will be able to clearly
prove the association of rs11568732 and efficacy. 1s12248560 did not affect the
efficacy of CLB.
15.04% of the study population attained seizure freedom. Only rs4244285 was
associated with seizure freedom. The number of patients who achieved seizure
freedom in PMs (50%) wassignificantly higher than heterozygous EMs (26.92%)
and homozygous EMs (9.64%). The number of patients with seizure freedom
increased with the numberof mutant alleles. The dose of CLB did not significantly
differ between the responders (patients who had more than 50% seizure reduction)
and non responders, contrary to the findings of Seo et al (2008). SNPs rs11568732
and rs12248560 did not affect this parameter.
Tolerance is a major drawback of CLB, the frequency of which varies widely
(Shorvon, 1998; Remy, 2007). This is hindering the wide spread prescription ofthis
relatively safe drug. 33.33% of the patients developed tolerance in this study. There
was no significant difference in the number of patients who developed tolerance
amongthe different genotypes of SNPs — rs4244285, in concordance with previous
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results (Seo, et al., 2008). rs11568732 and rs12248560 too did not influence the
developmentof tolerance.
For my thesis only drowsiness, weight gain and dizziness were evaluated, since
these were the common adverse effects reported in this study and in other studies.
42.5% of patients developed adverse drug effects. 23.3% complained of weight
gain, while 15% and 14.1% patients developed drowsiness and dizziness
respectively. Only SNP rs11568732 influenced the development of adverse drug
effects. Though there was only one patient with homozygous mutant allele, this
patient did not develop drowsiness, dizziness or weight gain. The patients who
complained of dizziness were significantly lower in group 1 than in group 0. There
was no significant difference in CLB dose between the genotypes of rs11568732.
However the concentration of NDCB was significantly lower (p = 0.02) in
heterozygous patients than in patients with homozygous major allele. If as
mentioned earlier, rs1 1568732 increases the activity of CYP2C19, the probability of
adverse drug effects occurring in heterozygous and homozygousminorallele patient
groups will be lower when compared to the homozygous majorallele group patients
as seen in this study. These findings and hypotheses are of modest value, until
replicated in a larger cohort of patients.
Thougha prospective study, this study has some drawbacks. Patient data including
weight, epilepsy type and baseline seizure frequency were not available for all
patients (for details kindly refer to respective result sections). Some patients have
missed their follow up (3 patients the 3rd month follow up and 4 patients the 6th
month follow up). So blood for CLB and NDCBconcentration estimation was not
obtained on their 3rd month or 6th month follow up.
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To summarise, I present here a prospective cohort study evaluating the role of
CYP2C19 polymorphisms in the metabolism, efficacy and development of adverse
effects of CLB.In addition I have investigated the factors affecting these parameters.
This could be the first step towards developing a genetic test which predicts an
individual’s predisposition to respond well to CLB or develop adverse effects. This
will help clinicians use this relatively safe drug judiciously, thus leading to
personalised medicine benefiting the patient and reducing the costs of health care.
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Chapter 6
General discussion
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Epilepsy is one of the most common neurological disorders, affecting 0.7% of the
UK population (Gao, et al., 2008). It is associated with significant mortality,
morbidity and psychosocial distress. Despite the fact that around 20 drugs are
available on the market today, almost 30% of the patients do not respond to any of
these drugs or drug combinations (Dalby, 2004). These patients are therefore treated
on a ‘trial and error basis’ initially by up-titration of the dosage, and subsequently by
addition of other drugs suchthat the patient ends up on multiple AEDsin aneffort to
gain seizure control.
VGB and CLBare drugs with someefficacy in these refractory patients (Gram,et
al., 1985; Koeppen, et al., 1987; Munn, et al., 1988; Guberman, et al., 1990;
Guberman and Bruni, 2000; Michael and Marson, 2008). VGB is particularly
effective in paediatric patients with West syndrome andtuberoussclerosis (Antoniuk
and Bruck, 1996; Herranz and Argumosa, 2000; Wheless, et al., 2007). However,
VGB produces VFD in almost 40% of patients (Wheless, et al., 2007). CLB,
though a relatively safe drug, causes tolerance in a large proportion of patients. Side
effects have been reported in 20-85% ofpatients in clinical trials. However, only 5-
15% of these lead to a change in dose or termination of treatment (Koeppen,et al.,
1987; Canadian Clobazam Cooperative Group, 1991). Drowsiness, dizziness,
headache, nausea and weight gain are listed as the most common adverse drug
effects (Allen, et al., 1983). These factors may deter clinicians from prescribing CLB
(Dalby, 2004).
The aim ofthe thesis wasto test the hypothesis that genetic factors may be important
in determining individual variability in response to these AEDs. Specifically for
VGB, my focus was on patients who developed VVFD, andto test the hypothesis
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that GABA-T, the enzymeirreversibly inhibited by VGB, may be implicated in the
pathogenesis of the variability. For CLB, identification of genetic variation in
patients who (1) vary in their response to CLB; (2) who develop tolerance; and (3)
whodevelop adverse drug effects would facilitate the stratification of prescribing of
CLB to maximiseits effectiveness.
In chapter 2, the aim was to define the phenotype-genotype relationship for the
GABA-T enzyme. Identifying functional SNPs whichare clinically relevant among
the 12 million SNPs in the human genomeis similar to searching for a ‘needle in a
haystack’ (http://www.ncbi.nlm.nih.gov/projects/SNP/). Therefore utmost
importance was given to selection criteria of SNPs. I predicted putative functional
SNPs from websites like dbSNP (http://www.ncbi.nlm.nih.gov/sites/entrez),
Ensemble (http://www.ensembl.org/index.html) and UCSC
(http://genome.ucsc.edu/) using software programs like PupaSNP (Conde, et al.,
2004) and SNPper (Riva and Kohane, 2004). By standardising and validating an
assay, I was able to evaluate the function of GABA-Tin platelets. Given the non-
invasive nature of my approach, and the need to control for confounding factors, I
first tested for the functional effects of SNPs using healthy volunteers. Though my
sample size was small (n=32), an association between rs1731017 and platelet
GABA-Tactivity was identified. This is a novelfinding.
Interestingly, however, Kinirons et al. (2006) failed to find an association between
this common SNP (minor allele frequency 40%) and VVFD. This illustrates an
important point. Targeting certain SNPs may notdefine a functional deficit if other
factors (genetic or non-genetic) are more important. In order to further investigate
this, platelet GABA-T activity was assessed in patients with VVFD in comparison to
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patients who had been on VGB without the development of VVFD. Interestingly,
platelet GABA-T activity was significantly lower in patients with VVFD than in
patients with normal vision (chapter 3), a highly unexpected finding given that only
14 patients were studied. The explanation for this is unknown, but may suggest the
presence of rare variants which have a marked effect on activity, or that other
genetic factors (beyond the ABAT gene) can influenceits activity. Alternatively,
epigenetic factors may also be important. These hypotheses need further testing —
wehaverecently initiated a deep re-sequencing project for the ABAT gene in order
to identify novel, and rare, variants. Clearly any finding from this will need to be
subject to replication in a larger cohort of patients, and functional analysis of any
mutants identified. However since VGBis givento only refractory epilepsy patients
(Eke, et al., 1997; James, et al., 2009), it might be difficult to get a large cohort of
patients. An alternative (and additional) approach, whichis also being undertaken as
part of the overall research programme, is to perform a genome-wide association
scan. Since the mechanism of VVFD is unknown, this will allow an unbiased
assessmentofpossible genetic variants on a genomescale, including CNV.
CLBis a relatively idiosyncratic drug, favored by someepileptologists, but perhaps
ignored by the majority. This may partly be related to its modest efficacy in the
overall population in which it is used, and the development of tolerance. The
polymorphic enzyme CYP2C19 is involved in the metabolism of CLB to its major
active metabolite NDCB. In order to assess the importance of the metabolism of
CLBin determining its response characteristics, I developed a reverse phase HPLC
method (Chapter 4) which had high sensitivity and specificity. This allowed the
estimation of the plasma concentrations of CLB and its major metabolite NDCBin a
prospective study setting, which has never been undertaken previously. These
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kinetic parameters were then related to polymorphisms in the CYP2C19 gene.
CYP2C19 is well known to be polymorphically expressed, and was initially
identified through variability in the metabolism of mephenytoin, and was thus
initially known as mephenytoin hydroxylase. There are many knownsubstrates for
CYP2C19 including CLB. The most intensively studied SNPs in CYP2C/9 include
those which cause loss of function (CYP2C19*2, and CYP2C19*3), and those
which cause a gain of function (CYP2C19*17). The patients in my cohort were
genotyped for all of these polymorphisms (chapter 5). I did not identify any
patients who were carrying the *3 allele, which was expected given the low
population frequency of this allele in the Caucasian population. I found an
association between the CYP2C19*2 polymorphism and (1) the metabolism of CLB
and (2) its efficacy. Prior studies have reported similar results in relation to the
kinetic parameters (Kosaki, et al., 2004; Seo, et al., 2008), and in relation to efficacy
(Seo, et al., 2008). By contrast, rs11568732 was associated with CLB-induced
dizziness, which was significantly lower in patients with variant alleles when
compared to those with two major alleles. Comparison of the homozygous major
allele group and heterozygous patients showed that the former had significantly
higher concentration of NDCB. This was done because there was only one patient in
homozygous minorallele group. Patients who were homozygousfor the minorallele
of CYP2C19*17 were on a significantly higher dose of CLB than the heterozygotes
or carriers of two major alleles. The effect of these SNPs - rs12248560 and
rs11568732 - has not previously been investigated in relation to CLB. These are
novel findings, but which nevertheless need to be replicated in another patient cohort
before being assessed forclinical validity and clinical utility.
197
There is a long road to travel before genetic tests for CLB are available for routine
clinical use. It has been stated that pharmacogenetic tests for drugs with a narrow
therapeutic index take a shorter time to be incorporated in clinical practice (Nebert
and Vesell, 2006). Clinical guidelines have been published for the use of
pharmacogenetic tests in the prescription of drugs with a narrow therapeutic index
like warfarin, tricyclic antidepressants and risperidone (Voora,et al., 2005; Hillman,
et al., 2005; de Leon, 2007). However, CLB has a wide therapeutic index and the
adverse drug effects associated with its use are mild. However, it can cause
tolerance and there seem to be sub-groups of patients who seem to respond well to
CLB. Thus, it can still be argued that there is a need to stratify patients for CLB
treatment, but the method by which this will be done, and whether it will be
effective, needs further investigation.
Many high penetrance, predominantly monogenic disorders in drug metabolism
were reported between 1940 and 1990. It was predicted that personalized medicines
were just around the corner. However, the human genome project revealed the
complexity of the human genome (Nebert, et al., 2008). In addition, many
pharmacogenetic studies could not be replicated. Examples include the association
of serotonin subtype 2 receptor genes and clinical response to clozapine in
schizophrenia patients (Masellis, et al., 1998; Joober, et al., 1999) and the effects of
apolipoprotein E genotype on clinical response to tacrine (Farlow, et al., 1996;
Rigaud,et al., 2000). Nowit is recognized that the concertedeffort of all the major
players - pharmaceutical industry/analytical industry, regulatory bodies,scientists,
clinicians and patients groups- will be essential to implement pharmacogenetictests
on a routine basis in clinics (Swen, et al., 2007). Since it has been proposed that
many genetic variants of small to moderate effects predispose or cause a complex
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disease or a complextrait, like efficacy or toxicity of a drug, there is a need to (a)
ensure that phenotypingstrategies are as accurate as possible, and (b)to collect large
sample sizes which will only be possible through multi-centre collaborations. Many
GWASstudies in complex diseases have now been completed. Although these have
shown manynewloci, the effect sizes have been quite low (RR 1.2-1.7) leading to
pessimism that these variants may never be used as genomic biomarkers (McCarthy,
et al., 2008). However, the importance of these studies has been to highlight novel
pathways whichare likely to lead to new drug targets. By contrast, genome wide
studies have produced some striking findings even with small sample sizes
indicating that pharmacogenomic biomarkers may in some cases have muchlarger
effect sizes than those seen in complex diseases (Nieminen,et al., 2008; Daly,et al.,
2009). Irrespective of the approachutilized, it is important that studies are of good
quality with appropriate reporting standards as recently highlighted (Jorgensen and
Williamson, 2008).
The human genomeis complex. On manyoccasions,it is difficult to ascertain either
an unequivocal phenotype or genotype. The study of gene transcripts
(transcriptomics) and the study of all the proteins that are encoded by the genome
(proteomics) may also be importantin delivering personalized medicines. The major
limitation of these branches of science is the source of tissue for analysis (blood,
excreta (e.g. urine and faeces)) and tissue that contains the relevant cDNA(e.g.
surgical biopsy of tumour, other tissue biopsies, placenta and foreskin).
Metabolomics, the study of metabolite profiling in ‘multicellular systems’ may also
help in predicting the drug response in individuals. All these branchesofscience -
pharmacogenomics, transcriptomics, proteomics and metabonomics - working
together will complement each other and ultimately lead to personalized medicine
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approachesin clinical practice (Nebert and Vesell, 2006). In accordance with this,
the findings from this thesis provide some interesting findings which need further
investigation, and support the concept that personalised medicine approaches may be
valuable in the future use of VGB and CLB.
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Appendix 1. Classification of epilepsy according to
the Commission on Classification and Terminology of
the International League Against Epilepsy, 2010.
Table 1. Classification of seizures *
 
 
Generalized seizures
Tonic—clonic (in any combination)
Absence
Typical
Atypical
Absence with special features
Myoclonic absence
Eyelid myoclonia
Myoclonic
Myoclonic
Myoclonic atonic
Myoclonic tonic
Clonic
Tonic
Atonic
Focal seizures
Unknown
Epileptic spasms
“Seizure that cannotbe clearly diagnosed into one of the preceding categories should
be considered unclassified until further information allows their accurate diagnosis.
This is not considereda classification category, however.
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Table 2. Descriptors of focal seizures according to degree of
impairmentduring seizure *
 
 
Without impairment of consciousness or awareness
With observable motor or autonomic components. This roughly corresponds
to the concept of ‘‘simple partial seizure. ‘‘Focal motor’? and ‘‘autonomic”’
are terms that may adequately convey this concept depending on the seizure
manifestations).
Involving subjective sensory or psychic phenomenaonly.
This corresponds to the concept of an aura, a term endorsed in the 2001
Glossary. With impairment of consciousness or awareness. This roughly
corresponds to the concept of complex partial seizure. ‘‘Dyscognitive’’ is a
term that has been proposed for this concept (Blumeet al., 2001).
Evolvingto a bilateral, convulsive” seizure
(Involving tonic, clonic, or tonic and clonic components). This expression replaces
the term ‘‘secondarily generalized seizure.”
“For more descriptors that have been clearly defined and recommended for use,
please see Blumeet al., 2001.
>The term ‘‘convulsive’’ was considered a lay term in the Glossary; however, we
note that it is used throughout medicine in various forms and translates well across
manylanguages.Its use is, therefore, endorsed.
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Table 3. Electroclinical syndromes and other epilepsies
 
 
Electroclinical syndromes arrangedby ageat onset”
Neonatal period
Benign familial neonatal epilepsy (BFNE)
Early myoclonic encephalopathy (EME)
Ohtahara syndrome
Infancy
Epilepsy of infancy with migrating focal seizures
West syndrome
Myoclonic epilepsy in infancy (MEI)
Benign infantile epilepsy
Benign familial infantile epilepsy
Dravet syndrome
Myoclonic encephalopathy in nonprogressive disorders
Childhood
Febrile seizures plus (FS+) (canstart in infancy)
Panayiotopoulos syndrome
Epilepsy with myoclonic atonic (previously astatic) seizures
Benign epilepsy with centrotemporal spikes (BECTS)
Autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE)
Late onset childhood occipital epilepsy (Gastaut type)
Epilepsy with myoclonic absences
Lennox-Gastaut syndrome
Epileptic encephalopathy with continuous spike-and-wave during
sleep (CSWS)
Landau-Kleffner syndrome (LKS)
Childhood absence epilepsy (CAE)
Adolescence — Adult
Juvenile absence epilepsy (JAE)
Juvenile myoclonic epilepsy (JME)
Epilepsy with generalized tonic-clonic seizures alone
Progressive myoclonusepilepsies (PME)
Autosomal dominantepilepsy with auditory features (ADEAF)
Other familial temporal lobe epilepsies
Less specific age relationship
Familial focal epilepsy with variable foci (childhoodto adult)
Reflex epilepsies
Distinctive constellations
Mesial temporal lobe epilepsy with hippocampal
sclerosis (MTLE with HS)
Rasmussen syndrome
Gelastic seizures with hypothalamic hamartoma
Hemiconvulsion—hemiplegia—epilepsy
Epilepsies that do notfit into any of these diagnostic categories can be distinguished
first on the basis of the presence or absence of a known structural or metabolic
condition (presumed cause) and then on the basis of the primary mode ofseizure
onset (generalized vs. focal).
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Epilepsies attributed to and organized by structural-metabolic causes
Malformations of cortical development (hemimegalencephaly, heterotopias,
etc.)
Neurocutaneous syndromes(tuberoussclerosis complex,
Sturge-Weber,etc.)
Tumor
Infection
Trauma
Angioma
Perinatal insults
Stroke
Etc.
Epilepsies of unknown cause
Conditions with epileptic seizures that are traditionally not diagnosed as a
form of epilepsy per se
Benign neonatal seizures (BNS)
Febrile seizures (FS)
“The arrangementofelectroclinical syndromesdoesnotreflect etiology.
’Sometimereferred to as Electrical Status Epilepticus during Slow Sleep(ESES).
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